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 Abstract 
Regulatorische T-Zellen und myeloide Suppressorzellen sind Immunzellen, deren 
Hauptfunktion nicht in der Abwehr von Pathogenen, sondern in der Regulation von 
Immunantworten liegt. Die Fehlfunktion dieser immunregulatorischen Zellen kann eine 
Vielzahl von fatalen Folgen haben. Falls die immunregulatorische Funktion geschwächt ist, 
kann dies zu einer fehlenden Hemmung von autoreaktiven Zellen führen. Diese 
überschießende Aktivität von Immunzellen gegen das köpereigene Gewebe kann zu der 
Entstehung von Autoimmunerkrankungen beitragen. Andererseits können die suppressiven 
Zellen auch verstärkt aktiv sein. Die gesteigerte Inhibition von Immunzellen kann in diesem 
Fall eine adäquate Immunreaktion gegen Krebszellen verhindern und begünstigt damit die 
Entwicklung und Ausbreitung von Tumoren. Neben einer Vielzahl von Mediatoren wird auch 
der Tumor Nekrose Faktor (TNF) als ein wichtiger Modulator jener immunsuppressiven 
Zellen gesehen. In vorausgehenden Experimenten in unserem Labor konnte gezeigt werden, 
dass bestimmte Agonisten von dem TNF-Rezeptor Typ 2 (TNFR2) die Suppression von CD4+ 
und CD8+ T-Zellen durch regulatorische T-Zellen hemmen. Ziel dieser Arbeit war es, die 
Auswirkungen von dem spezifischen TNFR2-Agonisten TNCscTNF80 auf die 
Suppressionsfähigkeit von regulatorischen T-Zellen und myeloiden Suppressorzellen zu 
bestimmen. Es konnte gezeigt werden, dass TNCscTNF80 die Suppression von T-Zellen 
durch diese regulatorischen Immunzellen hemmt. Des Weiteren wurde untersucht, welche 
Veränderungen TNCscTNF80 in regulatorischen T-Zellen auf molekularer Ebene auslöst. 
TNCscTNF80 führte zu einer verminderten Expression von bestimmten 
Oberflächenmolekülen, die charakteristisch für regulatorische T-Zellen sind und die zu deren 
Suppressorfunktion beitragen sollen. Es kann daher spekuliert werden, dass Agonisten am 
TNFR2 die Funktion von regulatorischen T-Zellen hemmen, indem sie die Zusammensetzung 
der Oberflächenmoleküle verändern. Außerdem wurde überprüft, ob TNCscTNF80 einen 
Einfluss auf intrazelluläre Signalkaskaden in regulatorischen T-Zellen hat. Dafür wurde die 
Aktivität von zwei Signalmolekülen untersucht; dem signal transducer and activator of 
transcription 5 (Stat5) und dem ζ-chain-associated protein of 70kD (ZAP70), welche in Folge 
der Stimulation von dem T-Zell Rezeptor (TCR) bzw. dem IL-2 Rezeptor (IL-2R) 
hochreguliert werden. TNCscTNF80 hatte jedoch keinen deutlichen Einfluss auf die 
Aktivierung dieser Signalmoleküle in regulatorischen T-Zellen. 
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1 Introduction 
1.1 The immune system 
An advanced immune system has emerged in highly developed species in order to 
provide efficient host defence against bacterial, viral, fungal or parasitic infections. This 
system is divided into two functionally different components, the innate (natural) and 
acquired (adaptive) immune system (1). 
The innate immune system is comprised of both cells and soluble factors, which are 
activated at the beginning of an infection to fight the invading pathogens. Innate immune 
responses are initiated following the detection of evolutionary conserved pathogen-associated 
molecular patterns (PAMPs) by pattern-recognition receptors (PRR) (2). Cells capable of 
phagocytosis, e.g. neutrophils, monocytes or mastocytes, or of producing proinflammatory 
factors, e.g. basophiles, mast cells or eosinophiles, and natural killer (NK) cells constitute the 
cellular compartment, whereas complement factors, acute-phase proteins and cytokines, 
including interleukins (IL) and interferons (IFN), represent the molecular section. In contrast 
to the adaptive immunity, innate immune responses are not directed against a specific antigen 
and do not improve upon reencounter with pathogens that have previously invaded the 
organism because no immunological memory remains (3). 
The adaptive immune system, however, is capable of forming memory cells, which 
initiate a quicker and more specific response upon reencounter with an antigen. T- and 
B-lymphocytes represent the effector cells of the adaptive immune system, which express 
receptors that are specific for a certain antigen. A large repertoire of those receptors is 
necessary in order to recognize a great variety of antigens. Therefore, extensive 
recombination of the T cell receptor (TCR) during the T cell development in the thymus and 
of the antibodies that form part of the B-cell receptor (BCR) is required. The TCR consists of 
α- and β-chains or γ- and δ-chains and non-covalently binds to the cluster of differentiation 
(CD) 3 complex, which is composed of four different polypeptides, the γ-, δ-, ε- and ζ-chains. 
The co-receptors CD4 or CD8 are additionally associated with the TCR complex. This 
receptor complex recognizes peptides that have been processed from antigen proteins and are 
subsequently presented on cell surfaces by the major histocompatibility complex (MHC). 
Activation of CD4+ cells is induced by the interaction of the TCR with peptide antigens 
presented by MHC II, which are especially found on antigen-presenting cells (APC), e.g. 
dendritic cells (DC), activated macrophages and B cells (1, 4). CD8+ cells, on the other hand, 
bind to MHC I, which are ubiquitously expressed on most nucleated cells and which present 
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cytosolic proteins. Cells that are virally infected or malignantly transformed can, thereby, 
present their intracellular antigens to CD8+. As CD8+ are cytotoxic, they can eliminate those 
pathogenic cells (1, 4, 5).  
1.2 CD4+ T helper cells 
In contrast to CD8+ T cells that are directly cytotoxic, CD4+ T helper cells 
predominantly secret cytokines and activate other cells of the immune system (5). In order to 
be activated, naïve CD4+ T cells need to receive two signals, the interaction of a MHC/peptide 
complex with their TCR and additional co-stimulatory signals. For instance, the 
co-stimulatory receptor CD28 is bound by the ligands CD80/CD86, which are expressed on 
the cell surface of mature APC (6). Thus, in order to initiate an adaptive immune response, 
those APC, such as macrophages or DC, need to recognize a foreign antigen, undergo 
maturation, including the upregulation of CD80/CD86, and migrate to the lymph nodes, 
where they present the processed antigen peptide on their MHC II. T cells that express the 
TCR specific for that certain antigen recognize the MHC/antigen complex, which, together 
with co-stimulatory signals, induces the activation and differentiation of T cells (7). Once 
activated, T cells secret cytokines and initiate the activation of B cells, thus, enabling somatic 
hypermutation of the BCR and the immunoglobulin class switch (5). 
1.2.1 T helper cells: Th1, Th2, Th17 
Depending on the cytokine milieu and factors that are present during the activation, 
CD4+ cells can develop into different T helper (Th) subtypes (8). Based on the profile of 
cytokine secretion, those CD4+ Th cells can be divided into three major groups, i.e. Th1, Th2 
and Th17 cells, as seen in Figure 1 (9). Cytokines produced by Th1 cells, e.g. IL-2 and IFN-γ 
promote the initiation of a cellular immune response, which includes the activation of 
macrophages and cytotoxic T cells to fight intracellular pathogens. Th2-speficic cytokines, 
e.g. Il-4, IL-5, IL-6 and IL-10, on the other hand, initiate the humoral immune response by 
inducing the differentiation of B cells into antibody-producing plasma cells (5, 10). Th17 cells 
produce the proinflammatory cytokines IL-17 and IL-22, which induce the secretion of other 
immunostimulatory cytokines, e.g. IL-6, IL-1β and tumor necrosis factor (TNF), and growth 
factors that promote the recruitment of neutrophils. Therefore, it is suggested that Th17 cells 
play an important role in the early defence against extracellular pathogens that are not 
efficiently cleared by Th1 or Th2 cells (9, 10).  
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REVIEWS
Induction and effector functions of
TH17 cells
Estelle Bettelli1, Thomas Korn1{, Mohamed Oukka1 & Vijay K. Kuchroo1
T helper (TH) cells constitute an important arm of the adaptive immune system because they coordinate defence against
specific pathogens, and their unique cytokines and effector functions mediate different types of tissue inflammation. The
recently discovered TH17 cells, the third subset of effector T helper cells, have been the subject of intense research aimed at
understanding their role in immunity and disease. Here we review emerging data suggesting that TH17 cells have an
important role in host defence against specific pathogens and are potent inducers of autoimmunity and tissue inflammation.
In addition, the differentiation factors responsible for their generation have revealed an interesting reciprocal relationship
with regulatory T (Treg) cells, which prevent tissue inflammation and mediate self-tolerance.
T
he hallmark of adaptive immunity in advanced vertebrates is
the existence of lymphocytes, which induce and regulate
immune responses.When activated by pathogens in a specific
cytokine environment, naive CD41 T cells differentiate into
different subsets with distinct effector functions aimed at orchestrating
andmobilizing other cell types to effectively clear invading pathogens.
Based on cytokine phenotypes, initially the existence of two distinct
effector TH subsets was proposed: TH1 and TH2 (ref. 1). TH1 cells
produce interferon-c (IFN-c) andmediate protection against intracel-
lular pathogens, whereas TH2 cells produce interleukin-4 (IL-4), IL-13
and IL-25 (also known as IL-17E) and orchestrate the clearance of
extracellular pathogens1,2 (Fig. 1). Recently this paradigm has been
updated following the discovery of a third subset of TH cells; these cells,
knownasTH17 cells (ref. 3), produce IL-17 and exhibit distinct effector
functions. In the past four years there has been an explosion of
information regarding this T-cell subset: the cytokines for their differ-
entiation have been identified, the key transcription factors that are
involved in their generation have been recognized and their function in
tissue inflammation has been established. This review summarizes this
information to develop a comprehensive view of the generation and
function of TH17 cells.
TH17 cells and TH17-specific effector cytokines
TH17 cells are characterized by the production of IL-17A (also called
IL-17), IL-17F and IL-22 (Box 1) and are thought to clear extracel-
lular pathogens not effectively handled by either TH1 or TH2 cells
(Fig. 1). Because TH17 cells produce large quantities of IL-17A, most
TH17-mediated effects are attributed to this cytokine. IL-17A is the
prototypic cytokine of the IL-17 family, which includes six members:
IL-17A, B, C, D, E and F4. IL-17 is a phylogenetically old cytokine that
is also detected in non-mammalian vertebrates5.
In addition to IL-17A, TH17 cells co-produce IL-17F
3,6. IL-17A and
IL-17F have similar functions. They induce the production of proin-
flammatory cytokines, chemokines and metalloproteinases from
various tissues and cell types (Box 1). As a result, they recruit neu-
trophils to tissues.
Although there is often a coordinated expression of IL-17A and IL-
17F in TH17 cells and other cell types, it is now clear that there are TH
cells expressing only IL-17A, IL-17F or an IL-17A–IL-17F heterodi-
mer7,8. In addition to IL-17A and IL-17F, TH17 cells produce other
effector cytokines, namely IL-21 and IL-22 (refs 6, 9–12). Neither IL-
21 nor IL-22 are TH17-exclusive cytokines, but are preferentially
expressed in TH17 cells.
Recent work from our group and others showed that IL-21, a
member of the IL-2 family of cytokines, is produced in large amounts
by TH17 cells and ICOS
1CXCR51CCR71 T follicular helper cells13.
These T follicular helper cells home to the B-cell areas of secondary
lymphoid tissue and provide cognate help to B cells. However, it
remains to be seen whether T follicular helper cells could represent
activated or memory TH17 cells that help B cells in secondary or
tertiary lymphoid organs.
1Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. {Present address: Neurologische Klinik, Klinikum
rechts der Isar, Technische Universita¨t Munich, Germany.
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Figure 1 | Subsets of T helper cells. Depending on the cytokine milieu
present at the time of the initial engagement of their T-cell receptor and co-
stimulatory receptors in the peripheral immune compartment, naive CD41
T cells can differentiate into various subsets of T helper cells (TH1, TH2 and
TH17). However, in the presence of TGF-b, naive T cells convert into
FOXP3-expressing induced Treg (iTreg) cells. For each T helper cell
differentiation programme, specific transcription factors have been
identified as master regulators (T-bet, GATA3 and ROR-ct). Terminally
differentiated T helper cells are characterized by a specific combination of
effector cytokines that orchestrate specific and distinct effector functions of
the adaptive immune system.
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Figure 1: T helper cell subpopulations. N ïve CD4+ ells can develop into different T 
helper cells subsets (T 1, Th2, Th17) or inducible regulatory T cells (iTreg) depending on the 
cytokines pr sent during the initial activation. Each sub-population expresses characteristic 
transcription factors (T-bet, GATA3, ROR-γt, FOXP3) (figur  from Bette li t al., 2008, 
p.1051 (9)). 
1.3 Control over inflammation 
A major question in immunology is how the immune system distinguishes between 
self and non-self. In order to effectively eliminate pathogenic antigens while inhibiting 
autoimmunity, various mechanisms have evolved to ensure self-tolerance. A key mechanism 
is the central tolerance established in the thymus. During negative selection, lymphocytes are 
eliminated if they bear TCR that have high affinities for self-peptides presented by medullary 
thymic epithelial cells or DC. But this mechanism is not perfect, as autoreactive T cells 
escape the negative selection if they express a TCR with low affinity for self-antigens or with 
specificities for self-antigens that are not sufficiently presented in the thymus (11, 12). 
Furthermore, the early development of conventional T cells in the neonatal period occurs 
faster than in adults due to a compromised negative selection, which results in a higher chance 
of autoreactive T cells being released into the periphery (13). Thus self-recognizing T cells 
are circulating in the periphery, which implies that further control mechanisms are necessary 
in order to reinforce self-tolerance and prevent destruction of healthy tissue. One way to stop 
possible autoimmune processes is the establishment of immunological privileged tissues. In 
the absence of inflammation, potential autoreactive T cells are excluded from those tissues, 
limiting the contact with tissue-restricted antigens and thus the occurrence of 
autoimmunological processes in those organs (12). Moreover, for full activation of T cells 
co-stimulatory signals are required in addition to the TCR stimulation, e.g. the interaction of 
CD28 with its ligands CD80/CD86 expressed by activated APC. Yet, APC are only 
completely activated after recognizing external pathogens; self-peptide presenting APC 
therefore do not upregulate CD80/CD86 on their surface. Thus, autoreactive T cells 
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recognizing MHC/self-peptide complexes do not receive co-stimulation via CD28 and 
subsequently become anergic. The necessity of co-stimulation represents an elegant 
mechanism, with which clonal activation of T cells in response to self-antigens is prevented 
(14). Self-reactive T cells are additionally controlled by the initiation of the 
activation-induced cell death (AICD), which is mediated via the interaction of the death 
receptor Fas (CD95) with its ligand (FasL/CD95L) or via mitochondrial proteins. CD28, 
however, rescues T cells from AICD, posing another way of how co-stimulatory signals are 
utilized to ensure the balance between self-tolerance and efficient pathogen control (15). 
1.3.1 Regulatory CD4+CD25+ cells 
In addition to the mechanisms acting directly on the T cells, T cell extrinsic 
mechanisms also promote peripheral tolerance. In this regard, peripheral lymphocytes 
themselves contribute to self-tolerance. A specific CD4+ cell subset, the CD4+CD25+ 
regulatory T cells (Treg), which express the high affinity IL-2 receptor α-chain (IL-2Rα), also 
referred to as CD25, and forkhead box protein P3 (Foxp3), exert a homeostatic control over 
the immune system. As early as 1970, the existence of suppressive immune cells, which could 
not only promote but also moderate immune responses, was proposed (16). While the 
existence of those suppressive T cells was doubted again during the 1980s, mostly due to the 
lack of specific markers, they once more became the focus of investigation in the 1990s. 
Sakaguchi et al. convincingly showed that a distinct subset of lymphocytes, the CD4+CD25+ 
T cells, was required to maintain self-tolerance in vivo (17). Further it was demonstrated that 
those cells responded in a hypoproliferative manner upon TCR stimulation and effectively 
suppressed CD4+CD25- cells in vitro (18). In contrast to the conventional CD4+ effector T 
cells (Teff), which exhibit an important function in the adaptive immune response by 
activating cytotoxic CD8+ T cells, B cells or macrophages, those regulatory T cells are of 
importance in the control and suppression of immune reactions. Depletion of these cells leads 
to various autoimmune disorders, e.g. inflammatory bowel disease (IBD), autoimmune 
gastritis, autoinflammatory Type 1 diabetes or thyroiditis (17, 19). Nevertheless, Treg also 
have negative effects as they strongly contribute to the pathogen persistence during chronic 
infections and the evasion of tumor cells from the immune control (20, 21). 
The CD4+CD25+ Treg constitute 5-10 % of the CD4+ T cells in the periphery of 
rodents, whereas in humans estimates vary from only 1-2 % to 7-8 % depending on the 
markers used (21, 22). Although Treg constitutively express CD25 and are usually purified 
based on their CD4+CD25+ phenotype, conventional T cells (Tconv) are also known to 
I- Introduction 5 
upregulate CD25 upon activation via their TCR (23–25). Thus, CD25 cannot be used as an 
exclusive and reliable marker for Treg. Yet, an additional and more specific marker, the 
transcription factor Foxp3, which is essential for both the development and the function of 
CD4+CD25+ Treg, was identified (26). A defect in the Foxp3 gene is responsible for the lethal 
over-proliferation of CD4+ cells in scurfy mice (27), while it causes the immune 
dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX) syndrome 
in humans, which is characterized by IBD, allergies and severe autoimmune diseases in 
various organs (28). As Foxp3 promotes the expression of Treg-associated cell surface 
molecules and acts as an initiator of the Treg specific genetic program, it is considered to be 
the master regulator for the phenotype, differentiation and lineage stability of Treg. Further, 
Foxp3 also inhibits the production of the T cell growth factor IL-2 (29) and of other 
proinflammatory cytokines, such as IL-4, IL-17, IL-21, IFN-γ and TNF (30). The expression 
of Foxp3 is specific for murine CD4+CD25+ Treg and is not upregulated upon TCR stimulation 
in naïve T cells (26). In humans however, a fraction of former CD4+CD25- cells gains 
transient FOXP3 expression upon stimulation via their TCR (31, 32). Apart from the 
expression of Foxp3, Treg also share other characteristic markers, e.g. cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), glucocorticoid-inducible tumor necrosis factor receptor 
family-related gene (GITR), and lymphocyte-activated gen 3 (LAG3) (33). Like CD25, both 
CTLA-4 and GITR are constitutively expressed on Treg but also show upregulation on Teff 
upon activation (34, 35). Furthermore, a variety of new markers for Treg has been described, 
e.g. the ectonucleoside triphosphate diphosphorhydrolase-1 CD39, ecto-5-nucleotidase CD73, 
latency-associated peptide, the homing-associated cell adhesion molecule CD44, CD103, 
chemokine receptors such as CCR6, members of the galectin family and the transcription 
factor Helios (36).  
1.3.2 Myeloid-derived suppressor cells 
In addition to regulatory T cells, myeloid-derived suppressor cells (MDSC) also 
represent an important type of immunoregulatory cells that are characterized by the capacity 
to suppress T and NK cell activity. Rather than being a specific subpopulation, MDSC are 
constituted of a heterogeneous group of immature myeloid cells that fail to fully differentiate 
into mature cells during pathological processes. Under physiological conditions, maturation of 
bone marrow (BM) cells into DC, macrophages or mature granulocytes is readily achieved. 
However, in pathologic conditions, such as cancer, microbial infections, chronic inflammation 
and trauma, there is a delay of cell maturation and immature myeloid cells expand, become 
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activated and acquire suppressor function (37). As MDSC suppress T cell activation 
especially in the cancer patients, they contribute to an impaired lymphocyte-mediated 
antitumor immunity and thereby promote tumor progression. Thus, great effort is put into 
finding strategies to decrease the number and suppressor function of MDSC (38). 
In mice, MDSC are defined by the simultaneous surface expression of Gr-1 and 
CD11b. Gr-1 was later identified to be a common epitope of two distinct surface molecules, 
Ly6G and Ly6C. Hence, MDSC can be further divided into two subsets, the granulocytic 
(CD11b+Ly6G+Ly6Clow) and monocytic (CD11b+Ly6G-Ly6Chigh) phenotype (39). Expansion 
and activation of the MDSC is achieved by a variety of factors, i.e. cyclooxigenase-2, 
prostaglandin E2, granulocyte-macrophage colony-stimulating factor (GM-CSF), stem cell 
factor, IL-6, IL-1β and vascular endothelial growth factor (40). In vitro, GM-CSF most 
accurately simulates the in vivo expansion of DC under inflammatory conditions (41). 
Conversely, it has been shown that in vitro stimulation with low-dose GM-CSF can induce 
the generation of suppressive MDSC after eight to ten days, while under high-dose conditions 
only three to four days are required (42). MDSC utilize various mechanisms of suppression, 
which include the upregulation of arginase-1 or of the inducible nitric oxide synthase (iNOS), 
enzymes that both metabolize the amino acid arginine, and increase the production of nitric 
oxide and reactive oxygen species (ROS) (43). Other reports also suggest that suppression is 
mediated via the induction of Treg (44), secretion of transforming growth factor-β (TGF-β) 
(45) or depletion of cysteine (46). 
1.4 Intracellular signalling in effector and regulatory T cells 
1.4.1 Signalling via the TCR in conventional T cells  
As shown in Figure 2 (47), TCR engagement initiates different signalling pathways 
that result in the activation of three major transcription factors that are important for the 
promotion of T cell proliferation and function, i.e. nuclear factor of activated T cell (NFAT), 
nuclear factor kappa B (NF-κB) and the activator protein-1 (AP-1) (48). Following the 
activation of the TCR, tyrosine residues in immunoreceptor tyrosine-based activation motifs 
(ITAMs), located in the TCR-associated CD3-chains, are phosphorylated by Src family 
kinases Lck and Fin, resulting in the binding of ζ-chain-associated protein of 70kDA 
(ZAP70). After being recruited to the receptor complex, ZAP70 is activated through 
phosphorylation by Lck or via autophosphorylation. Active pZAP70 in turn phosphorylates 
the adapter molecules linker for activation of T cells (LAT) and SH2-domain-containing 
leucocyte phosphoprotein of 76kDa (SLP-76) (49, 50). This leads to the recruitment of 
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downstream signalling factors and the activation of the phospholipase C-γ1 (PLCγ1) pathway, 
which is necessary for the activation of both NFAT and NF-κB. PLCγ1 splits 
phosphatidylinositol 4,5-biphosphate (PIP2) into diacylglycerol (DAG) and inositol 
1,4,5-triphosphate (IP3). IP3 increases calcium (Ca2+) release from the endoplasmatic 
reticulum and the extracellular space into the cytosol. Ca2+ binds calmodulin, which activates 
the phosphatase calcineurin (51). Activated calcineurin dephosphorylates NFAT, enabling it 
to translocate into the nucleus, where it acts as a transcriptional activator for various 
cytokines, e.g. IL-2, IL-4, IL-5, IFN-γ and TNF (52). Although NFAT alone is sufficient to 
promote transcription, it can also form complexes with other transcription factors. As such, 
the NFAT:AP-1 complex binds to specific sites at the DNA enhancing the transcription of the 
aforementioned cytokines (47). Further, the PLCγ1-induced generation of DAG is necessary 
for the induction of the NF-κB signalling pathway. In resting cells, NF-κB is associated with 
the inhibitor of κB (IκB) in the cytoplasm, which impedes the translocalization of NF-κB into 
the nucleus. DAG activates protein kinase C-θ (PKC-θ), which facilitates CARMA-1, 
BCL-10 and MALT to form a complex, allowing them to phosphorylate and thus activate the 
IκB kinase (IKK) complex. The activated IKK complex then in turn phosphorylates IκB, 
resulting in its polyubiquinitation and proteosomal degradation. Upon dissociation from its 
cytosolic inhibitor NF-κB is able to translocate into the nucleus and act as a transcriptional 
activator (47, 53). The third signalling pathway, the mitogen activated protein kinase (MAPK) 
cascade, leads to the activation of the transcription factor AP-1. The activation of various 
MAPKs, such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) 
and p38 kinase, is triggered by DAG and eventually results in the expression and activation of 
c-Fos and c-Jun, which together form AP-1 (47).  
In order to be fully activated, T cells do not only require stimulation via their TCR but 
also through co-stimulatory receptors, which enhance the calcium influx and activation of 
NFAT, NF-κB or AP-1 respectively. For instance, the CD28-CD80/CD86 interaction leads to 
an increased cytoplasmic Ca2+ concentration via a phosphatidylinositol 3-kinase 
(PI3K)-mediated PLCγ1 activation and is also necessary for DAG/PKC-θ-induced NF-κB 
activation (52). Moreover, via the CD28-induced PI3K pathway phosphatidylinositol 
3,4,5-triphosphate (PIP3) is generated, activating downstream targets such as mammalian 
target of rapamycin (mTOR) and the serine-threonin kinase (Akt), which are inductors of a 
variety of genes related to cell survival and proliferation (54). 
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Figure 2: T cell receptor signalling pathways. Three main transcription factors, i.e. AP-1, 
NFAT and NF-κB are induced upon engagement to the TCR. The activation of the MAPK 
pathway leads to AP-1 activation. The PKCθ-induced proteosomal degradation of IκB and 
increase in Ca2+ levels promote the NF-κB up-modulation. Ca2+-dependent activation of 
calcineurin induces the nuclear translocation of NFAT (figure from Schmidt et al., 2012, p.8 
(47)). 
1.4.2 Signalling via the TCR in Treg 
In order to become suppressive, Treg themselves need to be stimulated via their TCR 
initially. Once activated, they can readily suppress Teff in an antigen-nonspecific manner (55). 
However, Treg remain in a hyporesponsive and anergic state when activated via their TCR in 
vitro (17, 56). Only a combination of high amounts of IL-2 and optimal TCR signalling can 
break this anergy (56, 57). Furthermore, the antigen concentrations, which are required for 
Treg stimulation, are much lower in comparison to concentrations needed for Teff activation 
(18). Thus, it must be expected that there are differences in TCR signal pathways between 
CD4+CD25+ Treg and CD4+CD25- Teff. It has been proposed that the proximal signalling in 
Treg is altered compared to Tconv. It was shown that the phosphorylation of ITAMs in the 
TCR-CD3 complex was lower, which resulted in the inability of ZAP70 to bind to the CD3ζ 
chain and in an attenuated activation of SLP-76, a key substrate of ZAP70. As a consequence, 
VAV, a molecule essential for actin remodelling, was not recruited and the formation of an 
actin cytoskeleton, which normally facilitates the accumulation of various signalling 
molecules, was perturbed leading to a suboptimal functioning of the immunological synapse 
between APC and T cells (58). A reduction of activated ERK upon TCR stimulation on Treg 
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was also shown, indicating that the activation of MAPK pathway is inhibited (57, 58). Others 
have reported impairment of Akt activation upon CD3/CD28 co-stimulation (59). Further 
studies have demonstrated that the activity of PLCγ1 is markedly reduced in Treg upon TCR 
stimulation, especially in the presence of co-stimulatory signals via CD28. As PLCγ1 
catalyses the generation of DAG and IP3, those second messengers are also diminished in Treg 
cells. Lack of DAG results in a lower level of activation of the MAPK/AP-1 and 
PKCθ/NF-κB pathways, which contributes to the inability of Treg to produce IL-2 upon 
activation via their TCR (60). Deficiency of IP3 leads to a decreased Ca
2+ influx, hindering the 
activation of calcineurin and thus the dephosphorylation of NFAT, which subsequently limits 
the nuclear translocation of NFAT (60, 61). 
In addition, Foxp3 has been shown to modulate the function of different transcription 
factors. For example, Foxp3 binds to the DNA in a complex with NFAT, outcompeting 
NFAT:AP-1 complexes at binding sites for NFAT-target genes such as IL-2, IL-4 or CTLA-4 
(62, 63). Furthermore, Foxp3 forms a complex with the runt-related transcription factor 1 
(Runx1), which together with the co-factor Core-binding factor β (Cbf-β) binds to the 
promoters of Il2 and Ifng. This not only impedes the production of IL-2 and IFN-γ but also 
promotes anergy and suppressor function of Treg cells (64). Further, the Foxp3-Runx1-Cbf-β 
complex enhances Foxp3 expression and thus plays a crucial role in maintaining Treg stability 
(65). Foxp3 also inhibits the transcription of NF-κB-mediated proinflammatory genes through 
direct interaction with NF-κB (66). 
1.4.3 Signalling via the TCR in Tconv under Treg-mediated suppression  
Several studies have revealed alterations in the TCR signalling in Tconv under 
suppression. Although there is no alteration in proximal signalling in the course of 
suppression, the activation and nuclear translocation of NF-κB and NFAT is attenuated 
(48, 67). Upon encounter with Treg, Tconv fail to deplete their intracellular Ca2+ stores. As 
calcineurin activity and IKK degradation are dependent on Ca2+, Ca2+ is crucial for the 
activation of NFAT and NF-κB, whereas the activation of AP-1 is mostly Ca2+-independent 
(47, 48).  
1.4.4 Signalling via the IL-2 receptor in Tconv 
IL-2 is an immunoregulatory cytokine, which together with IL-4, IL-7, IL-9 IL-15 and 
IL-21 belongs to the common γ-chain (γc) cytokine family. Next to its importance for the 
proliferation and survival of activated T cells, IL-2 also is also required for Treg development, 
peripheral maintenance and function (13, 68). The IL-2 receptor consists of three subunits: 
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IL-2Rα (CD25), IL-2Rβ (CD122) and the common γc (CD132). The β- and γ-chains together 
only have an intermediate affinity, while combination with the α subunit leads to the 
formation of the high affinity IL-2R. Upon ligation by IL-2, the IL-2Rβ and IL-2Rγ chains 
heterodimerize and the tyrosine kinases Janus kinase 1 (JAK1) and JAK 3 are activated, 
leading to the phosphorylation of tyrosine residues in the IL-2R chains. Subsequently, adaptor 
proteins are recruited, which, as shown in Figure 3 (69), activate the MAPK and PI3K 
pathways, as well as the signal transducer and activator of transcription 5 (Stat5) (13, 70). 
Stat5 forms dimers and directly translocates into the nucleus where it positively regulates 
various cell cycle proteins and, importantly, also upregulates the IL2ra transcription (71). 
Thus, the expression of CD25 on T cells is increased upon stimulation with IL-2 (72). The 
initiation of the MAPK pathway eventually leads to the activation of the transcription factor 
AP-1 (71). Similar to CD28, signalling via IL2R also activates the PI3K pathway resulting in 
the activation of downstream targets such as Akt and mTOR (73). Thus, via Stat5, PI3K and 
MAPK IL-2 promotes cell cycle progression, survival and growth in T cells. 
© 2004 Nature Publishing Group
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R E V I EW S
these mice, lymphoproliferation and lethal autoimmu-
nity are prevented, and the mice are competent to mount
m stly normal T-cell-dependent immune responses.
Recently, the role of IL-2 in vivo has become clearer,
so this review reassesses the contribution of IL-2 to the
immune system by contrasting the requirement for IL-2
in tolerance and immunity. We discuss recent studies
that indicate that the main non-redundant role of IL-2 is
the production of TReg cells. Then, we focus on the role of
IL-2 in T-cell immune responses in vitro and in vivo,
including discussion of a model that attempts to reconcile
why IL-2 is important for in vitro responses but is dis-
pensable for effective immunity in vivo. The implications
of these findings for the immunotherapeutic targeting of
IL-2 and/or the IL-2R are also considered.
IL-2 is essential for TReg cells
TReg cells are a minor subpopulation of T cells that
develop in the thymus and migrate to the periphery,
where their main role is to suppress self-reactive T cells
that escape negative selection in the thymus15,16. TReg cells
not only prevent autoimmunity but also control a broad
range of T-cell-dependent immune responses in vivo17.
So, TReg cells also inhibit the rejection of transplants, pre-
vent the induction of antitumour responses and regulate
the immune response to infectious diseases. Although
much remains to be learned about the basis of TReg-cell
generation, specificity and inhibitory activity, there is
increasing evidence that points to a mandatory role for
IL-2–IL-2R signalling in the development and peripheral
activity of TReg cells (BOX 1).
Role of IL-2 in TReg-cell generation. TReg cells not only
express IL-2Rα but also IL-2Rβ and the γc: that is, all of
the subunits that are required to express a functional
high-affinity IL-2R18. However, TReg cells do not secrete
IL-2 (REFS 19,20), so they depend on PARACRINE IL-2 for any
responsiveness to this cytokine. The number of TReg cells
is markedly reduced in Il-2–/–, Il-2rα–/– and Il-2rβ–/–
mice18,19,21, and their absence correlates with the develop-
ment of autoimmune disease. Treatment of Il-2–/– mice
with IL-2, starting 5 days after birth, averted the activated
phenotype that is usually displayed by their T cells and
the symptoms of autoimmunity that are characteristic of
IL-2 deficiency22. Although this experiment did not dis-
tinguish whether IL-2 corrected an intrinsic T-cell defect
in autoreactive T cells or affected regulatory T cells, the
adoptive transfer of a large number of splenic or thymic
cells from these IL-2-treated Il-2–/– mice to neonatal
Il-2–/– mice delayed the onset of autoimmunity in some
recipients, hinting that regulatory cells might be present
among the cells isolated from IL-2-treated animals.
A subsequent study, however, using either mixed
bone-marrow or T-cell chimeric mice consisting of
wild-type and Il-2rβ–/– cells showed that wild-type cells
control the dysregulated behaviour that Il-2rβ–/– T cells
have when present alone23. In these experiments, IL-2
from the wild-type cells cannot act on the Il-2rβ –/–
T cells, providing strong support for the hypothesis that
this effect was due to the presence of a regulatory cell
among the wild-type donor cells. Other studies showed
PARACRINE
The production of a soluble
effector that functions on target
cells that are distinct from the
cell that produced it.
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Figure 1 | IL-2 receptor signalling. a | The high-affinity
interleukin-2 receptor (IL-2R) consists of three subunits: the 
α-chain of the IL-2R (IL-2Rα; also known as CD25), the 
β-chain of the IL-2R (IL-2Rβ; also known as CD122) and 
the common cytokine-receptor γ-chain (γc; also known as
CD132). It is thought that in the absence of IL-2, these
subunits are not pre-assembled on the surface of an IL-2R-
expressing T cell. b | The binding of IL-2 to IL-2Rα drives the
association of this subunit with IL-2Rβ and the γc to form a
stable heterotrimer, which then leads to the initiation of signal
transduction. Janus activated kinase 3 (JAK3) molecules that
are associated with the γc, and JAK1 molecules that are
associated with IL-2Rβ, phosphorylate key tyrosine residues 
in the cytoplasmic tail of IL-2Rβ, the γc and the JAK molecules
themselves. This amplifies the association of these tyrosine
kinases and induces the association of the adaptor SHC
(SRC-homology-2-domain-containing transforming protein C),
and either signal transducer and activator of transcription 5
(STAT5) or STAT3, with the cytoplasmic tail of IL-2Rβ. The
complexed SHC allows activation of the mitogen-activated
protein kinase (MAPK)- and phosphatidylinositol 3-kinase
(PI3K)–AKT-signalling pathways. Tyrosine residues in STAT5
are also phosphorylated, leading to the dimerization of STAT5
and its translocation to the nucleus where it regulates STAT5-
responsive genes. GRB2, growth-factor-receptor-bound
protein 2; SOS, son of sevenless homologue.
 
Figure 3: IL-2 eceptor signalling in T cells. IL-2 induces three major signalling cascades in 
T cells, i.e. the MAPK, the PI3K/AKT a  the STAT5 pathway. Following th  stimulation of 
the high affinity IL-2R complex, the JAK1 and JAK3 are activated, which in turn leads to the 
phosphorylation of tyrosine residues in the receptor chai s and JAK molecules them elves. 
This indu es the recruitment of STAT5 and SHC (SRC-homology-2-domain-containing 
transforming protein C). SHC mediates the activation of the PI3K/AKT and MAPK pathways. 
STAT5 is also phosphorylated at certain tyrosine residues, which allows it to dimerize and 
translocate into the nucleus. Together these transcri tion factors prom te T cell proliferation 
and function (figur  from Malek t al., 2004, p.666 (69)). 
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1.4.5 Signalling via the IL-2 receptor in Treg 
As Foxp3 induces the downregulation of IL-2 production, Treg are highly dependent on 
paracrine IL-2 for their survival and expansion (13, 26, 29). Yet, Treg remain hyporesponsive 
upon IL-2 stimulation in spite of constitutively expressing the high affinity IL-2R (56). 
Although IL-2 is important for the survival of both Tconv and Treg, it does not promote 
proliferation of Treg suggesting that the intracellular signals induced by IL-2 must differ 
between both cell lines (74). Strikingly, while the activation of the Stat5 pathway remains 
intact, the PI3K/Akt pathway is not activated in Treg. Stat5 is responsible for the upregulation 
of cell cycle-associated and anti-apoptotic proteins, thus enhancing both cell cycle 
progression and survival in Treg (74). Further, Stat5 induces the upregulation of Foxp3 and the 
IL-2Rα (75, 76). Foxp3 in turn enhances the expression of the IL-2Rα but also inhibits IL-2 
production. Thus, via the IL-2-dependent Stat5 activation the characteristic Treg phenotype is 
maintained (77). Signalling via the PI3K/Akt pathway, however, is impaired in Treg due to the 
strong expression of the phosphatase and tensin homolog (PTEN) that negatively regulates 
PI3K signalling (74, 78). Downstream targets of PI3K, such as Akt, mTOR and cell cycle 
regulators, are therefore inactive in Treg, explaining the hypoproliferative response towards 
IL-2 stimulation (74). Yet, when Treg encounter a combination of TCR and high dose IL-2 
stimuli, they break their anergic state (56, 79). At least in part this can be explained by the 
TCR-induced inactivation of PTEN, which results in the reactivation of the PI3K pathway and 
restoral of IL-2R signalling (74).  
1.5 Development of regulatory T cells 
1.5.1 Thymic development 
T cells develop in the thymus by passing through a positive and negative selection. 
During the positive selection double positive cells expressing both CD4 and CD8 are rescued 
from apoptosis if their TCR recognizes MHC expressed on thymic DC. If a double positive 
cell associates with MHC II, it will become a single positive (SP) CD4+ cell; recognizing 
MHC I, however, leads to the development of SP CD8+ cells. During negative selection, SP 
cells are eliminated if they bind to MHC that present self-peptides with high affinities (80). In 
addition to CD4+ and CD8+ cells, 90 % of Treg also develop in the thymus (77). Thus, those 
natural Treg (nTreg) constitute a separate thymus-derived population of T cells, which unlike 
other CD4+ T cell subsets do not differentiate from Tconv in the periphery. In the course of 
thymic differentiation, Treg require TCR-MHC engagement (62). Because thymocytes are 
normally eliminated when they recognize self-peptides, Treg must somehow evade the 
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negative selection. The current understanding of thymic Treg selection is based on the 
assumption that the TCR affinity is crucial for the fate of the developing thymocytes. 
Initiation of Treg differentiation requires an intermediate affinity of their TCR towards 
self-peptides presented by MHC, while lower TCR signal strength towards self-antigens 
results in the positive selection of Tconv and stronger signals lead to programmed cell death of 
self-reacting precursor T cells (14, 81). Further, several lines of evidence have shown that the 
development of Treg cells is a two-step process. According to this model, stimulation of 
developing Treg via TCR/CD28 leads to the generation of CD25+Foxp3- precursor cells, which 
strongly upregulate CD25 and thus show a high responsiveness towards paracrine IL-2. In a 
second TCR-independent step cytokines sharing the common γc, mainly IL-2, induce those 
precursor cells to completely differentiate into Treg (82, 83). Stimulation with IL-2 leads to 
phosphorylation and activation of Stat5, which in turn binds to the Foxp3 promoter and thus 
induces Foxp3 transcription (84). Nevertheless, the exact molecular mechanism of how Treg 
differentiation is initiated is still controversial. It has been found that in response to 
TCR/CD28 signalling the transcription factor c-Rel, a NF-κB family member, initiates Treg 
development in the thymus through epigenetic changes (85–87). The Foxp3 locus contains 
three evolutionary conserved non-coding sequences (CNS) with binding sites for a variety of 
transcription factors that function as Foxp3 enhancers, out of which CNS3 within the intronic 
region of Foxp3 is thought to be essential for the induction of Foxp3 expression during 
thymic Treg development (88). CNS3 is bound by c-Rel, which facilitates the demethylation of 
a CpG-rich island located within this site. Thereby, the chromatin structure is opened up and 
hence made more accessible for other transcription factors (88, 89).  
1.5.2 Peripheral differentiation  
Treg do not only derive from the thymus, but are also induced in the periphery. As the 
organism is chronically exposed to antigens even under non-inflammatory conditions, by 
encountering commensal bacteria, food and allergens for instance, the generation of Treg with 
TCR specific for those antigens is indispensable for the prevention of overshooting immune 
responses against non-pathogenic antigens. The inducible Treg (iTreg) therefore pose a key 
factor for the maintenance of peripheral tolerance (81, 90). Unlike thymus-derived nTreg, 
whose TCR repertoire shows specificity for self-antigens, the TCR expressed by iTreg 
recognize antigens the organism is constitutively exposed to. As an essential factor, TGF-β 
promotes iTreg differentiation upon antigenic stimulation of naïve CD4+ (91, 92). Smad3, a 
downstream effector molecule of the TGF-β signalling pathway, binds to a conserved region 
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within the Foxp3 promoter, the CNS1, modifies the acetylation of histones and subsequently 
regulates the transcription of Foxp3 (93). Moreover, IL-2 is also required for the peripheral 
transformation (94). During TGF-β-mediated iTreg induction, TGF-β downmodulates SOCS3, 
an inhibitor of the Stat5. IL-2-induced Stat5 in turn binds to CNS2, which harbours a CpG 
island, the so-called Treg-specific demethylation region (TSDR), whose methylation status is 
associated with the stability of Foxp3 expression (88). Because Stat5 binds CNS2 
independently of its methylation status, it is thought to contribute to the opening of this 
enhancer region. CNS2 is then bound by other transcription factors in a 
demethylation-dependent manner that are important for Treg function and Foxp3 expression 
(95–97). Additionally, retinoic acid released by specialized CD103+ DC in the gut can further 
facilitate the generation of iTreg (98). The gut-associated lymphoid tissue and mesenteric 
lymph nodes are sites of high prevalence of iTreg, since those sites serve as environmental 
interfaces where the immune system is in constant contact with commensal bacteria, food and 
environmental antigens (99). Underlining the importance of different factors contributing to 
the peripheral iTreg development is the notion that only together they can promote proper iTreg 
induction and inhibit differentiation into effector T cells. TGF-β induces the expression of 
Foxp3 but also RORγt, which is an essential transcription factor for the differentiation of 
naïve T cells into Th17 cells. The transcription of Foxp3 is favoured in the presence of IL-2 or 
retinoic acid. Foxp3 then directly interacts with RORγt and thus inhibits the generation of 
Th17 cells (100). Stimulation with TGF-β and IL-6, a cytokine that is released during the 
course of inflammation, on the other hand, results in the preferential generation of Th17 cells 
that can potentially promote autoimmunity through induction of tissue inflammation 
(101-103).  
1.6 Mechanisms of regulatory T cells  
Although Treg have been in the centre of attention for a long time, still little is known 
about the exact mechanisms that are used by Treg to suppress immune responses. Currently, as 
shown in Figure 4 (47), three major mechanisms are thought to be essential for the suppressor 
function exerted by Treg: cell-contact dependent suppression of T cells and APC, deprivation 
of growth factors and release of immunosuppressive mediators. 
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Schmidt et al. Signaling in Treg-suppressedT cells
FIGURE 1 | Mechanisms ofTreg-mediatedTcon suppression.Tregs have
been described to suppressTcons by different mechanisms, depending on
the experimental setup, site and type of immune response. Tregs can
generate immunosuppressive adenosine or transfer cAMP toTcons.Tregs can
rapidly suppressTCR-induced Ca2+, NFAT, and NF-κB signaling. Tregs can also
produce immunosuppressive cytokines (IL-10, TGF-β, IL-35), and they can
suppress by IL-2 consumption or induce effector cell death via granzyme and
perforin. Furthermore, Tregs can suppressTcons indirectly by downregulating
costimulatory molecules on APCs (such as DCs) via CTLA-4. Details are
described in the text.
1997), transduction of negative signals that induce cell cycle arrest
and prevent IL-2 secretion (Krummel and Allison, 1996; Walunas
et al., 1996), and limiting T cell contact with APCs (Schneider
et al., 2006). Recently, the molecular mechanism of Treg-mediated
suppression via CTLA-4 was elucidated in more detail. Downreg-
ulation of CD80/CD86 expression on APCs by Tregs (Cederbom
et al., 2000) was shown to be partly dependent on CTLA-4 and
the adhesion molecule LFA-1, thereby indirectly inhibiting Tcon
activation by APCs in vitro (Oderup et al., 2006; Onishi et al.,
2008) and in vivo (Wing et al., 2008). Mechanistically, downreg-
ulation of CD80/CD86 on target cells by CTLA-4-expressing cells
can involve capture of these ligands by CTLA-4, a process called
trans-endocytosis (Qureshi et al., 2011). Another study supports
the importance of CTLA-4 in in vivo suppression without direct
effects on the responder T cells (Friedline et al., 2009). Strikingly,
micewithTreg-specific ablationof CTLA-4 spontaneously develop
fatal autoimmune disease (Wing et al., 2008), underlining the
importance of CTLA-4 expression on Tregs for the maintenance
of peripheral tolerance.
In contrast to the studies showing necessity of CTLA-4 for Treg-
mediated suppression,Tran et al. (2009) applied amixed coculture
systemwithmurine andhumancells and showed that humanTregs
can suppress proliferation of murine Tcons by targeting murine
DCs through LFA-1:ICAM-1 interaction between Tregs and DCs.
Suppression was only evident in the presence of APCs, and it was
not abrogated when human CTLA-4 was blocked. Interestingly,
murine Tregs could not suppress human Tcons in the presence of
human APCs. These results argue for species-specific differences
in suppressive molecules, especially regarding CTLA-4.
Certain human and murine DC subsets express the enzyme
indoleamine 2,3-dioxygenase (IDO) that catalyzes degradation
of tryptophan to kynurenine, leading to starvation of effector T
cells and also to direct cell cycle arrest. At the same time, IDO
leads to iTreg generation (Fallarino et al., 2003, 2006; Curti et al.,
2007). Tregs themselves can, via CTLA-4-induced signaling, fur-
ther increase IDO expression in DCs. Additionally it was shown
that murine Tregs diminish glutathione synthesis in DCs, pre-
sumably CTLA-4-mediated, which leads to a redox environment
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Figure 4: Mechanis s of Treg-mediated suppression. Treg-mediated suppression is thought 
to be due to thr e major mecha ism . (A) Treg cells can mediate suppression of Tconv through 
cell-contact dependent mechanisms: The induction of apoptosis in neighbouring cells via 
granzymes and perforines, the increase of cAMP in Tconv through the transfer via gap 
junctions, the reduction f cyt solic Ca2+ concentration in Tconv leading to direct suppression 
of important transcription factors, such s NFAT and NF-κB. Moreover, Treg can inhibit APC 
function through the CTLA-mediated downregulat on o  the co-stimulatory molecules 
CD80/CD86 and through inc easing intracellula  cAMP in ose cells via gap junctions. (B) T 
cell suppres ion can be induced through preferential consumption of IL-2, thereby depriving 
Tconv of a cytokine important for cell prolifer tion. (C) S ppression can be also mediated 
through the release of soluble factors: The secretion of immunomodulatory cytokines such as 
IL-10, IL-35 and TGF-β or the generation of adenosine via CD73 and CD39, which can 
further enhance cytosolic cAMP levels in Teff (figure from Schmidt et al., 2012, p.8 (47)). 
1.6.1 Cell-contact dependent suppression 
1.6.1.1 CTLA-4: An immunosuppressive receptor 
CTLA-4 is a membrane receptor on T cells that binds to the co-stimulatory surface 
molecules CD80/CD86 in competition with CD28 (104). It is constitutively expressed only on 
CD4+CD25+ T cells, but not on CD4+CD25- T cells (33). Upon activation, however, the 
expression of CTLA-4 is upregulated on both Treg and Teff (105). CTLA-4 is an 
immunosuppressive molecule, which is important for the prevention of systemic 
autoimmunity (106). Several mechanisms of CTLA-4-mediated suppression are described. 
CTLA-4 is thought to inhibit CD28 co-stimulation by outcompeting CD28 for the binding to 
the shared ligands CD80/CD86 as it shows much higher affinity towards those ligands than 
CD28 (107). It also appears to directly suppress T cell proliferation and cytokine production 
through negative signalling into these cells (108). Yet, CTLA-4 is important for Treg 
suppressive function as well, which is shown by the notion that CTLA-4-deficiency in Treg 
results in a diminished suppressive capacity and severe autoimmune disorders (109). CTLA-4 
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expressed on Treg induces the production of indoleamine 2,3-dioxygenase (IDO) by APC, 
which, being a tryptophan-catabolizing enzyme, depletes T cells of this essential amino acid 
resulting in the inhibition of T cell proliferation (110). Furthermore, it has been described 
recently that the expression of CD80/CD86 on APC is reduced due to trans-endocytosis of 
CD86 into CTLA-4 expressing Treg, which limits the number of available ligands for CD28 
and thus attenuates CD28-induced co-stimulation (111, 112). CTLA-4 also induces an 
increased motility of Tconv cells, which shortens the contact time with APC. Treg, however, are 
resilient to CTLA-4-induced motility and are, thereby, able to outcompete Tconv over the 
binding to APC. Thus, the effector cells receive less co-stimulatory signals and Treg can 
further downregulate the expression of CD80/CD86 (113).  
1.6.1.2 LAG-3: In competition with CD4  
LAG3, a CD4 homologue, binds to MHC II on APC in competition with CD4. It is 
expressed on activated Teff and Treg, but shows a more stable and enhanced expression on the 
latter and has been found to play an important role in Treg-mediated suppression (114). Upon 
ligation with MHC II it suppresses the maturation and activity of APC, presumably through 
reverse signalling via MHC II (115). As MHC II molecules are expressed by a variety of 
immune cells, e.g. DC, B cells, monocytes, and macrophages, the inhibition through MHC II 
is antigen-independent and therefore explains how Treg can suppress immune responses in an 
antigen non-specific manner.  
1.6.1.3 Granzyme and perforin: Induction of Apoptosis 
Inducing apoptosis is another mechanism of suppression. Human nTreg mediate 
immune regulation via granzyme A and perforin, whereas iTreg conduct cytotoxicity in a 
granzyme B- and perforin-dependent manner (116). Murine Treg, on the other hand, only 
require granzyme B, but not perforin, to efficiently suppress a variety of immune cells (117). 
Granzymes are serine proteases that cleave caspases in their target cells and thus lead to 
apoptosis. Cytotoxic NK or CD8+ cells usually utilize granzyme- and perforin-mediated 
apoptosis to kill virus-infected or tumor cells. On the other hand, tumor cells induce the 
expression of granzyme B in Treg, enhancing the Treg-induced suppression of immune cells in 
the tumor environment and thereby inhibit efficient tumor cell clearing (118).  
1.6.1.4 cAMP: An immunosuppressive secondary messenger 
As a secondary messenger, cyclic AMP (cAMP) can lead to various intracellular 
responses and can mediate a great diversity of cellular functions. In the immune systems, one 
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important role of cAMP is to limit T cell proliferation, differentiation and cytokine production 
(119). In the course of Treg-mediated suppression Teff experience an increase in intracellular 
cAMP, resulting in an enhanced nuclear translocation of the inducible cAMP early repressor 
(ICER), which acts a potent suppressor of genes such as IL-2, TNF, IL-4 and IL-13 (120). 
Moreover, cAMP also augments the expression of the immunosuppressive receptor CTLA-4 
on T cells (121, 122). Underlining the importance of cell contact in the course of suppression, 
it has been shown that Treg promote cAMP upregulation in suppressed T cells via gap 
junctions (123). In addition to the effects cAMP exhibits in suppressed T cells, it also conveys 
negative signals into DC through the transfer via gap junctions. Accumulation of cAMP in the 
cytosol of DC results in the downregulation of co-stimulatory molecules, such as CD80/CD86 
and MHCII (124).  
1.6.2 Deprivation of IL2 
Treg constitutively express the high affinity IL-2R and their survival is strongly 
dependent one paracrine IL-2 (29, 77, 125). Because they are not capable of producing IL-2 
themselves, it has been suggested that the competition over IL-2 between Treg and Teff is a key 
mechanism of suppression (126–128). Teff deprived of the IL-2 stimulus cannot undergo 
proliferation or differentiation and enter apoptosis (128). Yet, this seems inconsistent with the 
observation that close proximity is required for suppression (56). Nevertheless, the effects of 
cytokines are restricted to a microenvironment around the cells, which can also be disturbed 
by physically separation (129). However, it has been repeatedly demonstrated that instead of 
IL-2 consumption Treg rather mediate suppression by abolishing IL-2 production in 
suppressed Tconv (18, 21, 56, 130). A possible explanation for the controversial results is that 
the consumption of IL-2 might only be important in physiological situations when Treg exert 
control over immune homeostasis. In the course of inflammation, however, IL-2 production is 
enhanced and those high amounts of IL-2 can overcome the suppressive capacity of Treg (18, 
21, 127, 128). Through the inhibition of Treg-mediated suppressor function an efficient 
immune response against the invading pathogens is enabled and other mechanisms of Treg 
suppression may be favoured.  
1.6.3 Soluble Mediators of Suppression 
1.6.3.1 Secretion of IL-10, TGF-β and IL-35 
Although the suppressor activity of Treg seems to be cell-contact dependent and 
cytokine-independent in in vitro studies (18, 56, 131), immunosuppressive cytokines such as 
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IL-10 and TGF-β may at least play a supportive role in suppressing immune cells in vivo 
(132–135). IL-10 is known to be an anti-inflammatory cytokine and has long been viewed as 
a key cytokine for Treg suppression. IL-10 represses the production of proinflammatory 
cytokines, such as IL-1, TNF, IL-12 and IFN-γ, and also downregulates the expression of 
MHCII and CD80/CD86 on APC (136, 137). IL-10 can directly suppress the proliferation of 
T cells as well as indirectly through the inhibition of IL-2 production by activated T cells 
(138). While IL-10 does not seem to be necessary for overall repression of immune responses, 
it is important for the control over intestinal inflammation (132, 139, 140). The IL-10-
producing CD4+Foxp3+ Treg are necessary in the prevention of excessive inflammation in 
tissues that constitute natural barriers towards the environment, i.e. the skin, the colon or 
airways (134). Furthermore, IL-10 itself can initiate differentiation of T cells into IL-10-
producing regulatory cells or induce IL-10 expression in preformed Treg (141–143). Another 
soluble molecule that is often associated with Treg-mediated suppression is TGF-β. However, 
it remains to be elucidated, if TGF-β is solely necessary for the peripheral induction and 
maintenance of Treg or if it contributes to Treg suppressor function (144). There is controversial 
data regarding this, but it appears that TGF-β is at least partially responsible for the 
suppressive effects on Teff cells (135, 145, 146). TGF-β especially seems to be essential for 
the Treg-mediated suppression of tumor specific cytotoxic CD8+ and NK cells (147, 148). A 
novel interleukin, IL-35, which is a heterodimer consisting of the Epstein-Barr-virus induced 
gene 3 (Ebi3) and IL-12α, was found to be preferentially produced by murine Treg and appears 
to be essential for maximal Treg-mediated inhibitory activity (149). Yet, in human FOXP3+ 
Treg expression or upregulation of IL-35 upon activation could not be demonstrated, whereas 
activated Teff showed elevated levels of both Ebi3 and IL-12α (150). Other data, however, 
showed that during the course of Treg-mediated suppression, IL-35 converts both human and 
murine Tconv into inducible Treg that produce IL-35. Those cells acquire a hyporesponsive 
phenotype and are highly suppressive, although they do not upregulate the expression of 
Foxp3 (151).  
Those anti-inflammatory cytokines appear to be important especially after the acute 
phase of inflammation, when Treg have to regain their suppressor function in order to protect 
the host from exaggerated immune responses that would be resulting in tissue damage and/or 
auto-immunological diseases. As Treg upregulate the production of IL-10, TGF-β and IL-35 
during highly inflammatory states they cannot only inhibit Teff directly, but also induce 
conversion of Tconv into suppressing T cells. Through this positive feedback loop, Treg 
themselves contribute to the expansion of regulatory cells that release anti-inflammatory 
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cytokines in situations when the immune system is strongly activated and is posing a potential 
threat to the healthy tissue (143, 151–153).  
1.6.3.2 Production of adenosine 
In addition to the transfer of cAMP via gap junctions, cAMP levels are also increased 
by adenosine, which induces a de novo synthesis of cAMP in suppressed Teff (154). Treg 
highly express CD39 and CD73, two ectonucleotidases that hydrolyse adenosine triphosphate 
(ATP) into adenosine (155–157). Expression of CD39 and CD73 is not limited to the Treg 
subset, since those surface molecules are expressed by a large amount of different cells. The 
highest proportions of CD39+ cells among lymphocytes are found in the B220+ B cell 
compartment, but also Langerhans cells, NK cells or macrophages express CD39 (155, 157). 
Teff do not constantly express CD39, but also upregulate it upon activation (158). CD73 is 
found on a variety of cells, such as DC, epithelial cells or fibroblasts (159). In the T cell 
compartment, however, only CD4+Foxp3+ Treg show coexpression of CD39 and CD73 (155). 
As ATP induces various proinflammatory responses, e.g. release of IL-1β by monocytes, 
maturation of DC, enhanced IL-2 production and proliferation of T cells, the sole degradation 
of ATP into adenosine can account for the anti-inflammatory effects of the ATP-hydrolysing 
enzymes (158, 160). Adenosine, however, is also a well-known anti-inflammatory agent 
(161–163). Regarding the T cell compartment, adenosine preferably mediates 
immunosuppressive effects via the A2A receptor (A2AR), which is expressed constitutively on 
Treg and on activated Teff (155, 164). In Teff, adenosine enhances cytosolic cAMP leading to an 
impaired cell proliferation and a reduced production of proinflammatory cytokines, such as 
IFN-γ, IL-2 and TNF (154, 156, 164). Moreover, adenosine indirectly inhibits T cell function, 
as it limits cytokine production by APC and their maturation (165). Signalling via A2AR on 
Treg, on the other hand, results in their expansion and increase of suppressor capacity. 
Strikingly, the adenosine receptor is upregulated only in the late phase of the immune 
response. At this stage the concentration of ATP is the highest due to cell destruction and 
hypoxia, which in turn can lead to an increase in local adenosine (155). By limiting only the 
late phase of immune activation, adenosine-mediated suppression of effector cells, therefore, 
might pose an elegant mechanism to balance out pathogen control and protection against 
tissue damaging immune responses. 
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1.7 Potential modulation of immunosuppression by TNF 
1.7.1 TNF: a cytokine with multiple function 
TNF is a pleiotropic cytokine that was first described in 1975 as a glycoprotein, which 
was released by macrophages in response to endotoxin and which showed necrotic effects on 
tumor cells (166). Initially it was suggested that TNF could be beneficial as an anti-tumor 
therapy, but efforts of using TNF to target cancer cells were detained due to the strong side 
effects caused by its systemic administration and the observation that TNF also plays a role in 
the genesis of certain tumors (166, 167). In addition to its necrotic effects on cancer cells, 
TNF is a key mediator in inflammatory processes and plays a role in the induction of fever, 
septic shock, infection-driven coagulation, cell proliferation and differentiation (167, 168). 
Moreover, TNF is important for host defence against several pathogens, especially viruses 
and intracellular bacteria. Since it is important for the formation of granulomas, control over 
mycobacterial infection is also dependent on TNF (169, 170). TNF is produced by a variety of 
hematopoietic cells including monocytes, B and T lymphocytes, mast cells, but also 
non-hematopoietic cells such as fibroblasts, endothelial cells and micro glia cells (168, 
170-172).  
1.7.2 Signalling pathways induced by TNF 
TNF signals via two structurally related but functionally distinct receptors, TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2) (170, 173). Whereas TNFR1 is 
ubiquitously expressed in most tissues, TNFR2 is predominantly found on lymphocytes (174). 
TNF can mediate its effects both in its membrane-bound (mTNF) and soluble (sTNF) form. 
sTNF is cleaved off from mTNF by the TNF converting enzyme (TACE) (169). Yet, in 
contrast to TNFR1, which is stimulated equally well by both sTNF and mTNF, the TNFR2 is 
more efficiently stimulated by mTNF (175).  
1.7.2.1 Signalling via TNFR1 
Signalling via TNFR1 mediates the proinflammatory, cytotoxic and apoptotic effects 
that are characteristically associated with TNF (170, 176). TNFR1 contains a TNF 
receptor-associated death domain (TRADD) in its cytoplasmic tail, which can initiate 
different signalling cascades, resulting in apoptosis or proinflammatory signals. Firstly, 
TRADD binds adaptor proteins like the Fas-associated death domain (FADD) and 
subsequently leads to caspases-mediated apoptosis (169, 176). However, as illustrated in 
Figure 5 (174), TRADD also recruits TNF receptor-associated factor 2 (TRAF2) and 
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receptor-interacting protein (RIP), adaptor proteins that mediate the induction of important 
proinflammatory signalling pathways, i.e. the JNK/c-Jun, IKK/NF-κB and p38-MAPK 
cascades (177–179). The MAPK cascade also mediates the activation of JNK, which 
eventually leads to the induction of c-Jun. c-Jun, as a heterodimer with c-Fos, forms the 
proinflammatory transcription factor AP-1 (170). TNF-driven activation of the transcription 
of NF-κB-associated genes requires the degradation of the NF-κB inhibitor I-κB facilitating 
nuclear translocation of NF-κB (170, 178). Activation of NF-κB-dependent transcription does 
not only promote proinflammatory stimuli but also inhibits the TNF-induced apoptosis. Thus, 
upon TNF-TNFR1 interaction immunoregulatory and anti-apoptotic effects are preferably 
induced instead of apoptosis (169, 170, 177). 
1.7.2.2 Signalling via TNFR2  
The TNF-induced effects on lymphocytes are mainly mediated via TNFR2, which 
functions as a co-stimulatory receptor for TCR-induced cell activation by lowering the 
threshold for T cell activation and promoting survival during the early phase of antigen-driven 
immune response (180, 181). While, in contrast to TNFR1, TNFR2 lacks a death domain, it 
can directly interact with adaptor proteins such as TRAF2 (182). Subsequently, the 
proinflammatory transcription factors NF-κB and AP-1, the latter through the activation of the 
MAPK/JNK/c-Jun cascade, are induced (174, 178). Moreover, it has been shown that TNFR2 
signalling promotes cell survival and IL-2 induction during TCR/CD28-induced immune 
responses through the enhanced activation of Akt and the anti-apoptotic molecule Bcl-xL 
(183). The stimulation of the Akt pathway poses a link between TNFR2 and CD28 
co-stimulation, as CD28 signalling also activates Akt as key mediator for IL-2 induction 
(184). Yet, TNFR2 signalling does not only induce cell proliferation, cytokine release and 
anti-apoptotic effects but also increases TNFR1-induced apoptosis (185–187). Upon 
co-ligation of TNFR1 and TNFR2, TRAF2 is subject to proteosomal degradation. Thus, the 
TRAF2-dependent activation of NF-κB and AP-1 downstream of TNFR1 are attenuated and 
the TRADD/FADD-mediated induction of apoptosis is preferentially promoted (187, 188).  
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Tumour necrosis factor
(TNF). A ubiquitous cytokine,  
it is a first responder to fight 
disease or infection. TNF acts 
on its target cell to regulate 
expression of up to 500 genes. 
Although its actions are 
simplified as being either 
pro-inflammatory or 
anti-inflammatory, TNF carries 
out far more complex actions, 
including cell death, survival, 
proliferation, differentiation 
and expression of other 
cytokines. TNF is described as 
a ‘regulatory’ cytokine because 
it controls the release of other 
cytokines necessary to wage 
the fight against disease or 
infection.
Type 1 diabetes
The autoimmune form of 
diabetes, as opposed to  
the more common type 2 
diabetes. With type 1, the 
immune system attacks and 
kills insulin-producing islet  
cells of the pancreas. Type 1 
diabetes is a chronic disease 
beginning most commonly in 
childhood (hence the synonym, 
juvenile diabetes).
NF-κB, in autoreactive T cells, have been found in both 
human and in mouse models of autoimmune disorders, 
including Crohn’s disease, Sjogren’s syndrome, multiple 
sclerosis, systemic lupus erythematosus (SLE), ankylosing 
spondylitis and type 1 diabetes26–44. Such defects include 
polymorphisms and depletion of proteins that disrupt 
the intracellular efficacy of the TNF signalling pathway. 
Defects in TNF signalling, of whatever type, alter the 
delicate balance between TNF’s pro-survival and apop-
totic effects26, and emerging evidence indicates that these 
defects may potentially be exploited in the treatment of 
autoimmune diseases. For example, type 1 diabetes can 
be caused largely by protein processing defects40 that 
result in a failure to kill autoreactive T lymphocytes, spe-
cifically CD8+ cytotoxic T cells45, during the process of nor-
mal development. The rogue autoreactive T cells enter 
the circulation and reach the pancreas where they kill the 
body’s insulin-producing cells26,46–50. When naive T cells, 
destined to mature into autoreactive T cells, leave their 
immune cell sanctuaries they, like their normal counter-
parts, depend on TNF for survival. However, when they 
are activated by their cognate antigens in the pancreas, 
they mature into autoreactive T cells. These cells have 
been found to be sensitive to death, induced by exog-
enous, low-dose TNF exposure. This is due to a defect in 
the activation of NF-κB26, which means that pro-survival 
genes are not transcribed in response to TNF and apop-
tosis of these cells is instead favoured. Indeed, in animal 
models, exogenous TNF effectively kills autoreactive 
T cells to treat and reverse type 1 diabetes51–57, restoring 
insulin production even in end-stage diabetes58.
The administration of TNF is seen as a new strategy to 
treat certain autoimmune diseases26, although it is not 
approved for human use. It has been given as a treat-
ment to patients with cancer59–61, but has proved to be 
systemically toxic. This is probably due to the wide-
spread expression of TNFR1 and the use of high-dose 
TNF when levels of this cytokine are already elevated. 
Figure 1 | TNF signalling though TNFR1 and TNFR2 in normal T cells compared to abnormal (autoimmune) 
T cells. a | Tumour necrosis factor (TNF) binds TNF receptor 1 (TNFR1) and TNFR2 for stimulation of two opposing 
signalling events. In general, exclusive TNFR1 signalling results in the trigger of a cascade that can result in apoptosis. 
This is dependent upon the cell type, the state of activation of the cell and the cell cycle. In contrast, an exclusive  
TNFR2 signal, especially in highly activated T cells, induces cell survival pathways that can result in cell proliferation.  
b | Autoreactive T cells in human and murine disease have been found to have protein defects in the TNFR2 signalling 
pathway at different levels. These signalling defects at various locations along the TNFR2 pathway result in blocks  
to inefficacies in the TNFR2 pathway for cell survival or cell proliferation. This then biases autoreactive T cells to 
preferentially use the TNFR1 pathway and selective apoptosis ensues. AP1, activator protein 1; cFLIP, cellular FLICE-like 
inhibitory protein (also known as CFLAR); cIAP, cellular inhibitor of apoptosis protein; FADD, Fas-associated death 
domain; IKK, inhibitor of ?B kinase; JNK, Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MEKK, 
mitogen-activated protein kinase kinase kinase; MKK3, dual specificity mitogen-activated protein kinase kinase 3;  
NEMO, nuclear factor-?B (NF-?B) essential modulator; RIP, receptor interacting protein; TRADD, TNFR1-associated 
death domain; TRAF, TNF receptor-associated factor.
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Figure 5: Signalling pathways in response to TNFR1 and TNFR2 signalling. Ligation to 
TNFR1 leads to the recruitme t of TRADD, which ei her initiates apoptosis vi  the 
FADD/caspase pathway or induces proinflammatory signals via the recruitment of the adaptor 
protein TRAF2. TRAF2 is also r cruit d to the TNFR2. This eventually results in the 
activation f NF-κB, MAPK and AP-1, transcription factors that promote cell survival and 
proliferation. More ver, NF-κB activati n also results in the inhibition f th  F D-induc d 
apoptotic pathway (figure from Faustman et al., 2010, p.483 (174)). 
1.7.3 TNF: An important mediator in autoimmunity 
Several lines of evidence have shown that TNF plays a crucial role in the development 
of autoimmu e disorders (171, 189–192). Accordingly, TNF blockade is beneficial in a 
variety of autoinflammatory diseases, e.g. rheumatoid arthritis, IBD, juvenile idiopathic 
arthritis, psoriatic arthritis or ankylosing spondylitis (193–196). Nevertheless, in some 
individuals anti-TNF treatment results in the induction of inflammat ry disorders (194, 197). 
It has been reported that patients d ve op or show enhancement of psoriatic kin lesion , 
systemic lupus erythematodus or lupus-like conditio s and inflammatory demyelination of th  
central nervous system similar to multiple sclerosis while being treated with TNF blockers 
(198–200). Thus, although neutralizing TNF has shown promising results in many patients 
suffering from autoimmune diseases, it can also aggravate inflammatory processes. The 
outcome for individual patients is therefore not always predictable. Great effort has been put 
into revealing the distinct proinflammatory and immunoregulatory functions of TNF. 
Nevertheless, still little is known about how TNF influences the activity of different immune 
cell subsets. Similarly, it remains to be clarified if TNF has enhancing or inhibiting effects on 
immunosuppressive cells like Treg and MDSC.  
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1.7.3.1 TNF and Treg: promoting or interrupting suppressor capacity? 
As both Treg and TNF play a vital role in the development of auto-inflammatory 
disorders, a link between them has long been suspected. Treg numbers are not reduced in the 
peripheral blood of patients suffering from autoimmune diseases when compared to healthy 
individuals and in some cases Treg cells can even be enriched at the site of inflammation. Yet, 
Treg show impaired suppressor function and fail to suppress tissue inflammation in various 
types of autoimmunity (201–204). Thus, not an actual deficiency of Treg numbers but 
diminished Treg function, caused by factors such as TNF, may contribute to the defective 
Treg-induced suppression of autoreactive T cells. Correspondingly, it has been shown that 
anti-TNF therapy increased Treg numbers and restored their compromised function in patients 
with rheumatoid arthritis (205, 206). Moreover, patients suffering from IBD also benefit from 
treatment with anti-TNF agents (193), which has been attributed to increased Treg numbers 
and function (207–209). Thus, it has been proposed that TNF has inhibitory effects on Treg 
function. Yet, there is conflicting data on the interaction of Treg and TNF. While various 
reports have shown that TNF decreases Treg suppressor capacity (210–215), several lines of 
evidence, on the other hand, suggest that TNF has enhancing effects on Treg proliferation and 
suppressor function (216–223).  
1.7.3.2 TNF and MDSC: promoting suppressive function? 
MDSC have a great capacity to suppress antitumor immune responses as explained 
before (refer to 1.3.2). Therefore, downregulation of their suppressor function could provide 
an effective anti-cancer treatment. Strong efforts have been made in order to reveal factors 
that modulate the accumulation and suppressor capacity of MDSC (38). It appears that TNF 
does not only influence the function of Treg but also of immunosuppressive MDSC. It could 
be demonstrated that TNF promotes MDSC survival through inducing anti-apoptotic signals 
via TNFR2 (224) and increases MDSC-induced suppression of T cell proliferation (225, 226). 
Thus, it is suggested that blocking TNF inhibits the expansion of MDSC and, thereby, the 
suppression of antitumor immunity. Therefore, anti-TNF therapy seems to be a promising 
way to limit tumor progression (224).  
1.7.4 TNF mutants with increased specificities for TNFR1 or TNFR2 
Previous studies have revealed that TNF-induced effects on effector lymphocytes and 
Treg are mainly mediated via the TNFR2 (180, 211, 216–218). Yet, especially regarding the 
Treg and MDSC compartments little is known about the potential effects of TNFR1 and 
TNFR2 signalling on their suppressor function. In order to study to which extend MDSC and 
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Treg function is influenced by ligation to those receptors, specific agonistic TNF mutants are 
required. 
1.7.4.1 TNCscTNF80: a TNFR2-specific agonist 
Single chain TNF (scTNF) consists of three TNF monomers that are connected via a 
dipeptide linker forming a trimeric construct. This scTNF trimer shows greater stability and 
binds TNFR1 and TNFR2 with higher affinities than sTNF (227). Selectivity for the TNFR2 
is achieved by introducing mutations of two amino acids in scTNF (sc(mu)TNF80 
D134/A145R) (231). However, although TNFR2 is bound by both sTNF and mTNF, it is only 
fully stimulated by the membrane-bound form (175). Thus, the TNF variant needs to form 
aggregates that resemble mTNF (227). Therefore, the Flag-tagged trimerization domain of 
Tenascin C (TNC) is linked to scTNF80. As illustrated in Figure 6 (228), this allows the 
self-assembly of three trimeric scTNF80 molecules. This TNF mutant, i.e. 
sc(mu)TNF80-FLAG-TNC (TNCscTNF80), simulates mTNF and thereby efficiently 
activates TNFR2 (228). 
 
has retained the potential of neuronal differentiation into a
dopaminergic phenotype [17,18,19,20].
Results
Expression and characterization of human TNC-scTNFR2
A prototype of a TNFR2-selective highly bioactive TNF variant
has been recently reported [16], comprised of the chicken TNC
trimerization domain and a TNFR2-selective TNF mutant
(D143N/A145R; [12]) in the single chain TNF format [13]. To
obtain a fully human TNF reagent we here fused the trimerization
domain of human TNC (AA 110–139) to the N-terminus of the
TNFR2-selective scTNF variant (TNC-scTNFR2), which was
further modified for improved production. Thus, peptide linkers
connecting the three TNF monomers were reduced to GGGGS
and overall codon usage was adapted for expression in
mammalian cell systems. Bioactivity of TNC-scTNFR2 was
compared to the monomeric TNFR2-selective scTNFR2 (sche-
matic overview in Fig. 1a and b).
Both scTNFR2 and TNC-scTNFR2 were expressed in
HEK293T cells and isolated by immobilized metal ion chroma-
tography (IMAC) in a single step using a N-terminal his-tag
present in the molecule. Purity was confirmed by SDS-PAGE and
Coomassie staining (Fig. 1C). Under reducing conditions the TNF
variants exhibited an apparent molecular mass of approximately
51 kDa and 54 kDa, matching the calculated molecular mass of
53.5 kDa and 56.8 kDa for scTNFR2 and TNC-scTNFR2,
respectively. Under non-reducing conditions additional bands of
110 kDa (dimer) and above 170 kDa (trimer) were observed for
TNC-scTNFR2 (Fig. 1C and D). The oligomerization state of
TNC-scTNFR2 was further characterized by size exclusion
chromatography (SEC; Fig. 1E). Both scTNFR2 and TNC-
scTNFR2 eluted as a single major peak and TNC-scTNFR2 with
a higher molecular mass than scTNFR2, indicating that the TNC
domain, as expected, causes stable oligomerization of scTNFR2
molecules. The fact that TNC-scTNFR2 elutes in a single peak
while migrating in non-reducing SDS-PAGE as dimers and
trimers is in good accordance w th the find ng that the TNC
trimerization domain assembles into stable trimers without
stabilization of disulfide bridges.
Receptor selectivity and bioactivity of TNC-scTNFR2
TNF receptor selectivity of scTNFR2 and TNC-scTNFR2 was
analyzed using TNFR12/2/TNFR22/2 mouse embryonic fibro-
blasts (MEF) stably expressing chimeric TNFRecd-Fasicd receptors
that bind human TNF and trigger Fas-associated signaling
pathways, e.g. apoptosis induction [21]. In contrast to human
soluble recombinant TNF (huTNF), the TNFR2-selective TNF
variants generated here induced no apoptosis in MEF TNFR1-Fas
cells (Fig. 2A), verifying that both variants had highly reduced
affinities for TNFR1 due to the mutations D143N/A145R. In
contrast, TNC-scTNFR2 induced a strong apoptotic response in
MEF TNFR2-Fas cells. Treatment with huTNF and scTNFR2
caused cell death only at high concentrations, which could be
enhanced by addition of the cross-linking TNFR2-specific
monoclonal antibody 80M2 (Fig. 2A) to similar values as obtained
for TNC-scTNFR2 alone, thus in concert mimicking the action of
memTNF [15]. Similar results were obtained using the human
Figure 1. Genetic engineering of the TNFR2-selective TNF muteins. (A,B) Schematic representation of the TNF variants used in this study. CT:
cys-tag, HT: his-tag; TNF: huTNFR2-specific (D143N/A145R) TNF module (aa 80–233); L: GGGGS-linker; TNC: trimerization domain of human tenascin C
(aa 110–139). (C) Coomassie staining and (D) immunoblot analysis of scTNFR2 (1) and TNC-scTNFR2 (2). Purified TNF variants were analyzed by 8%
SDS-PAGE under reducing (r.) or non-reducing (n.r.) conditions and either stained with Coomassie or immunoblotted with anti-his-tag antibodies.
(E) TNF muteins were analyzed by HPLC size exclusion chromatography using a BioSep-Sec-2000 column. Peak positions of relevant standard
proteins are indicated (200 kDa; 67 kDa and 29 kDa).
doi:10.1371/journal.pone.0027621.g001
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Figure 6: Structure of TNCscTNF. By connecting three TNF monomers a trimeric TNF 
construct, scTNF, is formed. Linking scTNF to the trimerization domain of TNC allows the 
self-assembly of three of those scTNF constructs, resulting in an oligomeric structure that 
simulates mTNF (figure from Fischer et al., 2011, p.2 (228)). 
1.7.4.2 TNCwtTNF 
TNCwtTNF binds to both TNFR1 and TNFR2, as there are no mutations introduced. 
Yet, in order for it to fully activate TNFR2, the trimerization of wtTNF is required, which is 
achieved by linking it to TNC. 
1.7.4.3 Human TNF: a T F agonist that specific lly binds mouse TNFR1 
Human TNF (hTNF) can o ly signal via murine TNFR1 but not via murine TNFR2 
(173, 229). Thus, any effect hTNF shows in mouse models must be mediated via TNFR1, 
which potentially allows excluding TNFR2 involvement (229).  
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1.8  Aim of the thesis 
Previous studies in our laboratory had shown that TNFR2 signalling reduced the 
Treg-mediated inhibition of CD4+ and CD8+ proliferation. The aim of this thesis was to study 
the specific functions of TNFR2 on effector lymphocytes and suppressive immune cells, i.e. 
regulatory T cells and myeloid-derived suppressor cells. To this end, the effect of different 
TNFR agonists on the proliferation and cytokine production of T cells was examined. 
Moreover, in order to shed some light on the impact of TNFR2 signalling on the suppressor 
capacity of immunoregulatory cells, we analysed to what extend different TNFR agonists 
changed the function, phenotype and intracellular signalling events in those cells, with focus 
on regulatory T cells. The analysis of TNFR1- and TNFR2-deficient cell populations 
complemented these studies. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Instrumentation 
Item     Manufacturer  City (Country) 
Centrifuge 5417R   Eppendorf   Hamburg (GER) 
Centrifuge 54810   Eppendorf   Hamburg (GER) 
CO2-Incubator   Heraeus   Hanau (GER) 
CO2-Incubator   Integra Bioscience  Zizers (CH) 
Flow Cytometer BD FACSCalibur BD Biosciences  Heidelberg (GER) 
Flow Cytometer BD LSRII  BD Biosciences  Heidelberg (GER) 
MACS Milteny Chill (15,50)  Miltenyi Biotec   Bergisch-Gladbach (GER) 
MACS Multistand   Miltenyi Biotec  Bergisch-Gladbach (GER) 
Microscope Axiostar plus  Zeiss    Oberkochen (GER) 
Microscope CK2   Olympus   Hamburg (GER) 
Multichannel Pipette (100, 300 µl) Eppendorf Research  Hamburg (GER) 
MS2 mini shaker   IKA    Staufen (GER) 
Neubauer hemocytometer  Brandt    Wertheim (GER) 
Neubauer hemocytometer  HBG    Giessen (GER) 
Pipette Discovery (1000 µl)  Abimed   Langenfeld (GER) 
Pipette Labmate (10, 200 µl)  Abimed   Langenfeld (GER) 
Pipette (2, 10, 100, 200, 1000 µl) Eppendorf    Hamburg (GER) 
Pipette (200 µl)   Glison    Middleton (USA) 
Pipette (2, 20, 200, 1000 µl)  Thermo Scientific  Langenselbold (GER) 
Pipette Controller accu-jet® pro Brandt    Wertheim (GER) 
Tissue culture hood HERAsafe Thermo Scientific  Langenselbold (GER) 
Water bath TW20   Julabo    Seelbach (GER) 
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2.1.2 Consumables  
Item     Manufacturer  City (Country) 
FACS Tubes    BD Biosciences  Heidelberg (GER) 
Cell Strainer (40 µm)   BD Biosciences  Heidelberg (GER) 
Centrifuge tube (15, 50 ml)  Sarstedt   Nümbrecht (GER) 
MACS Separation Columns   Miltenyi Biotec  Bergisch-Gladbach (GER) 
Microtubes original eppendorf® Eppendorf    Hamburg (GER) 
Minisart ® Syringe Filters (0.2 µm) Satorius    Göttingen (GER) 
Multiwell Plate (6-, 24-, 96-well) BD FalconTM   Heidelberg (GER) 
Petri dish    BD Biosciene   Heidelberg (GER) 
Pipette Tips (10, 20, 200, 1000 µl) Sarstedt   Nümbrecht (GER) 
Serological Pipettes (2, 5, 10, 25 ml) Sarstedt   Nümbrecht (GER) 
Syringe (2 ml)   BD DiscarditTM  Heidelberg (GER) 
2.1.3 Chemicals and Reagents 
Item     Manufacturer  City (Country) 
Acetone    Merck    Darmstadt (GER)  
Albumin from bovine serum  Sigma-Aldrich  München (GER) 
Anti-mouse CD4+CD25+ isolation Milteny Biotec  Bergisch-Gladbach (GER) 
microbeads        
ConA     Sigma-Aldrich  München (GER) 
DPBS      PAN Biotech GmbH  Aidenach (GER) 
Formaldehyde (36.5-38 %)  Sigma-Aldrich  München (GER) 
Foxp3 Staining Buffer Set  eBioscience   Frankfurt (GER) 
H2O2 (30 %)    Merck    Darmstadt (GER) 
IL-2     Immunotools   Friesoyethe (GER) 
Recombinant mouse IL-3  Immunotools   Friesoyethe (GER) 
Methanol    Merck    Darmstadt (GER) 
Penicillin/Streptomycin  Invitrogen   Darmstadt (GER)  
RPMI 1640 PAA   PAN Biotech GmbH  Aidenach (GER) 
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Streptavidin-HRP   R&D Systems   Minneapolis (USA) 
Streptavidin-AF488 (1:200)  Invitrogen   Darmstadt (GER) 
Streptavidin-APC (1:200)  BD Biosciences Pharmingen Heidelberg (GER) 
Streptavidin-FITC (1:300)  BD Biosciences Pharmingen Heidelberg (GER) 
Streptavidin-PE (1:200)  Dianova   Hamburg (GER) 
Streptavidin-PerCP (1:250)  BD Biosciences Pharmingen Heidelberg (GER)  
Substrate Solution A (ELISA) OptEIATM BD Biosciences Heidelberg (GER) 
Substrate Solution B (ELISA) OptEIATM BD Biosciences Heidelberg (GER) 
Triton X-100    Serva Feinbiochemica Heidelberg (GER) 
Tween® 20    AppliChem   Darmstadt (GER) 
2.1.4 TNF receptor agonists 
Generously provided  by Harald Wajant, University of Würzburg (GER). The compounds 
were provided as cell culture supernatants of producer cell lines, without further purification. 
Item    Concentrations 
sc(mu)TNF80-Flag-TNC  3.5 µg/ml, 2.7 µg/ml  
TNCsc(mu)TNF(wt)Flag  4.6 µg/ml 
Human TNF   10 µg/ml 
Control Supernatant (CS) Used in equal volumes as sc(mu)TNF80-Flag-TNC   
2.1.5 Buffers and Solutions 
Item       Composition 
ACK (red cells lysis buffer)    Na2EDTA, pH 7.4  
Antibody Diluent Buffer    DBPS, 1 % FCS, 0.3 % Triton X-100 
Blocking Buffer (intracellular staining)  DPBS, 5 % FCS, 0.3 % Triton X-100 
Buffer for extracellular staining (FACS buffer) DPBS, 1 % FCS  
Buffer for magnetic cell separation (MACS buffer) DPBS, 0.5 % BSA, 2mM EDTA 
Cell culture medium     RPMI, 10 % FCS, 100 U/ml Penicillin, 
       0.1 mg/ml Streptomycin, 100 µM  
       ß-mercaptoethanol 
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Cell culture medium for MDSC preparation  RPMI, 10% FCS, 10% GM-CSF  
       supernatant, 100 U/ml Penicillin,  
       0.1mg/ml Streptomycin, 50 µM  
       ß-mercaptoethanol 
ELISA Washing Buffer (IFNγ, IL-10)  DPBS, 0.05 % Tween® 20 
ELISA Blocking Buffer (IFNγ)   DPBS, 1 % BSA 
ELISA Reagent Diluent (IFNγ)   Tris-buffer Saline, 0.1 % BSA, 0.05 % 
       Tween® 20  
FC-Block anti-CD16/CD32    20 µg/ml αmFcyRII/II-antibody in FACS
       buffer 
Stop Solution for HRP (ELISA)   2N H2SO4 
2.1.6 Antibodies 
Antibody   Clone (Dilution) Manufacturer City 
Anti-mouse B220-PE  RA3-6B2 (1:1000) BD Biosciences Heidelberg (GER) 
Anti-mouse B220-PerCP  RA3-6B2 (1:600) eBioscience  Frankfurt (GER) 
Anti-mouse CD3ε   145-2C11  BD Biosciences Heidelberg (GER) 
Anti-mouse CD4-AF488  GK1.5 (1:1000) Biolegend  Fell (GER) 
Anti-mouse CD4-AF647  RM 4-5 (1:1000) eBioscience  Frankfurt (GER) 
Anti-mouse CD4-PE   RM 4-5 (1:1000) eBioscience  Frankfurt (GER) 
Anti-mouse CD4-PercP SK3 (1:1000)  BD Biosciences Heidelberg (GER) 
Anti-mouse CD8a-AF647 53-67 (1:1000) BioLegend  Fell (GER) 
Anti-mouse CD8a-PerCP 53-6.7 (1:800)  eBioscience  Frankfurt (GER) 
Anti-mouse CD25-APC  PC61 (1:200)  BD Biosciences Heidelberg (GER) 
Anti-mouse CD25-Biotin  PC61 (1:400)  eBioscience  Frankfurt (GER) 
Anti-mouse CD25-FITC  7D4 (1:100)  BD Biosciences Heidelberg (GER) 
Anti-mouse CD25-PE  PC61 (1:100)  BD Biosciences Heidelberg (GER) 
Anti-mouse CD45.1-PE  A20 (1:50)  BD Biosciences Heidelberg (GER) 
Anti-mouse CD45.2-PerCP 104 (1:200)  eBioscience  Frankfurt (GER) 
Anti-mouse FoxP3-PE  FJK-16s (1:100) eBioscience  Frankfurt (GER) 
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Anti-mouse FoxP3-FITC  FJK-16s (1:100) eBioscience  Frankfurt (GER) 
Anti-hamster IgG-Biotin cocktail  BD Biosciences Heidelberg (GER) 
Anti-rabbit IgG CyTM-5 1:500   Dianova  Hamburg (GER) 
Rabbit mAB pStat5 Tyr694  D47E7 (1:600) Cell Signaling  Danvers (USA) 
Rabbit mAB pStat5 Tyr694 C71E5   Cell Signaling  Danvers (USA) 
Rabbit mAB pZap 70  Tyr319/Syk Tyr352 Cell Signaling  Danvers (USA) 
    (1:100) 
2.1.7 Kits 
Item     Manufacturer  City (Country) 
CD4+CD25+ Regulatory T cell  Milteny Biotec  Bergisch-Gladbach (GER) 
Isolation Kit  
DuoSet ELISA Development  R&D System   Minneapolis (USA) 
Kit IFNγ  
Mouse IL-10 ELISA   eBioscience   Frankfurt (GER) 
Ready-Set-GO!   
2.1.8 Software 
Item     Manufacturer  City (Country) 
CellQuestTM Pro   BD Biosciences  Heidelberg (GER) 
GraphPad Prism 5   GraphPad Software   San Diego (USA) 
Microsoft Office 2011  Microsoft   Redmond (USA) 
2.1.9 Mouse strains 
Strain   Characteristics 
C57BL/6   wild type (WT) mouse strain 
TNFR2-/-  C57BL/6 background; genetic knock-out of TNF receptor 2 
TNFR1-/-  C57BL/6 background; genetic knock-out of TNF receptor 1 
CD45.1  C57BL/6 background; carries the CD45.1 isoform of the CD45 gene. 
This can be used to identify hematopoietic cells based on their 
expression of CD45.1 instead of the isoform CD45.2 that is expressed 
by the parental C57BL/6 line. 
II- Materials and Methods 30 
2.2 Preparation of cell cultures 
2.2.1 Cell culture conditions 
The preparation of cell cultures was performed in the laminar flow cabinet 
HERAsafe® using sterile reagents, pipettes and consumables. The specific mediums and 
reagents are listed in 2.1.5. Cells were cultured in multiwell cell culture plates at the following 
conditions: 37 °C, 5 % CO2 and 95 % humidity.  
2.2.2 Isolation and purification of spleen cells 
Following anaesthesia with ether, the mice were killed by cervical dislocation. The fur 
was sterilized with 70% ethanol. A small skin cut was made, the peritoneum opened and the 
spleen was extracted. The spleen was placed in 5 ml cell culture medium. From this point 
forward the work was performed under a laminar flow cabinet. The spleen was pressed out 
with a 2 ml syringe plunger and the cell suspension was transferred into a 15 ml centrifuge 
tube. After letting the debris settle down, the suspension was transferred into a new 15 ml 
centrifuge tube. The cell suspension was centrifuged with 300 g for 5 minutes at 4 °C and the 
supernatant was discarded. In order to remove erythrocytes from the whole splenocyte 
preparations, the cells were resuspended in 5 ml ACK buffer, pelleted with 300 g for 
5 minutes at 4 °C and the supernatant was discarded. The cells were then resuspended in 
10 ml cell culture medium, centrifuged with 300 g for 5 minutes at 4 °C and the supernatant 
was discarded. 
2.2.3 Preparation of bone marrow cells 
Myeloid-derived suppressor cells were generated from bone marrow cells by applying 
a previously described method (230). For this purpose E67L2 mice were used. The mice were 
killed by cervical dislocation after anaesthesia with ether. 70 % ethanol was sprayed onto the 
fur for sterilization. The femora and tibiae were extracted and cleaned with a paper towel. The 
following steps were performed under a laminar flow cabinet. The bones were placed into 
70 % ethanol for two minutes in order to sterilize them, dried by gentle tapping them on a 
petri dish and then transferred into DPBS. After incubation in DPBS for one minute, they 
were dried again and the epiphyses were removed with scissors. The bone marrow was rinsed 
with 5 ml cold DPBS using a 20G cannula. The cell suspension was collect in a cold 50 ml 
centrifuge tube. After the resuspension, a centrifugation step (300 g, 10 min, 4 °C) followed 
and the supernatant was decanted. Then, the cells were picked up in 5 ml cell culture medium 
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that contained 10 % GM-CSF supernatant, which is referred to as GM-CSF medium 
throughout the work with MDSC.  
2.2.4 Determination of cell numbers 
Cell numbers were determined with a Neubauer hemocytometer. Therefore, a small 
volume was taken from the cell suspension. This was resuspended in adequate volumes of 
Turck staining solution or cell culture medium to create a 1:5 dilution. 10 µl of this dilution 
were placed in between the hemocytometer and the glass microscope slide. A total of 100 to 
200 cells were counted in four different big squares and the mean value was determined. The 
total cell number was calculated by applying Formula 1.  
cells in a big square( )×dilution factor ×104 =cells/ml  
Formula 1 Calculation of cell number using a Neubauer hemocytometer. 
2.2.5 CFSE labelling 
Carboxyfluorescein diacetate succinimidyl ester (CFSE) staining was utilized to 
measure proliferation of CD4+ and CD8+ cells. The colourless CFSE contains two acetate 
groups that allow the passive diffusion into cells, where intracellular esterases quickly remove 
the acetate groups. The resultant molecule carboxyfluorescein shows green fluorescence and 
reduced permeability for plasma membranes. Moreover, the succinimidyl ester reacts with 
amines of cytosolic proteins forming stable conjugates. Those dye-protein adducts are also 
formed with low turnover proteins. Thus, they are stably retained within the cells during cell 
division and do not diffuse into adjacent cells ensuring high stability of fluorescence (231, 
232). However, the carboxyfluorescein-tagged molecules are divided between daughter cells 
upon cell division. With each cell cycle progression the fluorescence intensity is thereby 
progressively halved, which allows the monitoring of lymphocyte proliferation by flow 
cytometry (233). Up to eight cell divisions can be measured with CFSE before the dye dilutes 
to levels below the autofluorescence of unlabelled cells (234). 
For the CFSE labeling, splenocytes were isolated and lysed as described in 2.2.2. 
Before staining with CFSE cells were washed twice DPBS. Each wash step included 
resuspension in 5 ml DPBS, centrifugation (300 g, 5 min, 4 °C) and removal of the 
supernatant. After the first wash step, the cell numbers were determined using Formula 1. 
Following the second wash step, cells were resuspended in a DBPS solution containing 1 % 
of foetal calf serum (FCS) and 2 µM CFSE, and incubated in a water bath at 37 °C for 
10 minutes. 1 ml of the CFSE-solution was used for 107 cells. The reaction was stopped by 
II- Materials and Methods 32 
adding four volumes of 5 % FCS-DPBS and centrifuging with 300 g for 5 minutes at 4 °C. 
The supernatant was removed and the cells were washed twice in 5 ml 5 % FCS-DPBS. For 
cultivation, the cell pellet was resuspended in 5 ml cell culture medium. Then, cells were 
counted again as explained above.  
2.2.6 MACS separation of CD4+CD25+ regulatory T cells 
In order to separate CD4+CD25+ regulatory T cells from whole splenocyte 
preparations, magnetic cell separation (MACS) was performed with the Regulatory T cell 
Isolation Kit listed in 2.1.7. Cells and the MACS buffer were kept cold throughout this 
protocol. For this procedure the spleen was placed in a cell strainer over 5 ml MACS buffer, 
pressed out with a 2 ml syringe plunger and the cell suspension was transferred into a 15 ml 
centrifuge tube. This cell suspension was then pelleted (300 g, 5 min, 4 °C) and the 
supernatant was decanted. Then, cells were then resuspended in 10 ml MACS buffer and the 
total cell number was determined using Formula 1. A cell suspension volume containing 
108 cells was used for the subsequent separation process. Cells were centrifuged with 300 g 
for 5 minutes at 4 °C, the supernatant was removed carefully and the pellet was picked up in 
400 µl MACS buffer. 50 µl biotin-antibody cocktail were added and the suspension was 
incubated at 4 °C for 10 minutes in the dark. Then 300 µl MACS buffer, 100 µl anti-biotin 
beads and 50 µl CD25-PE were added, the mixture was well resuspended and incubated for 
15 minutes at 4 °C in the dark. To stop the reaction 13 ml MACS buffer were added and the 
suspension was centrifuged with 300 g for 5 minutes at 4 °C. Then, the supernatant was 
removed and the cell pellet was resuspended in 500 µl MACS buffer. In order to deplete cells 
that were not CD4+, the cell suspension was run over a LD-Column. To remove any particles 
remaining in the cell suspension, a cell strainer (40 µl) was placed over the opening of the LD 
column. The cell suspension was transferred completely onto the column, which was then 
rinsed twice with 1 ml MACS buffer. The first rinse was performed over the cell strainer, 
whereas the buffer was pipetted directly into the column for the second rinse. The cells that 
were not of interest, i.e. all non-CD4+, had been marked by the biotin-antibody cocktail and 
thus bound to the column. Therefore, all cells collected in the effluent were CD4+. The 
effluent was then transferred into a 15 ml centrifuge tube and centrifuged with 300 g for 
5 minutes at 4 °C, the supernatant was removed carefully and the cells were resuspended in 
900 µL MACS buffer. 50 µl anti-PE beads were added and the suspension was incubated in 
the dark for 15 minutes at 4 °C. The reaction was stopped by the addition of 13 ml MACS 
buffer and subsequent centrifugation with 300 g for 5 minutes at 4 °C. The supernatant was 
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discarded and cells were resuspended in 500 µl MACS buffer. For the positive selection of 
CD25+ cells the cell suspension was run over a MS column. All cells that had been marked by 
the anti-PE beads, i.e. the CD25+ cells, bound to the column and could therefore be collected 
when cells were extracted from the column. The MS column containing the cell suspension 
was rinsed three times with 500 µl MACS buffer. Then, it was placed over a new 15 ml 
centrifuge tube, rinsed with 1 ml MACS buffer and flushed out by firmly applying the 
plunger. This suspension was run over a second MS column, which was also rinsed with 
500 µl MACS buffer three times. The second column was placed over a 15 ml centrifuge 
tube, rinsed with 1 ml MACS buffer and flushed out by firmly applying the plunger. This cell 
suspension, containing only CD4+CD25+ cells, was centrifuged with 300 g for 5 minutes at 
4 °C and the supernatant was discarded. The cells were resuspended in 500 µl cell culture 
medium and cell numbers were acquired by applying Formula 1.  
2.3 Cultivation of cells 
2.3.1 Cultivation of bone marrow derived dendritic cells 
Bone marrow-derived cells were obtained as described in 2.2.3. After resuspending the 
cells in 5 ml GM-CSF medium, they were pelleted with 300 g for 10 minutes at 4 °C and the 
supernatant was discarded. The cell pellet was resuspended in 1 ml GM-CSF medium and the 
suspension was transferred into a new centrifuge tube using a cell strainer (40 µl) to remove 
remaining particles. To determine the total cell number, 50 µl were taken off the suspension 
and diluted in Turck solution at a ratio of 1:1. Cells were counted using Formula 1. Then, 
2 x 105 cells were cultivated for four days in 6-well cell culture plates containing 2 ml 
GM-CSF medium. Half of the wells were additionally treated with 10 ng/ml TNCscTNF80. 
On day three, the cells were fed with 2 ml GM-CSF medium, again 10 ng/ml TNCscTNF80 
was added to half of the wells. 
2.3.2 Suppression assays with MDSC 
For the MDSC suppression assays, CFSE-labelled splenocytes and bone 
marrow-derived MDSC were co-cultured. In order to generate the MDSC, bone marrow cells 
were cultured with GM-CSF as described in 2.3.2. Following the generation, the MDSC were 
harvested using a 5 ml pipette. This cell suspension was transferred into a 15 ml centrifuge 
tube, the cells were pelleted (300 g, 5 min, 4 °C) and the supernatant was discarded. 
Following resuspension in 1 ml normal cell culture medium, cells were counted as indicated 
in Formula 1. Splenocytes were prepared as described in 2.2.2 and labelled with CFSE as 
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described in 2.2.5. The cell numbers were calculated using Formula 1 and per well 2 x 105 
CFSE-labelled splenocytes were cultured in 96-well culture plates. The MDSC were added to 
the cultures at ratios to the splenocytes of 1:1, 1:2, 1:4 and 1:8. Thus, 2 x 105, 1 x 105, 
0.5 x 105 and 0.25 x 105 MDSC were placed into the wells respectively. All wells apart from 
the negative control got stimulated with 1 µg/ml anti-CD3ε antibody alone or a combination 
of 1 µg/ml anti-CD3ε antibody and 0.5 µg/ml anti-CD28 antibody. Additional cell culture 
medium was placed into the wells beforehand so that each well had a final volume of 200 µl. 
2.3.3 Proliferation assays 
In the proliferation assays CFSE-labelled splenocytes were cultivated and stimulated 
with different reagents for up to 72 hours. Splenocytes were prepared and labelled with CFSE 
as described before. Cell numbers were determined using Formula 1 and 1.5 x 105 cells were 
placed into each well. For cell stimulation 0.5 µg/ml anti-CD3ε antibody was added per well. 
Some wells were additionally treated with 10 ng/ml TNCscTNF80 or TNCwtTNF. When 
Control Supernatant (CS) was used, it was added in equivalent volumes to 10 ng/ml 
TNCscTNF80. 96-well cultures plates were used and the final volume per well was 200 µl.  
2.3.4 Suppression assays with CD4+CD25+ regulatory T cells 
For the Treg suppression assays CFSE-labelled splenocytes from TNFR2-deficient 
(TNFR2-/-) mice were co-cultured with MACS-isolated CD4+CD25+ Treg from WT mice. 
Splenocytes from TNFR2-/- mice were prepared and labelled with CFSE as described before, 
cell numbers were determined using Formula 1 and a total number of 1.5 x 105 cells was 
transferred into each well. CD4+CD25+ cells were purified from whole splenocyte 
preparations of WT mice by using MACS as shown in 2.2.6. The separated CD4+CD25+ cells 
were cultivated with the CFSE-labelled splenocytes from the TNFR2-/- mice at ratios of 1:3, 
1:6 and 1:12. Thus, 0.5 x 105, 0.25 x 105 or 0.125 x 105 CD4+CD25+ cells were added to the 
wells. For activation 0.5 µg/ml anti-CD3ε antibody was given into each well. Some wells 
were additionally treated with 10 ng/ml TNCscTNF80 or TNCwtTNF.  
2.3.5 Cell culture for the analysis of phosphorylated Stat5  
In order to analyse the expression of phosphorylated Stat5 (pStat5) and extracellular 
markers, monocultures of splenocytes were stimulated for various periods of time. The 
splenocytes were prepared as described in 2.2.2 and then washed in 10 ml cell culture 
medium. After pelleting and discarding the supernatant, the cells were resuspended in 5 ml 
cell culture medium. Total cell numbers were determined using Formula 1 and 2 x 106 cells 
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were cultivated in 6-well culture plates that had a total volume of 1000 µl. Except for the 
negative controls, 0.5 µg/ml anti-CD3ε antibody was added to all wells to stimulate cells. 
Cells that were activated with anti-CD3ε antibody alone served as a positive control. For the 
short-term studies, the cell cultures were additionally treated with various combinations of 
10 ng/ml IL-2 and TNFR agonists at a concentration of 10 ng/ml for either 30 or 60 minutes. 
Long-term studies with incubation times of up to 72 hours were also performed. For this 
purpose, the cells were cultivated in the following manner: non-stimulated control, activated 
with 0.5 µg/ml anti-CD3ε antibody, activated with 0.5 µg/ml anti-CD3ε antibody and 
10 ng/ml of either TNCscTNF80 or hTNF. Those cell cultures plates were incubated for three, 
24, 48 and 72 hours at 37 °C and analysed by flow cytometry.  
In one experiment, CD4+CD25+ were purified from CD45.2 mice with MACS and 
then co-cultured with splenocyte preparations from CD45.1 mice. In this experiment 1.5 x 105 
CD45.1+ cells were cultured with various numbers of CD4+CD25+ from CD45.2 mice in 
presence of 0.5 µg/ml anti-CD3ε antibody and different TNFR agonists at concentrations of 
10 ng/ml. The stimulation was performed in 96-well culture plates for three up to 72 hours.  
2.3.6 Cell culture for the analysis of phosphorylated ZAP70  
Splenocytes were prepared as described in 2.2.2 and resuspended in 10 ml cell culture 
medium. The cell suspension was centrifuged (300 g, 5 min, 4 °C), the supernatant was 
discarded and the cell pellet was resuspended in 10 ml cell culture medium. Cell numbers 
were determined using Formula 1 and 2 x 106 cells were cultured in fluorescence-activated 
cell sorting (FACS) tubes with a total volume of 1000 µl. For stimulation cells were treated 
with 0.01 % H2O2 with or without additional 10 ng/ml TNCscTNF80. The tubes were placed 
in a water bath at 37 °C during this activation process. To stop the reaction the tubes were put 
on ice and 1 ml DPBS was added immediately. This was followed by a centrifugation step 
with 300 g at 4 °C for 5 minutes. For the subsequent flow cytometric analysis, cells were 
placed in FACS tubes that had been prefilled with 1000 µl DPBS. Throughout this procedure, 
tubes, reagents and solutions were kept on ice as far as possible. 
2.3.7 Harvesting of cells 
Before the harvesting of the cells, the multiwell plates were examined in a microscope 
in order to ensure that no contamination had taken place. FACS tubes were prefilled with 1 ml 
FACS buffer or DPBS, depending on the buffer that was used subsequently in the staining 
process for flow cytometric analysis. Then, for a number experiments, supernatants were 
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collected and stored at -20 °C. In order to harvest cells, cell suspensions were resuspended in 
the multiwell culture plates and then transferred into the prepared FACS tubes.  
2.4 Flow cytometry analysis 
2.4.1 Staining of surface markers for flow cytometry analysis 
The FACS tubes, which contained the cell suspensions in 1 ml FACS buffer, were 
centrifuged with 300 g for 5 minutes at 4 °C and the supernatant was decanted. Then, the 
tubes were repeatedly tapped on paper towels to remove the remaining fluid. In order to block 
unspecific binding, 1 µg of the αmFcyRII/II-antibody was added to each tube. The tubes were 
centrifuged with 300 g for 1 minute at 4 °C, shaken to resuspend the cell pellet and incubated 
at room temperature (RT) in the dark for 5 minutes. Antibody master mixes were prepared 
using antibodies in the recommended dilutions, which are listed in 2.1.6. Following the 
incubation with the αmFcyRII/II-antibody, the antibody mixes were added. The tubes were 
centrifuged with 300 g for 1 minute at 4 °C, shaken and incubated at RT for 5 minutes or at 
4 °C for 10 minutes. A wash step was performed that included the addition of 1 ml of FACS 
buffer, centrifugation (300 g, 5 min, 4 °C) and discharge of the supernatant. If a 
biotin-labelled antibody had been used in the antibody master mix, cells were additionally 
treated with fluorochrome-conjugated streptavidin, which was followed by centrifugation 
with 300 g for 1 minute at 4 °C, shaking of the tubes and incubation for 5 minutes at RT. 
Then the wash step was repeated. Cells were fixed with a 2 % formaldehyde solution, which 
had been prepared in FACS buffer, and stored at 4 °C until FACS analysis. Additional FACS 
buffer was added before the measurements in the flow cytometer. 
2.4.2 Staining of pStat5 and pZAP70 for flow cytometry 
The FACS tubes, which contained the harvested cell in 1 ml DPBS, were centrifuged 
with 300 g for 5 minutes at 4 °C. The supernatant was decanted and remaining drops were 
dried by repeatedly tapping the tubes on paper towels. The cells were fixed by incubation in 
500 µl of a 4 % formaldehyde solution at RT for 15 minutes. After a centrifugation step 
(300 g, 5 min, 4 °C), the supernatant was discarded and cells were washed three times. These 
wash steps included resuspension in 1 ml DPBS, centrifugation (300 g, 5 min, 4 °C), 
discharge of the supernatant and tapping the tubes on paper towels. After the last wash step, 
the supernatant was aspirated completely instead of being decanted. Cells were resuspended 
in 1 ml 100 % methanol, which had been stored at -20 °C, and incubated for 5 minutes 
at -20 °C. After the incubation, cells were centrifuged, the supernatant was discarded and two 
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additional wash steps followed. The cells were incubated with 1 ml blocking buffer, as listed 
in 2.1.5, for 60 minutes at RT. After incubation, a centrifugation step followed (300 g, 5 min, 
4 °C) and the supernatant was removed. In order to block unspecific binding, 1 µg of 
αmFcyRII/II-antibody was added per tube. The tubes were centrifuged with 300 g for 1 minute 
at 4 °C, shaken and incubated for 10 minutes at RT. Antibody master mixes were prepared 
using antibodies against both intra- and extracellular markers at the same time, including the 
monoclonal antibodies (mAB) against pStat5-Tyr694 or pZAP70. Cells were resuspended 
with the antibody master mix and incubated overnight at 4 °C. After the incubation, a wash 
step in 1 ml DPBS followed. Then, the secondary antibody anti-rabbit IgG CyTM-5 was added. 
If a biotin-labelled primary antibody had been used previously, fluorochrome-conjugated 
streptavidin was also added in this step. The dilutions of the secondary antibody and 
streptavidin were prepared in DBPS, cells were resuspended in those solution and incubated 
for 60 minutes at 4 °C. Following the incubation, the cells were resuspended in 1 ml DPBS, 
pelleted with 300 g for 5 minutes at 4 °C and the supernatant was decanted. Between 200 and 
250 µl of 1 % FCS-DBPS were added for FACS analysis.  
2.5 Detection of cytokine secretion in the supernatants of proliferation 
and suppression assays with ELISA 
Enzyme-linked immunosorbent assays (ELISA) were performed to detect cytokines in 
the supernatant of proliferation and suppression assays. Therefore, the DuoSet ELISA 
Development kit IFNγ and the mouse IL-10 ELISA Ready-SET-Go!® Kit, which are listed in 
2.1.7, were used. All additional buffers that were required are listed in 2.1.5. First, each well 
of a 96-well plate was coated with 50 µl of an unlabelled capture antibody. The plate was 
firmly sealed with plastic wrap to prevent evaporation and incubated overnight at RT for 
IFN-γ detection or at 4 °C for IL-10 detection. After the overnight incubation, the capture 
antibody solution was removed and remaining drops were dried by firmly blotting the plate 
onto paper towels. Then the plate was washed by adding 400 µl wash buffer per well, 
discarding the buffer and drying the plates as described above. This procedure is referred to as 
the wash step throughout this protocol. This wash step was repeated twice for a total of three 
repetitions. Then, 300 µl of the blocking buffer (IFN-γ ELISA) or the Assay Diluent (IL-10 
ELISA) was added per well, the plate was sealed and incubated for 60 minutes at RT. 
Afterwards, the blocking buffer was discarded, the plate was dried and three wash steps were 
performed. After blocking the plate, the standards and the samples were added. First, the 
standards needed to be prepared. Therefore, they were diluted in Reagent Diluent 
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(IFN-γ ELISA) or Assay Diluent (IL-10 ELISA) to a final concentration of 2000 pg/ml or 
4000 pg/ml respectively. Then, two-fold serial dilutions were prepared in Reagent diluent 
(IFN-γ ELISA) or Assay Diluent (IL-10 ELISA) in order to obtain an eight point standard 
curve. 50 µL of those standard dilutions were transferred as duplicates into the wells. In 
addition, 50 µl of the samples were given into the other wells. Some samples were used in 
their original concentration, while other samples were used as a 1:3 dilution in Reagent 
diluent (IFN-γ ELISA) or Assay Diluent (IL-10 ELISA). Following the addition of the 
standards and samples, the plate was sealed and incubated for two hours at RT. After the 
incubation, the liquid was removed and three wash steps were performed. Then 50 µl of the 
detection antibody was added to each well. The plate was sealed and incubated at room 
temperature for two hours (IFN-γ ELISA) or 60 minutes (IL-10 ELISA). The detection 
antibody was removed and the plate was dried. Three wash steps followed. 50 µl of 
horseradish-peroxidase (HRP) conjugated to streptavidin (IFN-γ ELISA) or Avidin-HRP 
(IL-10 ELISA) were added per well. The plate was covered and incubated at room 
temperature for 20 minutes (IFN-γ ELISA) or 30 minutes (IL-10 ELISA). Streptavidin-HRP 
and Avidin-HRP were removed, the plate was dried and washed three times. Then, 50 µl 
Substrate Solution was transferred into each well. For the detection of IFN-γ a 1:1 mixture of 
Substrate Solution A and Substrate Solution B was used, whereas an undiluted Substrate 
Solution was provided in the kit for IL-10 detection. For the incubation process, the plate was 
placed in the dark for 15 minutes, which was terminated by the addition of 25 µl Stop 
Solution (2 N H2SO4). Then, the intensity of fluorescence was analysed using a microplate 
reader set to 450 nm. Wavelength correction was set to 570 nm to correct optical 
imperfections.
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3 Results 
3.1 Proliferation of CD4+ and CD8+ lymphocytes in responses to the 
TNFR2 agonist TNCscTNF80 
TNF is known to be a proinflammatory mediator in the immune system, which exerts 
its effect via two receptors, TNFR1 and TNFR2 (170). Previous studies have shown that TNF 
promotes T cell proliferation through TNFR2 (181, 183). Yet, the effect on Treg proliferation 
and function remains to be revealed. Throughout this work, TNCscTNF80, an agonist that 
binds specifically to TNFR2 with a high bioactivity (228), was used to determine the effect of 
TNFR2 signalling on Treg function. In order to study how this specific TNFR2 agonist 
interferes with CD4+ and CD8+ cell expansion, TNCscTNF80 was added to T cell 
proliferation assays. Those assays were performed using both lymphocytes from wild type 
(WT) and TNFR2-deficient (TNFR2-/-) mice in order to control for interactions of 
TNCscTNF80 and TNFR1. 
3.1.1 Comparison of the behaviour of wild type and TNFR2-/- lymphocytes 
3.1.1.1 Proliferation of CD4+ cells from wild type and TNFR2-/- mice 
In this experiment the behaviour of CD4+ cells from WT and TNFR2-/- mice was 
compared. The relative proportions of proliferating out of all CD4+ cells were determined 
after lymphocytes had been cultured with anti-CD3ε antibody for 72 hours. In general, CD4+ 
cells from the wild type mice proliferated more than CD4+ cells from the TNFR2-/- mice. If a 
higher concentration of anti-CD3ε antibody was used for stimulation, the proportion of CD4+ 
cells that were proliferating increased. TNCscTNF80 further enhanced the proliferation of 
WT CD4+ cells. This statistically significant effect was seen after stimulation with 
0.06 µg/mL (Figure 7A) and 0.5 µg/mL anti-CD3ε antibody (Figure 7B). The addition of 
control supernatant (CS), however, did not increase the proliferation of WT CD4+ cells. CD4+ 
cells from the TNFR2-/- mouse did not show an increased proliferation when TNCscTNF80 
had been added to the culture.  
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Figure 7: Impact of TNCscTNF80 on proliferation of CD4+ cells from WT and TNFR2-/- 
mice. CFSE-labeled naïve splenocytes from WT (black bars) or TNFR2-/- (white bars) mice 
were cultured alone, with 10 ng/ml TNCscTNF80 or with CS used in equivalent volume in 
the presence of 0.06 µg/ml anti-CD3ε (A) or 0.5 µg/ml anti-CD3ε (B) for 72 hrs. The data is 
derived from a representative of two experiments, shown is the mean + SD of three technical 
replicates. * indicates a statistically significant difference of the indicated groups. Statistical 
analysis was done by two-way ANOVA with Bonferroni post-test. 
3.1.1.2 Proliferation of CD8+ cells from wild type and TNFR2-/- mice 
The relative proportions of proliferating out of all CD8+ cells were also determined. 
Corresponding to the findings in the CD4+ cell subset, the TNFR2-/- CD8+ cells were 
proliferating less than the WT CD8+ cells after stimulation with 0.06 µg/ml anti-CD3ε. 
Additional stimulation with TNCscTNF80 significantly enhanced the proliferation rate of WT 
CD8+ cells (Figure 8A). This effect was far less pronounced when compared to the CD4+ 
cells. In the repeat of this experiment, however, TNCscTNF80 increased the proliferation of 
CD8+ to a stronger extend (data not shown). The addition of TNCscTNF80 did not 
considerably enhance the proliferation of TNFR2-/- CD8+ cells. Stimulation with 0.5 µg/mL 
anti-CD3ε antibody resulted in a strong proliferation of CD8+ cells from both WT and 
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TNFR2-/- mice. TNCscTNF80 could not further enhance the proliferation in this case (Figure 
8B).  
 
Figure 8: Impact of TNCscTNF80 on proliferation of CD8+ cells from WT and TNFR2-/- 
mice. CFSE-labeled naïve splenocytes from WT (black bars) or TNFR2-/- (white bars) mice 
were cultured alone, with 10 ng/ml TNCscTNF80 or with CS used in equivalent volume in 
the presence of 0.06 µg/ml anti-CD3ε (A) or 0.5 µg/ml anti-CD3ε (B) for 72 hrs. The data is 
derived from a representative of two experiments, shown is the mean + SD of three technical 
replicates. * indicates a statistically significant difference of the indicated groups. Statistical 
analysis was done by two-way ANOVA with Bonferroni post-test. 
3.1.2 Serial dilution of anti-CD3ε antibody: Proliferation of T cells 
A serial dilution of the anti-CD3ε antibody was performed and lymphocyte cultures 
were stimulated with the different concentrations of anti-CD3ε antibody for 72 hours in order 
to determine if the anti-CD3ε concentration influences the effect of TNCscTNF80 on the 
proliferation rate of CD4+ and CD8+ cells. 
3.1.2.1 Proliferation of CD4+ cells depending on anti-CD3ε concentration 
As shown in Figure 9, following stimulation with anti-CD3ε antibody, the 
proliferation of CD4+ cells increased in a concentration-dependent manner. Additionally, 
lymphocytes were treated with TNCscTNF80, which enhanced proliferation of CD4+ cells 
III- Results 42 
even further. The correlation between the level of CD4+ proliferation and the concentration of 
the anti-CD3ε antibody could also be observed if the cells were treated with TNCscTNF80. 
Nevertheless, the proliferation reached a plateau after stimulation with 0.25 µg/ml anti-CD3ε 
antibody and TNCscTNF80; a higher concentration of anti-CD3ε antibody did not result in an 
increased proliferation anymore. The addition of CS did not enhance the level of proliferation 
of CD4+ cells.  
	  
Figure 9: Proliferation of CD4+ cells with increasing concentrations of anti-CD3ε 
antibody. CFSE-labeled splenocytes from WT mice were cultured alone (grey line, squares), 
with 10 ng/ml TNCscTNF80 (black line, triangles) or with CS used in equivalent volume 
(dotted line, circles) in the presence of increasing concentrations of anti-CD3ε antibody for 
72 hrs. The data represents three individual experiments, shown is the mean + SD of two 
technical replicates. * indicates a statistically significant difference of the indicated groups as 
determined by two-way ANOVA with Bonferroni post-test.  
3.1.2.2 Proliferation of CD8+ cells depending on anti-CD3ε concentration 
The same effect, which was shown for the CD4+ cells, was also observed in the CD8+ 
cell population (Figure 10). The CD8+ cells generally proliferated to a higher extend than the 
CD4+ cells. With increasing concentrations of anti-CD3ε antibody the proliferation enhanced 
in a dose-dependent manner. Addition of TNCscTNF80 could further augment the 
proliferation, while addition of CS in equivalent amounts to TNCscTNF80 could not. The 
proliferation of CD8+ reached a plateau if the lymphocytes had been stimulated with 
0.25 µg/mL anti-CD3ε antibody and TNCscTNF80. Further increasing the concentration of 
anti-CD3ε antibody did not elevate the level of proliferation anymore. 
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Figure 10: Proliferation of CD8+ cells with increasing concentrations of anti-CD3ε 
antibody. CFSE-labeled splenocytes from WT mice were cultured alone (grey line, squares), 
with 10 ng/ml TNCscTNF80 (black line, triangles) or with CS used in equivalent volume 
(dotted line, circles) in the presence of increasing concentrations of anti-CD3ε antibody for 
72 hrs. The data represents three individual experiments, shown is the mean + SD of two 
technical replicates. * indicates a statistically significant difference of the indicated groups as 
determined by two-way ANOVA with Bonferroni post-test. 
3.1.3 Serial dilution of TNCscTNF80: Proliferation of T cells 
Throughout this work, TNCscTNF80 was utilized in a concentration of 10 ng/mL, 
according to the TNF concentration used in previous studies with Treg (216). The objective of 
the following experiments was to assess if changing the concentration of TNCscTNF80 alters 
the enhancing effect it has on T cell proliferation.  
3.1.3.1 Proliferation of CD4+ cells depending on TNCscTNF80 concentration 
As seen in Figure 11, TNCscTNF80 enhanced the proliferation of activated CD4+ cells 
in a dose-dependent manner. While the proliferation could not be increased with 0.001 ng/ml 
or 0.01 ng/mL TNCscTNF80, it was steadily increasing when TNCscTNF80 was added to the 
culture in a concentration of 0.1 ng/mL or higher. No effect on the proliferation of CD4+ cells 
could be observed if the CS had been given into the culture in equivalent volumes to 
TNCscTNF80.  
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Figure 11: Proliferation of CD4+ cells with increasing concentrations of TNCscTNF80. 
CFSE-labelled naïve splenocytes from WT mice were cultured with increasing concentrations 
of TNCscTNF80 (black line, triangles) or increasing amounts of CS used in equivalent 
volumes (dotted line, circles) in the presence of 0.5 µg/ml anti-CD3ε for 72 hrs. The data 
originates from a representative of three experiments, shown is the mean + SD of two 
technical replicates. * indicates a statistically significant difference of the indicated groups as 
determined by two-way ANOVA with Bonferroni post-test. 
3.1.3.2 Proliferation of CD8+ cells depending on TNCscTNF80 concentration 
Adding higher concentrations of TNCscTNF80 also increased the proliferation of 
activated CD8+ cells (Figure 12). While treatment with up to 0.01 ng/mL TNCscTNF80 only 
slightly augmented the CD8+ proliferation, treatment with 0.1 ng/ml, 1 ng/ml and 10 ng/mL 
TNCscTNF80 increased the proliferation in a concentration-dependent manner. 
Corresponding to the CD4+ cell population, CD8+ cells did not proliferate to a stronger extend 
if CS was present in the culture.  
	  
Figure 12: Proliferation of CD8+ cells with increasing concentrations of TNCscTNF80. 
CFSE-labelled naïve splenocytes from WT mice were cultured with increasing concentrations 
of TNCscTNF80 (black line, triangles) or increasing amounts of CS used in equivalent 
volumes (dotted line, circles) in the presence of 0.5 µg/ml anti-CD3ε for 72 hrs. The data 
originates from a representative of three experiments, shown is the mean + SD of two 
technical replicates. * indicates a statistically significant difference of the indicated groups as 
determined by two-way ANOVA with Bonferroni post-test. 
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3.1.4 Effect of TNFR agonists on the proliferation of lymphocytes 
TNCscTNF80, which has been used in this work so far, is specific for the TNFR2. 
TNCwtTNF, on the other hand, can activate both TNFR1 and TNFR2. Although several 
studies have suggested that TNFR2 is predominately responsible for the co-stimulatory effect 
TNF has on lymphocyte proliferation (180, 181, 183), signalling via TNFR1 might also 
contribute to enhanced cell activation. Thus, the proliferative response of CD4+ and CD8+ 
cells towards the TNFR1 and TNFR2 agonist TNCwtTNF was compared to effect of the 
TNFR2-specific agonist TNCscTNF80. 
3.1.4.1 Proliferation of lymphocytes in response to stimulation with TNFR agonists for 
48 hours  
Figure 13A shows that the proliferation of CD4+ cells was only marginally increased 
by TNCscTNF80 and only if used in higher concentrations, whereas TNCwtTNF had an 
enhancing effect on the proliferative response of CD4+ cells. The proliferation rate of CD8+ 
was promoted by both TNCwtTNF and TNCscTNF80; TNCwtTNF, however, influenced the 
proliferative response of CD8+ cells to a higher extend (Figure 13B). Nevertheless, the overall 
proliferation of CD8+ and especially CD4+ cells following stimulation for 48 hours was 
uncommonly low. The 48 h time-point is therefore too early to adequately detect an impact of 
TNFR agonists on T cell proliferation. 
	  
Figure 13: Proliferation of CD4+ (A) and CD8+ (B) cells with increasing concentrations 
of TNFR agonists after 48h of stimulation. CFSE-labeled naïve splenocytes from WT mice 
were cultured with increasing concentrations of TNCscTNF80 (grey bars), TNCwtTNF (black 
bars) or increasing amounts of CS utilized in equivalent volumes as TNCscTNF80 (white 
bars) in the presence of 0.5 µg/ml anti-CD3ε for 48 hrs. The dotted line shows the 
proliferation rate of CD4+ cells that were stimulated with 0.5 µg/ml anti-CD3ε alone. Shown 
is the mean + SD of two technical replicates. 
3.1.4.2 Proliferation of lymphocytes in response to stimulation with TNFR agonists for 
72 hours  
The proliferative response of both CD4+ and CD8+ cells was generally higher 
following stimulation for 72 hours, as demonstrated in Figure 14. TNCwtTNF and 
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TNCscTNF80 only slightly enhanced the proliferation of CD4+ (Figure 14A) and CD8+ 
(Figure 14B) cells. However, no difference could be seen between the effect of TNCscTNF80 
and TNCwtTNF. CS had only marginal effects on both cell populations.  
	  
Figure 14: Proliferation of CD4+ (A) and CD8+ (B) cells with increasing concentrations 
of TNFR agonists after 72h of stimulation. CFSE-labeled naïve splenocytes from WT mice 
were cultured with increasing concentrations of TNCscTNF80 (grey bars) and TNCwtTNF 
(black bars) or increasing amounts of CS utilized in equivalent volumes to TNCscTNF80 
(white bars) in presence of 0.5 µg/ml anti-CD3ε for 48 hrs. The dotted line shows the 
proliferation rate of CD4+ cells that were stimulated with 0.5 µg/ml anti-CD3ε alone. Shown 
is the mean + SD of two technical replicates. 
3.2 Cytokine production in the course of proliferation  
Cytokines play an important role in mediating immune responses. IL-10 functions as 
an anti-inflammatory factor reducing the proliferation of different immune cells and the 
production of proinflammatory cytokines (137). It is secreted by a variety of immune cells, 
including CD4+ regulatory T cells (153). IFN-γ, on the other hand, is an immunostimulatory 
cytokine that is mainly released by Th1 cells (235). As TNF, via TNFR2, promotes T cell 
proliferation, it was of interest if TNF-TNFR2 interaction could also alter the secretion of 
IL-10 or IFN-γ by T cells. While IFN-γ was detectable in the cell culture supernatants of 
various experiments, IL-10 was not found at all (data not shown). 
3.2.1 Production of IFN-γ during proliferation assays in the presence of TNCscTNF80 
First of all, it was assessed if the presence of the TNFR2 agonist TNCscTNF80 could 
alter the production of IFN-γ during the course of T cell proliferation. IFN-γ was detectable in 
the cell culture supernatants following T cell activation for 72 hours with 0.5 µg/ml 
anti-CD3ε antibody. Addition of TNCscTNF80 resulted in a sharp increase of IFN-γ in those 
supernatants, whereas CS did not have any effect on the level of production (Figure 15). 
When cells were activated with only 0.06 µg/ml anti-CD3ε antibody, no IFN-γ was found in 
the supernatants, not even in the presence of TNCscTNF80 (data not shown). 
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Figure 15: Production of IFN-γ depending on the presence of TNCscTNF80. CFSE-
labeled naïve splenocytes from WT mice were cultured alone (white bar), with CS (grey bar) 
or with TNCscTNF80 (black bar) in the presence of 0.5 µg/ml anti-CD3ε antibody for 72 hrs. 
The supernatants of three technical replicates were pooled and the concentration of IFN-γ was 
measured using ELISA.  
3.2.2 Production of IFN-γ depending on the concentration of anti-CD3ε antibody 
It was observed in the previous experiment that the activation with 0.06 µg/ml 
anti-CD3ε antibody failed to induce IFN-γ production. Thus, it was examined if increasing the 
concentrations of the stimulatory antibody has an effect on the secretion of IFN-γ by T cells. 
There was no IFN-γ detectable in cultures that had received 0.004 µg/ml, 0.015 µg/ml or 
0.06 µg/ml anti-CD3ε antibody for activation, neither with nor without additional 
TNCscTNF80 (data not shown). Nevertheless, a dose-dependent increase of IFN-γ was 
observed when cells had been activated with 0.25 µg/ml or 0.5 µg/ml in the presence of 
TNCscTNF80 (Figure 16).  
	  
Figure 16: Increased production of IFN-γ due to higher concentration of anti-CD3ε 
antibody. CFSE-labeled naïve splenocytes from WT mice were cultured alone (white bars), 
or with TNCscTNF80 (black bars) in the presence of increasing concentrations of anti-CD3ε 
antibody for 72 hrs. The supernatants of two technical replicates were pooled and the 
concentration of IFN-γ was measured using ELISA. ND: IFN-γ was not detectable. 
3.2.3 Production of IFN-γ depending on the concentration of TNCscTNF80 
In addition to the effect of increasing concentration of anti-CD3ε antibody, the impact 
of enhancing TNCscTNF80 concentration was also studied. If the cell cultures were treated 
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with more TNCscTNF80, the concentration of IFN-γ in the cell culture supernatants increased 
in a dose-dependent manner (Figure 17). The addition of CS equivalent in volume to 10 ng/ml 
of TNCscTNF80, however, only resulted in a limited secretion of IFN-γ, which was 
comparable to the concentration found in the absence of TNCscTNF80. 
	  
Figure 17: Increased production of IFN-γ due to higher concentration of TNCscTNF80. 
CFSE-labeled naïve splenocytes from WT mice were cultured with increasing concentrations 
of TNCscTNF80 (black line, squares) or CS used in equivalent amounts to 10 ng/ml of 
TNCscTNF80 (triangle) in the presence of 0.5 µg/ml anti-CD3ε for 72 hrs. The supernatants 
of two technical replicates were pooled and the concentration of IFN-γ was measured using 
ELISA. 
3.2.4 Effect of different TNFR agonists on the production of IFN-γ  
In the previous experiments it was demonstrated that the TNFR2 specific agent 
TNCscTNF80 increased the ability of T cells to produce IFN-γ. Yet, signalling via TNFR1 
might also influence IFN-γ secretion. Therefore, the level of IFN-γ in cell culture supernatants 
of activated lymphocytes in the presence of TNCwtTNF, which activates both TNFR1 and 
TNFR2, was measured and compared to the amount of IFN-γ present in the cultures that were 
treated with TNCscTNF80. As illustrated in Figure 18, stimulation with TNCwtTNF for 72 
hours generally increased the concentration of IFN-γ in the cell culture supernatants to a 
higher extend than TNCscTNF80. The production of IFN-γ was also dependent on the 
concentration of TNCwtTNF, which is in line with the previous observations made for 
TNCscTNF80. If cell cultures were stimulated for 48 hours in the presence of high-dose 
TNCwtTNF, the amount of IFN-γ found in the supernatant was even greater than after 
treatment with TNCwtTNF for 72 hours. Yet, stimulation with TNCscTNF80 for 48 hours 
failed to induce IFN-γ production. In the presence of CS no IFN-γ production was detectable 
either (data not shown). 
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Figure 18: Increased production of IFN-γ in the presence of different TNFR agonists. 
CFSE-labeled naïve splenocytes from WT mice were cultured with increasing concentrations 
of TNCscTNF80 (blue symbols) and TNCwtTNF for (black symbols) in the presence of 
0.5 µg/ml anti-CD3ε for 48 hrs (dotted lines) and 72 hrs (solid lines). The supernatants of two 
technical replicates were pooled and the concentration of IFN-γ was measured using ELISA. 
3.3 Suppression assays: Proliferation of Teff under the suppression of Treg 
CD4+CD25+ Treg are important for the maintenance of immune tolerance as they 
suppress the proliferation and function of Teff and thus inhibit overshooting immune responses 
(18). It has been found that Treg express the TNFR2 on their surface to a stronger extend than 
Teff (216). Further, it has been suggested that TNF promotes proliferation and suppressor 
capacity of Treg cells (217). Yet, other groups have reported that TNF has inhibitory effects on 
Treg function (210, 211). Thus, the goal of the following experiments was to determine how 
TNF-TNFR2 signalling affects the Treg-mediated suppression of effector T cells. 
3.3.1 Effect of TNCscTNF80 on the suppressive activity of CD4+CD25+ cells 
In this study, the suppression assays were performed in the absence or presence of the 
TNFR2-specific agent TNCscTNF80 in order to examine the effect of TNFR2 signalling on 
the suppressive capacity of CD4+CD25+ cells. TNCscTNF80 cannot signal via TNFR1 (236) 
and thus does not have any effects on TNFR2-deficient lymphocytes. This has been 
demonstrated in the proliferation assays with splenocytes from TNFR2-/- mice that were 
performed for this thesis (refer to 3.1.1). To ensure that TNCscTNF80 only modulates Treg 
function without influencing Teff cells, lymphocytes from TNFR2-/- mice were cultivated with 
MACS sorted CD4+CD25+ Treg cells from WT mice. Changes in the proliferative response of 
TNFR2-/- CD4+ and CD8+ cells must, therefore, be due to direct effects of TNCscTNF80 on 
the suppressive activity of the CD4+CD25+ cells.  
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As expected, CD4+CD25+ Treg suppressed the proliferation of CD4+ (Figure 19A) and 
to a lesser extend also of CD8+ (Figure 19B) cells from TNFR2-/- mice. In the presence of Treg, 
the average proliferation rate of anti-CD3-stimulated CD4+ cells was reduced to 77.80 % of 
its initial level. The mean proliferation level of CD8+ cells was reduced to 91.26 % 
respectively. In the presence of TNCscTNF80, however, the proliferation of TNFR2-/- CD4+ 
cells under Treg-mediated suppression was markedly higher. If TNCscTNF80 was added, the 
average proliferation rate of CD4+ cells that were co-cultured with CD4+CD25+ Treg was 
enhanced to 102.06 % of the initial level found in the absence of Treg (Figure 19A). Likewise, 
the proliferation of CD8+ cells under Treg-induced suppression was enhanced to 94.74 % of the 
initial rate in the absence of Treg (Figure 19B). Thus, it could be shown that TNF, through 
signalling via TNFR2 on CD4+CD25+ Treg, reduced the suppressive capacity of Treg over 
CD4+ and CD8+ lymphocytes. CS in equivalent volumes as TNCscTNF80 did not reduce the 
suppressive activity of Treg, it even slightly enhanced the Treg-mediated suppression of CD4+ 
and especially CD8+ cells. 
  
Figure 19: Impact of TNCscTNF80 on the suppressive capacity of CD4+CD25+ cells over 
the proliferation of CD4+ (A) and CD8+ (B) cells. CFSE-labeled naïve splenocytes from 
TNFR2-/- mice were cultured together with MACS-sorted CD4+CD25+ cells from WT mice at 
ratios of 3:1 either alone, with 10 ng/ml TNCscTNF80 or with CS used in equivalent volume 
in the presence of 0.5 µg/ml anti-CD3ε antibody for 72 hrs. The proliferation of TNFR2-/- 
cells that were stimulated with 0.5 µg/ml anti-CD3ε in the absence of CD4+CD25+ cells 
served as a control. The data was then normalized to those controls; the proliferation levels of 
these controls are defined as 100% and the proliferation rate of the CD4+ and CD8+ cells 
under suppression is shown as the fold change in comparison to the controls. The data 
originates from four different experiments; every group of dots represents one individual 
experiment. Every dot shows the mean of two technical replicates; the mean values for all the 
experiments are additionally shown (black lines). 
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3.3.2 Comparison of the effect of TNCscTNF80 on CD4+CD25+ cells from TNFR1-/- and 
TNFR2-/- mice  
Whereas the majority of cells express TNFR1, lymphocytes mainly express TNFR2 
(170). Moreover, it is generally believed that TNF preferentially mediates its effects on 
lymphocytes through TNFR2 (183). The TNF-associated effects on Treg cells have also been 
attributed to TNFR2 (211, 217). Since the TNF mutant TNCscTNF80 is supposed to be 
specific for TNFR2, the objective of this experiment was to verify that TNCscTNF80 did not 
have any effect on the function of CD4+CD25+ Treg that was mediated via a receptor other 
than TNFR2. Therefore, it was assessed if incubation with TNCscTNF80 could also change 
the suppressive activity of CD4+CD25+ from TNFR2-/- mice. CD4+CD25+ from TNFR1-
deficient (TNFR1-/-) mice served as a control. As seen in Figure 20, CD4+CD25+ cells from 
both TNFR1-/- and TNFR2-/- mice suppressed the proliferation of CD4+ and CD8+ cells, 
although the inhibitory effect of TNFR1-/- CD4+CD25+ cells on T cell proliferation was 
relatively low. Nevertheless, TNCscTNF80 completely reversed the suppressive activity of 
CD4+CD25+ cells from TNFR1-deficient mice. In the presence of TNCscTNF80, the 
proliferation of CD4+ and CD8+ cells in co-cultures with TNFR1-/- Treg was higher than in the 
controls without Treg. However, TNCscTNF80 did not reduce the suppressive activity of 
TNFR2-/- CD4+CD25+ cells. The effect of TNCscTNF80 on the TNFR1-/- Treg-mediated 
suppression must be due to direct effects on Treg, because the suppressed Teff were TNFR2-
deficient and therefore could not respond to TNCscTNF80. Thus, it can be excluded that 
TNCscTNF80 inhibits T cell suppression by reducing the susceptibility of Teff towards 
Treg-mediated suppression. Taken together, it could be shown that the attenuation of 
Treg-induced T cell suppression by TNCscTNF80 is mediated through TNFR2 and not TNFR1 
on Treg cells. 
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Figure 20: Effect of TNCscTNF80 on the suppressive activity of TNFR1-/- and TNFR2-/- 
CD4+CD25+ Treg over the proliferation of CD4+ (A) and CD8+ (B) cells. CFSE-labeled 
TNFR2-/- splenocytes were cultured with MACS-sorted CD4+CD25+ cells from TNFR1-/- 
(white bars) and TNFR2-/- (black bars) mice at ratios of 3:1 and activated with 0.5 µg/ml 
anti-CD3ε antibody with or without 10 ng/ml TNCscTNF80 for 72 hrs mice. Shown is the 
mean + SD of two technical replicates. The mean value for the proliferation of 
TNFR2-/- splenocytes that were cultured without purified CD4+CD25+ cells in the presence of 
0.5 µg/ml anti-CD3ε is shown as a solid line. 
3.3.3 Change of the suppressive activity of CD4+CD25+ cells: Comparison of 
TNCwtTNF and TNCscTNF80  
It was shown in the previous experiment that TNCscTNF80 inhibits Treg suppressor 
capacity exclusively through signalling via the TNFR2. Yet, Treg-induced suppression might 
also be influenceable by TNFR1 signalling. In order to reveal if the additional activation of 
TNFR1 can interfere with Treg function, suppression assays were performed in the presence of 
the combined TNFR1 and TNFR2 agonist TNCwtTNF as well. The proliferation of 
TNFR2-/- CD4+ and CD8+ cells in presence of WT CD4+CD25+ Treg and either TNCwtTNF or 
TNCscTNF80 was compared. When Treg were co-cultured with splenocytes at ratios of 1:3, 
they suppressed the anti-CD3ε-induced proliferation of CD4+ (Figure 21A) and CD8+ (Figure 
21B). Both TNCscTNF80 and TNCwtTNF reduced the Treg-mediated suppression of 
anti-CD3ε-activated CD4+ and CD8+ cells. The effect of TNCscTNF80, however, was less 
pronounced. TNCwtTNF was able to reverse the suppression induced by Treg, while 
TNCscTNF80 reduced the Treg-induced suppression but did not completely abrogate it. 
Treatment with CS, on the other hand, did not decrease the suppression but enhanced T cell 
suppression to a certain degree instead. Taken together, it could be shown that additional 
activation of TNFR1 did not reverse the TNFR2-induced reduction of Treg suppressive 
function but rather enhanced it. 
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Figure 21: Impact of different TNFR agonists on the suppression of CD4+ (A) and CD8+ 
(B) cells by Treg. CFSE-labeled TNFR2-/- splenocytes were cultured with MACS-sorted 
CD4+CD25+ cells from WT mice at ratios of 3:1 for 72 hrs and stimulated either with 
0.5 µg/ml anti-CD3ε antibody alone or with anti-CD3ε antibody together with 10 ng/ml 
TNCwtTNF, 10 ng/ml TNCscTNF80 or CS used in equivalent volumes as TNCscTNF80. 
Shown is the mean + SD of two technical replicates. The mean value for the proliferation of 
TNFR2-/- splenocytes that were cultured without purified CD4+CD25+ cells in the presence of 
0.5 µg/ml anti-CD3ε is shown as a solid line. * indicates a statistically significant difference 
of the indicated groups as determined by one-way ANOVA with Bonferroni post-test. 
3.3.4 Serial dilution of TNCscTNF80: Effect on the suppression by Treg 
In the suppression assays throughout this work, TNCscTNF80 was used at a 
concentration of 10 ng/ml. Previous reports that had assessed the effects of TNF on Treg 
suppressor function also used TNF at concentrations of 10 ng/ml (216). Yet, the 
TNFR2-specific agonist TNCscTNF80 has a higher affinity for its receptor (228), and might, 
therefore, mediate stronger effects when used in equal concentrations. Thus, it was of interest, 
how much the suppressive activity of WT CD4+CD25+ cells is changed when the 
concentrations of TNCscTNF80 is reduced. TNCscTNF80 decreased the Treg-induced 
suppression of TNFR2-/- CD4+ (Figure 22A) and CD8+ (Figure 22B) cells in a dose-dependent 
manner. However, in contrast to previous experiments (refer to 0), 10 ng/ml TNCscTNF80 
completely reversed Treg suppression of CD4+ cells. The proliferation was higher in this case 
when compared to the proliferation of CD4+ cells in the absence of Treg (Figure 22A). 
Addition of CS to the co-culture did not have any effect on the suppressive capacity of the 
CD4+CD25+ cells on CD4+ or CD8+ cells (data not shown). 
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Figure 22: Effect of the concentration of TNCscTNF80 on the Treg-mediated suppression 
of CD4+ (A) and CD8+ (B) cells. CFSE-labeled TNFR2-/- splenocytes were culture with 
MACS-sorted WT CD4+CD25+ cells in the presence of 0.5 µg/ml anti-CD3ε antibody and 
increasing concentrations of TNCscTNF80. Shown is the mean + SD of two technical 
replicates. TNFR2-/- splenocytes that were cultured alone in the presence of 0.5 µg/ml 
anti-CD3ε served as a control (dotted line). 
3.4 Surface markers 
There are a variety of surface molecules, which are preferentially expressed by resting 
and activated Treg cells but which are only found on conventional T cells upon activation (33). 
In the previous experiments it was demonstrated that the TNFR2 agonist TNCscTNF80 limits 
the Treg-mediated suppression of T lymphocytes. Because some of the surface markers are 
also associated with Treg function (36), downregulation of those characteristic molecules could 
lead to an abrogation of Treg suppressor capacity. This might pose a possible mechanism for 
the observed TNF-induced attenuation of Treg function. Thus, it was assessed if TNCscTNF80 
influences the expression of a selection of typical surface markers, i.e. CD25, CD39, CD73, 
OX40, GITR and CTLA-4. Therefore, splenocytes were activated with anti-CD3ε antibody 
for up to 72 hours in the absence or presence of TNCscTNF80 and the expression levels of 
those markers were measured on lymphocytes that were gated on FoxP3+.  
As seen in Figure 23A, the expression of CD25 after incubation for three hours was 
equally high for both the non-stimulated and the activated cells and there was no alteration 
observed when TNCscTNF80 was present in the culture. An increase in CD25 was noticed 
following anti-CD3ε-induced stimulation for 24 hours or more. Addition of TNCscTNF80 
reduced CD25 expression after 48 and 72 hours. The majority of Foxp3+ cells were CD39+, 
regardless of stimulation or not. Yet, TNCscTNF80 lead to a sharp decrease of CD39 
expression after 48 and 72 hours, while addition of CS did not alter the expression at all 
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(Figure 23B). The level of CD73 was constantly high, almost all cells were positive for CD73, 
ranging from 97.50 % to 99.71 %, over the whole time span independently of additional 
TNCscTNF80 or CS (Figure 23C). Generally, the expression of OX40 was relatively high and 
was enhanced further when cells were activated with anti-CD3ε, reaching a plateau after 48 
hours. Yet, there was only a slight difference when TNCscTNF80 was present in the culture 
(Figure 23D). CTLA-4 was the surface marker that was least expressed by Treg, only between 
52.08 % and 55.56 % of Foxp3+ cells showed this receptor on their surface. While the non-
stimulated cells maintained similar levels of CTLA-4 over the whole incubation time, 
stimulation with anti-CD3 for 48 and 72 hours resulted in a strong decrease of CTLA-4 
expression regardless of additional TNCscTNF80 or CS (Figure 23E). GITR was found on the 
majority of Foxp3+ cells, both on activated and non-stimulated cells. Yet, the addition of 
TNCscTNF80 led to a decline of its expression after 48 and 72 hours (Figure 23F). In 
conclusion, TNCscTNF80 did not considerably alter the expression of CD73, OX40 and 
CTLA-4, while it decreased the expression of CD39, GITR and to a smaller extend also of 
CD25.  
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Figure 23: Expression of surface markers on Foxp3+ cells. Naïve splenocytes were 
cultured alone (black line, circles), with CS (grey line, triangles) or TNCscTNF80 (blue line, 
squares) in the presence of 0.5 µg/ml anti-CD3ε antibody for up to 72 hrs. Non-stimulated 
cells (dotted line, circles) served as a negative control. The percentages of cells positive for 
the surface markers were obtained in dot plots gated on Foxp3+ cells. Shown is the 
mean + SD of two technical replicates.  
3.5 Establishment of a method for intracellular staining of pStat5 
We demonstrated that TNFR agonists limit Treg suppressor function. Although TNF is 
widely accepted as a mediator of Treg function, the underlying molecular mechanisms still 
have not been revealed. It is known that Treg cells require TCR and IL-2R stimulation in order 
to function adequately (18, 29). Correspondingly, various lines of evidence have 
demonstrated that IL-2-dependent activation of Stat5 is important for Treg development and 
maintenance (76, 83, 84, 237). Thus, TNF might influence the signalling cascade downstream 
of the IL-2R and thereby change the suppressor function of Treg. While conventional T cells 
activate various signalling pathways upon ligation to the IL-2R, Treg predominantly activate 
the JAK-Stat5 pathway (74, 77). The inhibition of Stat5 activation, could therefore pose a 
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potential mechanism used by TNF to abrogate Treg function. Thus, the ability of TNFR 
agonists to influence the activation of Stat5, i.e. the expression of phosphorylated Stat5 
(pStat5), in activated Treg was examined in this work. 
3.5.1 Variations of staining protocol for pStat5 with BAF3 cells 
Traditionally, western blot is used for studying cell-signalling events. Yet, large cell 
numbers are required to perform those immunoblots, which is a great limitation for the 
applicability of this technique in small cell populations such as Treg (238). Additionally, 
western blot only allows the measurement of the average expression of a phospho-protein in 
non-separated cell subsets. By using flow cytometry, however, signalling events can be 
evaluated on a single-cell basis while cell subsets can be identified simultaneously based on 
their surface maker expression (239). Therefore flow cytometry was used to examine the 
phosphorylation status of Stat5 in response to TNF in this study. However, the pStat5 protocol 
supplied by the manufacturer was only available for western blotting. Therefore, a variety of 
experiments were required in order to find the most adequate variation for flow cytometry. 
Ba/F3 cells were used for the establishment of this staining protocol as they expand easily and 
express high levels of pStat5 under specific circumstances. The Ba/F3 cell line is generated 
from pre-B cells and depends on IL-3 for growth. Removing IL-3 for six up to twelve hours 
leads to a strong induction of pStat5 once the cultures are re-stimulated with IL-3 (240). Thus, 
for the following experiments, starved BA/F3 cells were incubated with IL-3 for 30 minutes 
at 37 °C and then stained with the rabbit monoclonal antibody (mAB) against pStat5/Tyr694.  
3.5.1.1 Alterations in fixation, permeabilization and incubation with the primary 
antibody 
In all of the following results, the protocol for intracellular staining of pStat5 as 
described in 2.4.2 is referred to as the standard protocol. In order to establish the most 
adequate procedure, variations of this final protocol had to be performed beforehand.  
First of all, it was tested if the time of incubation was relevant for the quality of flow 
cytometry data. As shown in Figure 24, it was possible to stain pStat5 after incubation with 
the primary antibody overnight and for 30 minutes. However, if the incubation was performed 
overnight, the separation of the pStat5+ and pStat5- populations was more defined 
(Figure 24A). Then, it was of interest if the fixation with 4 % formaldehyde or the 
permeabilization with 100 % methanol was necessary for an adequate staining of pStat5. 
Previous data has demonstrated that a strong permeabilization agent, such as methanol, is 
required for pStat5 detection due its nuclear location (241). Further, it has been shown that 
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rapid fixation, which can be achieved by applying formaldehyde together with methanol, is 
necessary in order to inhibit the activity of intracellular phosphatases and, thereby, capture the 
original phosphorylation status (242). It was seen here that it was possible to stain pStat5 if 
cells were not fixed in formaldehyde but permeabilized with methanol, both after incubation 
overnight (Figure 24C) and for 30 minutes (Figure 24D). Nevertheless, without fixation the 
pStat5+ cells were generally not as distinguishable from the pStat5- cells. The separation of 
both subsets was less precise if the unfixed cells were incubated with the primary antibody for 
only 30 minutes (Figure 24D). On the other hand, it was not possible to detect pStat5 if cells 
were not permeabilized with methanol but fixed with formaldehyde (Figure 25). Therefore, in 
every future experiments cells were fixed with 4 % formaldehyde, permeabilized with 100 % 
methanol and incubated with the primary antibody overnight. 
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Figure 24: Variations of staining protocol: Non-stimulated (A1-D1) vs. activated with 
1 µg IL-3 (A2-D2). Ba/F3 cells were cultivated without IL-3 for 12 hours before 
restimulation with IL-3 (right panels, “2”) or left without IL-3 (left panels, “1”). 30 min later, 
cells were harvested and assayed for pStat5 by various protocols. Standard protocol, antibody 
incubation overnight (A); Standard protocol, antibody incubation for 30 min (B); without 
formaldehyde, incubation overnight (C); without formaldehyde, incubation for 30 min (D). 
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Figure 25: Staining of pStat5 without permeabilization with methanol: Non-stimulated 
(A) vs. stimulated with 1 µg IL-3 (B). Ba/F3 cells were cultivated without IL-3 for 12 hours 
before restimulation with IL-3 (B) or left without IL-3 (A). 30 min later, cells were harvested 
and assayed for pStat5 according to the standard protocol without permeabilization with 
methanol. 
It was also assessed if pStat5 was detectable when the protocol recommended by 
eBioscience for Foxp3 staining was performed, which includes using the fixation and 
permeabilization solutions supplied in their Foxp3 staining kit. However, this was not 
successful, as, unlike expected, none of the IL-3 stimulated Ba/F3 cells showed pStat5 
expression after the staining procedure (Figure 26).  
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Figure 26: Staining of intracellular pStat5 with Foxp3 staining protocol in 
non-stimulated (A) and IL-3 activated cells (B). Ba/F3 cells were cultivated without IL-3 
for 12 hours before restimulation with IL-3 (B) or left without IL-3 (A). 30 min later, cells 
were harvested and assayed for pStat5 using the Foxp3 staining kit from eBioscience. 
3.5.1.2 Concentration of Triton X-100 in the required buffers 
The staining protocol states that 0.3 % of Triton X-100 should be used in all buffers. 
In order to identify if the addition of Triton X-100 was necessary, cells were stained using 
buffers that contained 0 %, 0.1 % and 0.3 % Triton X-100. After performing the staining 
procedure with the different concentrations of Triton X-100, no relevant differences of the 
percentages of pStat5+ cells or of the separation of pStat5+ and pStat5- populations were 
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noticed (data not shown). Thus, Triton X-100 was used in the buffers at the suggested 
concentration of 0.3 %.  
3.5.1.3 Titration of Rabbit mAB pStat5 Tyr694 (clones: D47E7 and C71E5) 
Titrations of two antibody clones against pStat5 were conducted in order to find an 
appropriate dilution of the mAB, with which good quality flow cytometry data could be 
achieved. A two-fold serial dilution of the D47E7 clone was performed, starting with 1:200. 
The C71E5 clone was utilized in dilutions of 1:100, 1:200 and 1:400. If the cells were stained 
with the C71E5 clone the staining was most effective if a 100- or 400-fold dilution had been 
used (data not shown). Yet, the D47E7 clone generally produced better results. The highest 
proportions of pStat5+ populations in response to IL-3 re-stimulation were obtained using a 
400- and 800-fold dilution of the D47E7 clone (Figure 27). Since there was no relevant 
difference between the 1:400 and a 1:800 dilution, a 600-fold dilution was used standardly in 
the following experiments.  
	  
Figure 27: Proportion of pStat5+ cells depending on the dilution of the rabbit anti-mouse 
mAB pStat5/Tyr694 (D47E7 clone). Ba/F3 cells were cultivated without IL-3 for 12 hours 
before restimulation with IL-3. 30 min later cells were harvested and stained with a 
monoclonal antibody against pStat5/Tyr694 (D47E7 clone) at various dilutions starting from 
1:200.  
3.5.1.4 Comparison of starved BA/F3 cells with continuously cultured BA/F3 cells 
Starved and IL-3-stimulated Ba/F3 cells had been used throughout all of the previous 
experiments in order to determine the most effective alteration of the western blot protocol for 
staining against intracellular pStat5. A positive control would also be needed in future 
experiments on the expression of pStat5 in lymphocytes. As starved Ba/F3 cells are not as 
rapidly available as regular growing Ba/F3 cells, it was of question if the continuously 
cultured cells could be used as a substitute. The quality of flow cytometry data following the 
staining against intracellular pStat5 was, therefore, compared between continuously cultured 
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and starved Ba/F3 cells. As demonstrated in Figure 28, the pStat5+ population was smaller 
and less separated from the pStat5- subset in the continuously cultured Ba/F3 cells when 
compared to the starved Ba/F3 cells. Yet, 88.87 % of growing cells were pStat5+ in response 
to stimulation with IL-3. This was accepted to be sufficient and staining of pStat5 in 
continuously cultured Ba/F3 was used as a positive control in future experiments. 
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Figure 28: Positive control for staining against intracellular pStat5 using starved BAF3 
after re-st mu ation (A) and continuously cu tured (B) cells. (A) Ba/F3 cells were 
cultivated without IL-3 for 12 hours, and after restimulation with IL-3 for 30 min they were 
harvested and assayed for pStat5. (B) Ba/F3 cells that had continuously been cultured with 
1 µg IL-3 were harvested in the pro-B cell stadium and assayed for pStat5. 
3.5.2 Variations of staining protocol with lymphocytes 
3.5.2.1 Altering the order of the staining protocol 
As it was of interest how TNFR agonists change pStat5 expression in different sub-
populations of lymphocytes, it had to be determined if staining against pStat5 was also 
possible in T cells using the method that was established for the Ba/F3 cell line. Furthermore, 
naïve splenocytes also needed to be stained with antibodies against extracellular markers in 
order to identify different cell populations, such as CD4+CD25+ Treg. Yet, the staining protocol 
for pStat5 includes methanol, which could potentially interfere with the staining process of 
surface molecules for flow cytometric analysis. Thus, it was required to find a method that 
produced high quality data for flow cytometric analysis of both extracellular and intracellular 
molecules. Therefore, the comparability of staining against intracellular pStat5, which 
includes the fixation and permeabilization processes, and staining against extracellular 
markers was assessed. The standard FACS staining, which is described in 2.4.1, was used as a 
control for the extracellular staining. The following variations of the standard protocol were 
applied: [1] staining against extracellular markers followed by fixation and permeabilization; 
[2] fixation and permeabilization followed by staining against extracellular markers; 
[3] staining against extracellular markers followed by permeabilization; [4] permeabilization 
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followed by staining against extracellular markers. The fixation process was always 
performed, because it had been shown that pStat5 was only detectable if cells were fixed with 
formaldehyde (Figure 25). A method was found to be effective if an adequate number of cells 
were positive for the surface marker in question and if the discrimination between the positive 
and negative populations could be made based on the surface marker. If the surface staining 
was performed after the cells were either fixed and permeabilized [2] or only permeabilized 
[4], the staining against CD4 and B220 was effective with every antibody. However, the cell 
populations could not be discriminated if surface staining was conducted prior to the 
permeabilization process, regardless of fixation [1] or not [3]. Yet, staining against CD25 did 
not show constant results. Thus, the emphasis was put on finding a method, which could 
readily detect CD25. The percentages of CD25+ cells within the CD4+ cell subset were 
assessed. If approximately 10 % were CD25+, which is the expected proportion of Treg cells in 
mice, the particular staining method was considered acceptable. For the results refer to Table 
1. Similar to CD4 and B220, detection of CD25 was not possible if staining was performed 
before the permeabilization with methanol [1], [3]. The most reliable method was the method 
that had been proposed by Cell Signalling, i.e. treating cells with formaldehyde and methanol 
for fixation and permeabilization before the immunostaining [2].  
 Standard FACS 
staining 
[1] 
1.FACS staining 
2.Fixation and 
permeabilization 
 
[2] 
1.Fixation and 
permeabilization 
2.FACS staining 
[3] 
1.FACS staining 
2.Permeabilization 
 
[4] 
1.Permeabilization 
2.FACS staining 
 
CD4-AF488  ✓ ✓ ✓ ✓ ✓ 
CD4-PE  ✓ X ✓ X ✓ 
CD4-AF647  ✓ ✓ ✓ ✓ ✓ 
B220-PerCP ✓ X ✓ X ✓ 
B220-PE ✓ X ✓ X ✓ 
CD25-APC ✓ (✓) X X X 
CD25-B/Strep-
FITC 
✓ X (✓) X (✓) 
CD25-B/Strep-
PerCP 
✓ X X X X 
CD25-PE ✓ NA ✓ NA ✓ 
CD25-B/Strep-PE ✓ NA ✓ NA NA 
CD25-FITC 
(7D4 clone) 
✓ X X NA NA 
Table 1 Comparison of the results of staining against extracellular markers while 
altering the standard protocol for staining against pStat5. ✓ = staining possible; 
X = staining not possible; NA = not available  
3.5.2.2 Alteration of fluorochromes conjugated to streptavidin 
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In the former experiments, the staining of CD25 was more precise if a biotin-labelled 
primary antibody had been utilized, but the quality of the acquired data was also dependent on 
the fluorochromes conjugated to streptavidin. Thus, different types of streptavidin-coupled 
fluorochromes were compared. The staining process was performed in the following orders: 
[1] fixation, permeabilization, incubation with the biotin-labelled primary antibody, 
incubation with streptavidin and other antibodies or [2] incubation with the biotin-labelled 
primary antibody, fixation, permeabilization, incubation with streptavidin and other 
antibodies. No relevant differences in the data quality could be identified between those two 
variations (data not shown). Therefore, for reasons of convenience, staining with both the 
biotin-labelled primary antibody and streptavidin was performed after fixation and 
permeabilization [1]. In contrast to preliminary experiments, it was observed here that the 
quality of data and the percentages of CD25+ within the CD4+ population were equally 
satisfying for all of the fluorochromes tested (Figure 29). 
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Figure 29: Staining against CD25 depending on the streptavidin-conjugated 
fluorochrome. Naïve Splenocytes were stained against CD4 and CD25, for the latter 
biotin-labelled primary antibodies and a variation of fluorochromes conjugated to streptavidin 
were used. The percentages of CD4+CD25+ cells (upper right, UR) were calculated. 
3.5.2.3 Alteration of fixation solution and buffers 
In order to analyse the importance of Triton X-100 and the concentration of 
formaldehyde, which are used in the fixation solutions, splenocytes were stained against 
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extracellular markers following the standard FACS staining protocol. Cells were then fixed 
using 2 % formaldehyde, 4 % formaldehyde or 4 % formaldehyde with 0.3 % Triton X-100. 
The highest proportions of CD25+ cells out of all CD4+ cells were found after fixation with 
4 % formaldehyde without any additional Triton X-100 in the fixation solution (data not 
shown). Fixation with formaldehyde and Triton X-100 led to a complete loss of the CD25+ 
cell population when using APC-labeled anti-CD25-mAB (data not shown). 
Further, the impact of different concentrations of Triton X-100 in the required buffers 
for the intracellular staining protocol on the efficiency of surface staining was assessed. The 
highest proportion of CD4+CD25+ cells and the best staining results were seen if 0.3 % Triton 
X-100 was used. Therefore, 0.3 % was the standard concentration of Triton X-100 in the 
buffers in future applications of this protocol, while the fixation was performed with 4 % 
formaldehyde without any additional Triton X-100. 
3.5.2.4 Substitution of methanol by acetone 
Acetone could be less aggressive for the cells during the permeabilization step, and, 
therefore, it was assessed if the substitution of methanol by acetone was applicable. 
Extracellular markers could not be detected by flow cytometry when the staining process was 
performed before the permeabilization with acetone. However, the extracellular makers were 
detectable if cells first were permeabilized with acetone and then incubated with the 
antibodies against those markers. This is consistent with the previous results for the 
permeabilization with methanol, which had shown that surface molecules were not detectable 
when staining was performed before the permeabilization process (Table 1). Moreover, 
staining of CD25-Biotin/Streptavidin-PE was performed both with methanol and acetone. In 
direct comparison, the separation of CD4+CD25+ from CD4+CD25- was more defined after the 
permeabilization with methanol (data not shown). Thus, acetone was not used as a substitute 
for permeabilization in future experiments. 
3.5.2.5 Staining against CD45.1, CD45.2 and Foxp3 for further identification of Treg 
Additional reliable markers for the identification of Treg other than CD25 were 
required. For this purpose, it was tested if staining with antibodies against CD45.1, CD45.2 
and Foxp3 were compatible with the staining against intracellular pStat5. For both CD45.1 
and CD45.2 (data not shown) the data was satisfactory. Thus, mouse lines, which are specific 
for CD45.2, could be used as source for CD4+CD25+ Treg. By staining against CD45.2 and 
CD45.1 it was, therefore, possible to differentiate between regulatory and effector T cells. 
Assaying against Foxp3 with the pStat5 staining protocol was also tested. The proportion of 
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CD4+Foxp3+ out of all CD4+ cells was 7.36 % (Figure 30), which is close to the estimated 
10 % Treg cells in the CD4+ population. Thus, Foxp3 could be used as an additional Treg 
marker in the experiments regarding pStat5 expression in Treg and Teff. 
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Figure 30: Staining against Foxp3 with pStat5 protocol. Naïve splenocytes were stained 
with Foxp3-PE and CD4-AF647 using the standard staining protocol for pStat5. Dot plot was 
gated on CD4+ cells and the percentage of CD4+Foxp3+ cells (UR) was calculated. 
3.6 Expression of phosphorylated Stat5 in regulatory and effector T cells 
Treg are highly dependent on IL-2 for their activation and function (13) and induce 
Stat5 as the main mediator of signal transduction downstream of the IL-2R (74). As shown in 
the previous experiments, TNCscTNF80 has a negative effect on Treg function (refer to 3.3). 
In Teff, TNFR2 signalling serves as a co-stimulator for IL-2 induction during early T cell 
activation through the activation of the Akt/NF-κB pathway (181, 243). Yet, the effect of 
TNFR agonists during activation of Treg remains unknown. It was hypothesized that 
TNCscTNF80 attenuates signal transduction in response to TCR/IL-2R stimulation and 
thereby inhibits Treg suppressor capacity. 
3.6.1 Change in expression of phosphorylated Stat5 after short-term incubation with 
TNFR agonists 
Following IL-2-driven activation, T cells are expected to express pStat5 rapidly (244). 
However, specific data on the kinetics of Stat5 upregulation in CD4+Foxp3+ Treg cells is rare. 
Yet, it is likely that Stat5 is also activated quickly in Treg cells upon stimulation. TNFR2 
signalling might therefore affect Treg function through interaction with intracellular processes 
during early cell activation. Thus, the influence of different TNFR agonists on the expression 
of pStat5 during short-term incubation for up to three hours was examined. Regulatory and 
non-regulatory T cells were identified using the extracellular markers CD4+ and CD25+. 
Subsequently, expression of pStat5 was analysed in the CD4+CD25- and CD4+CD25+ subsets. 
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3.6.1.1 Expression of pStat5 after 30 minutes 
Lymphocytes were stimulated with anti-CD3ε antibody, IL-2 and a TNFR agonist for 
30 minutes and the expression of pStat5 was compared between CD4+CD25+ and CD4+CD25- 
T cells. As seen in Figure 31A, CD4+CD25+ cells showed a higher expression of pStat5 after 
incubation with IL-2 and anti-CD3ε together in comparison to the non-stimulated cells and 
cells that had only received anti-CD3ε. If TNFR agonists were present in the culture, the 
expression of pStat5 in CD4+CD25+ cells was further enhanced. There were minor differences 
between the different TNFR agonists. The TNFR1 agonist hTNF had the smallest effect on 
pStat5 enhancement, while the TNFR2 agonist TNCscTNF80 enhanced pStat5 expression the 
most and the combined TNFR1 and TNFR2 agonist TNCwtTNF showed intermediate effects. 
In CD4+CD25- cells, however, the level of pStat5 did not change at all, neither following the 
stimulation with anti-CD3ε alone nor after incubation with anti-CD3ε and IL-2 together 
(Figure 31B). 
	  	  
	  
Figure 31: Expression of pStat5 in CD4+CD25+ (A) and CD4+CD25- (B) cells after 
activation with different TNFR agonists for 30 minutes. Naïve splenocytes were cultured 
alone, with hTNF (light grey bars), TNCwtTNF (dark grey bars) or TNCscTNF80 (black 
bars) in the presence of 10 ng/ml IL-2 and 0.5 µg/ml anti-CD3ε antibody. Non-stimulated (ns) 
cells served as a negative control; incubation with anti-CD3ε antibody alone served as a 
positive control. Shown is the mean fluorescence intensity (MFI) of pStat5 in 
CD4+CD25+ (A) cells and CD4+CD25- cells (B) as the mean + SD of two technical replicates. 
III- Results 68 
3.6.1.2 Expression of pStat5 after 60 minutes 
A culture of lymphocytes was stimulated with anti-CD3ε antibody, IL-2 and various 
TNFR agonists for 60 minutes. Some cells were incubated with IL-2 for 30 minutes before the 
TNFR agonists were added for another 30 minutes, others were incubated with the TNFR 
agonist first and IL-2 was added after 30 minutes. 
Figure 32A demonstrates that the CD4+CD25+ cells showed a stronger expression of 
pStat5 after incubation with anti-CD3ε and IL-2 for 60 minutes in comparison to the 
CD4+CD25+ cells that had received anti-CD3ε alone. If the cells were incubated with IL-2 
before the TNFR agonist was added, the expression of pStat5 only marginally increased 
compared to the incubation with IL-2 and anti-CD3ε alone. On the other hand, pre-incubation 
with a TNFR agonist for 30 minutes followed by the addition of IL-2 for another 30 minutes 
enhanced the expression of pStat5 in CD4+CD25+ cells. The greatest effect was seen after 
pre-incubation with TNCscTNF80, whereas the effect of TNCwtTNF was weaker and hTNF 
again only induced minor changes. Similar to the results upon stimulation for 30 minutes, the 
expression of pStat5 in the CD4+CD25- cells did not change at all following the different 
stimulation processes for 60 minutes (Figure 32B).  
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Figure 32: Expression of pStat5 in CD4+CD25+ (A) and CD4+CD25- (B) cells after 
activation with different TNFR agonists for 60 minutes. All cells but the non-stimulated 
(ns) negative control were activated with anti-CD3ε antibody. Cells were additionally treated 
with different combination of 10 ng/ml IL-2 and 10 ng/ml TNFR agonists. In one approach 
cells were incubated with IL-2 for 60 min and a TNF agonist was added for the last 30 min of 
incubation; in another approach the cells were incubated with a TNFR agonist for 60 min and 
IL-2 was added for the last 30 min. Incubation with anti-CD3ε antibody alone or anti-CD3ε 
antibody and IL-2 served as positive controls. Shown is the MFI of pStat5 of CD4+CD25+ (A) 
and CD4+CD25+ (B) cells as the mean + SD of two technical replicates. 
3.6.1.3 Expression of pStat5 after three hours 
Next, the behaviour of pStat5 in CD4+CD25- and CD4+CD25+ cells following 
incubation for three hours was analysed. The expression was generally low in non-stimulated 
CD4+CD25- and CD4+CD25+ cells. Yet, CD4+CD25+ cells showed an enhanced expression of 
pStat5 following stimulation with anti-CD3ε alone or in combination with IL-2 for three 
hours (Figure 33A). However, there was only a slight increase in the pStat5 expression in 
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CD4+CD25- cells after stimulation with anti-CD3ε for three hours. The level of pStat5 in 
CD4+CD25- cells, which had been stimulated with both anti-CD3ε and IL-2, was even lower 
when compared to cells that only received anti-CD3ε stimulation (Figure 33B).  
	  
Figure 33: Expression of pStat5 in CD4+CD25- (A) and CD4+CD25+ (B) cells after 
stimulation for three hours. Naïve splenocytes were activated with 0.5 µg/ml anti-CD3ε 
antibody alone or together with 10 ng/ml IL-2 for 3 hrs. Non-stimulated (ns) cells that were 
stained either directly or after 3 hrs in culture served as a negative control. Demonstrated is 
the mean + SD of two technical replicates. The values show the MFI for pStat5 of 
CD4+CD25+ (A) or CD4+CD25- (B) cells. 
3.6.1.4 Expression of CD25 in CD4+Foxp3- cells after stimulation with anti-CD3ε 
antibody for three hours  
In order to examine the expression of pStat5 in Treg, a reliable marker was needed for 
the identification of Treg. In the standardisation of the protocol for staining against 
intracellular pStat5, which is described in 3.5, the focus was put on CD25, the IL-2 receptor 
α-chain. However, the CD4+CD25- cells, presumably Teff, did not show any upregulation of 
pStat5 upon short-term stimulation, while the CD4+CD25+ strongly activated Stat5. CD25 is 
known to be upregulated on T cells upon stimulation of their TCR or IL-2R (72, 249). Thus, 
gating on CD4+CD25+ cells might identify activated effector cells rather than Treg, even after 
short-term stimulation. Therefore, it was of interest if the CD4+CD25+ cells actually represent 
the Treg population in those short-term studies. In the non-stimulated cells the proportion of 
CD4+CD25+Foxp3+ Treg out of all CD4+ cells was 7.48 %, which was similar to the 
percentage of CD4+CD25+Foxp3+ Treg after stimulation with anti-CD3ε antibody for three 
hours (8.09 %). Yet, a high proportion of CD4+ expressed CD25 but not Foxp3 following 
activation with anti-CD3ε for only three hours; 18.58 % of the stimulated CD4+ cells were 
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CD4+CD25+FoxP3- vs. 2.87 % of the non-stimulated CD4+ cells (Figure 34). Therefore, it 
could be shown that CD25 is upregulated on non-regulatory CD4+Foxp3- cells even upon 
TCR stimulation for as short as three hours. Thus, CD25 could not be used as an exclusive 
marker to identify Treg during short-term studies.  
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Figure 34: Expression of CD25 and Foxp3 in CD4+ cells after stimulation for 3 hours. 
Splenocytes were cultivated either alone, which served as the non-stimulated control (A), or 
in the presence of 0.5 µg/ml anti-CD3ε antibody (B) for 3 hrs. The data is representative for a 
total of four repeats. The dot plots were gated on CD4+ cells and the percentages of 
CD25+Foxp3+ (UR) and CD25+Foxp3- (lower right, LR) cells were calculated. 
3.6.2 Expression of pStat5 during long-term incubation 
3.6.2.1 Expression of pStat5 in the CD4+ cell population 
In addition to the expression of pStat5 during short-term incubation, it was also 
planned to observe the development of pStat5 expression in Treg over long-term incubation, as 
the inhibitory effect of TNCscTNF80 on the suppressive capacity of Treg was demonstrated in 
suppression assays over 72 hours. Thus, TNFR2 signalling might abrogate Treg function in the 
later phases of cell activation. Initially, the development of pStat5 expression in CD4+ cells 
during incubation for 72 hours was assessed in order to determine the effect of long-term 
stimulation with anti-CD3ε on the activation of Stat5 in T cells. Figure 35 shows that there 
was a slight increase of pStat5 expression in CD4+ cells after stimulation with the anti-CD3ε 
antibody three hours. Following stimulation for 24 hours, the expression of intracellular 
pStat5 reached its maximum and then started to decline after 48 hours. After 72 hours of 
stimulation, the expression in the activated cells was nearly as low as in the non-stimulated 
cells. Thus, pStat5 is only transiently upregulated in CD4+ cells upon TCR stimulation. 
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Figure 35: Expression of pStat5 in CD4+ cells over 72 hours. Naïve splenocytes were 
cultivated without (white bars) or with 0.5 µg/ml anti-CD3ε antibody (black bars) for 72 hrs. 
The data demonstrates the mean fluorescence intensity of pStat5 of CD4+ cells. Shown is the 
mean + SD of two technical replicates. * indicates a statistically significant difference of the 
indicated groups as determined by two-way ANOVA with Bonferroni post-test. 
3.6.2.2 Upregulation of CD25 on CD4+Foxp3- cells after stimulation with anti-CD3ε 
antibody 
CD4+ lymphocytes showed maximal pStat5 expression after 24 hours of stimulation. 
Yet, the expression of pStat5 during long-term incubation might show different kinetics in 
Treg. However, a reliable marker for Treg was required in order to study cell-signalling events 
in Treg cells during long-term incubation. As explained in 3.6.1.4, the expression of CD25 on 
CD4+Foxp3- Teff cells is already enhanced after short-term activation with anti-CD3ε 
antibody. Additionally, the expression of CD25 on non-stimulated and activated CD4+Foxp3- 
Teff cells was assessed during incubation for up to 72 hours. While CD25 expression remained 
at the same level on non-stimulated CD4+Foxp3- cells during the whole course of incubation, 
it was increased on cells that had been activated with anti-CD3ε antibody. The majority of 
CD4+Foxp3- cells were CD25+ after stimulation for 24 and 48 hours (74.16 % and 85.05 % 
respectively). The increase of CD25 expression, however, was not as pronounced after 
stimulation for three and 72 hours (Figure 36). Therefore, it was shown that CD25 on its own 
does not a serve as a reliable marker for Treg cells during long-term incubation. 
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Figure 36: Expression of CD25 in CD4+Foxp3- cells during long-term incubation. Naïve 
splenocytes were cultivated either alone (dotted line, circles) or in the presence of 0.5 µg/ml 
anti-CD3ε antibody (line, squares) for up to 72 hrs. The percentages of CD25+ cells in the 
CD4+Foxp3- population were determined. The data is a representative of three individual 
experiments, shown is the mean + SD of two technical replicates. * indicates a statistically 
significant difference of the indicated groups as determined by two-way ANOVA with 
Bonferroni post-test. 
3.6.2.3 Expression of pStat5 in CD4+Foxp3+ cells 
As CD25 could not be used as a reliable marker for Treg, Foxp3 was utilized to identify 
Tregs in the experiments regarding the long-term expression of pStat5. The level of pStat5 in 
CD4+Foxp3- and CD4+Foxp3+ cells was compared after activation for up to 72 hours in the 
presence of TNCscTNF80 in order to determine if TNFR2 signalling has different effects on 
the activation of Stat5 in Treg and Teff. As demonstrated in Figure 37A, the expression of 
pStat5 was increased in the CD4+Foxp3+ cells after activation for three hours and was {Romio 
2011 #402}at its maximum upon activation for 24 hours, both after stimulation with 
anti-CD3ε antibody alone or with anti-CD3ε antibody and TNCscTNF80 together. Then, 
following stimulation for 48 hours or more, the level of pStat5 declined rapidly. Interestingly, 
after incubation for 48 and 72 hours the expression of pStat5 in CD4+Foxp3+ cells was highest 
in the non-stimulated controls. Moreover, stimulation with anti-CD3ε and TNCscTNF80 for 
48 and 72 hours resulted in a slightly lower expression of pStat5 when compared to 
stimulation with anti-CD3ε alone. Stimulation with hTNF for 24 hours reduced pStat5 
expression in the CD4+Foxp3+ cells to a small extend, but did not alter pStat5 levels after 48 
or 72 hours (data not shown). In the CD4+Foxp3- cell subset expression of pStat5 was only 
observed after activation with anti-CD3ε antibody for 24 hours, both alone and in the 
presence of TNCscTNF80; TNCscTNF80 slightly enhanced pStat5 expression at this time 
point (Figure 37B). Taken together, it was shown that TNFR agonists did not considerably 
alter the expression of pStat5, neither in Treg or Teff cells. 
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Figure 37: Expression of pStat5 in CD4+Foxp3+ (A) and CD4+Foxp3- (B) cells during 
long-term incubation. Naïve splenocytes were cultivated for up to 72 hrs either in the 
absence of stimuli (ns; dotted line), with 0.5 µg/ml anti-CD3ε antibody (black line) or with 
0.5 µg/ml anti-CD3ε antibody and 10 ng/ml TNCscTNF80 (blue line). The data originates 
from an experiment representing a total of three repetitions. The data is shown as the 
mean + SD of two technical replicates. 
3.6.2.4 Expression of pStat5 in CD4+CD45.2+ Treg cells 
In a different approach the CD45.1/CD45.2 model was used to identify Treg during the 
experiments on the effect of TNFR agonists on pStat5 expression. Therefore, splenocytes 
from mice with different isoforms of CD45, i.e. CD45.1 and CD45.2, were used for the 
suppression assays. CD4+CD25+ cells were purified from naïve splenocytes from CD45.2 
mice by magnetic separation; subsequently staining against CD45.2 could identify Treg. This 
method allowed studying the different effects of TNCscTNF80 on pStat5 expression in Teff 
that were stimulated alone and in Treg or Teff that were co-cultured in suppression assays.  
First, the percentages of pStat5+ Teff cells in cultures of CD4+CD45.2- Teff alone or in 
co-cultures with purified CD4+CD25+ Treg cells from CD45.2 mice at ratios of 3:1 were 
analysed during long-term incubation. When cultured alone, the stimulation with anti-CD3ε 
alone and with anti-CD3ε and TNCscTNF80 together similarly enhanced the percentages of 
pStat5+ in the Teff population. The only difference was that treatment with TNCscTNF80 for 
24 hours slightly increased the proportion of pStat5+ cells when compared to stimulation with 
anti-CD3ε alone (Figure 38A). However, if CD4+CD25+ cells were present in the culture, the 
percentage of pStat5+ cells in the CD4+CD45.2- subset was enhanced by the stimulation with 
TNCscTNF80 for 24 hours, but reduced by TNCscTNF80 stimulation for 72 hours 
(Figure 38B).  
Furthermore, the percentages of pStat5+ cells in the CD4+CD45.2+ cell population, 
representing the purified CD4+CD25+ Treg, were analysed. Figure 38C shows that the 
maximum of pStat5+ expressing Treg was seen following stimulation for 24 hours. Stimulation 
with additional TNCscTNF80 slightly increased the proportion of pStat5+ cells after three and 
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24 hours. Yet, the proportion of pStat5+ cells was reduced following TNCscTNF80 treatment 
for 48 and 72 hours. In addition, the MFI of pStat5 was used to analyse the activation of Stat5 
in CD4+CD45.2+ Treg cells that had been in co-cultures with CD4+CD45.2- cells in the 
presence of different TNFR agonists for 24 and 48 hours. As seen in Figure 38D, TNCwtTNF 
and TNCscTNF80 increased the level of pStat5 after 24 hours. Interestingly, the expression of 
pStat5 was significantly (p<0.05) reduced by TNCscTNF80 treatment for 48 hours, whereas 
the other TNFR agonist did not notably change the expression of pStat5 at that time point. 
	   	   	  
	   	  
Figure 38: Expression of pStat5 in CD4+CD45.2- T cells and CD4+CD45.2+ Treg cells. (A), 
(B) CFSE-labelled CD45.1 splenocytes were cultured alone (A) or with purified CD4+CD25+ 
cells from CD45.2 mice at ratios of 3:1 (B) for up to 72 hrs and stimulated with 0.5 µg/ml 
anti-CD3ε alone (black lines) or with 0.5 µg/ml anti-CD3ε and 10 ng/ml TNCscTNF80 (blue 
lines). Non-stimulated cells (dotted lines) served as a negative control. Shown are the 
percentages of pStat5+ cells in the CD4+CD45.2- subset as the mean + SD of two technical 
replicates. (C) The percentages of pStat5+ were analysed in CD4+CD45.2+ cells that had been 
co-cultured with CD4+CD45.2- at ratios of 1:3 in the presence of anti-CD3ε alone (black lines) 
or anti-CD3ε and TNCscTNF80 (blue lines) for up to 72 hrs. Shown is the mean + SD of two 
technical replicates. (D) The MFI of pStat5 was analysed in CD4+CD45.2+ cells that had been 
co-cultured with CD4+CD45.2- cells at ratios of 1:3 for 24 and 48 hrs in the presence of anti-
CD3ε alone or anti-CD3ε together with different TNFR2 agonists. Shown is the mean + SD of 
two technical replicates. * indicates a statistically significant difference of the indicated 
groups as determined by two-way ANOVA with Bonferroni post-test. 
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3.7 Expression of phosphorylated ZAP70 
Treg need to be stimulated via their TCR in order to gain suppressor function. 
However, once activated they suppress responder cells in an antigen non-specific manner 
(18, 55). It was shown in previous experiments of this work that TNFR agonists attenuate Treg 
suppressor function. Because signalling events downstream of the IL-2R were only 
marginally changed in Treg after TNCscTNF80 treatment, it was hypothesized that TNFR2 
signalling might alter TCR-dependent signal induction. The phosphorylation status of the 
tyrosine kinase ZAP70 was chosen for the studies on the effects of TNCscTNF80 on TCR 
signalling, because it is one of the first mediators to be activated and it is required for 
activation of most downstream signalling cascades (49, 50).  
3.7.1 Establishment of a method for stimulation of T cells leading to the expression of 
pZAP70 
In order to study the effects of TNFR agonists on the rapid upregulation of 
phosphorylated ZAP70 in Treg, it was necessary to establish a method, which allowed staining 
against both surface markers and intracellular molecules shortly after the activation of 
lymphocytes. First of all, an adequate activation method needed to be found. Therefore, 
splenocytes were stimulated with anti-CD3ε antibody for up to 60 minutes and stained against 
pZAP70 and various Treg markers. Then, the expression of pZAP70 was analysed in both 
effector and regulatory T cells. Yet, although the anti-CD3ε antibody has been proven to be 
an appropriate stimulus for T cell (245) and T cells had been activated with the anti-CD3ε 
antibody in the former experiments, no relevant change of pZAP70 expression was detectable 
in stimulated cells. The expression of pZAP70 in CD4+CD25+Foxp3+ cells was only slightly 
increased by stimulation with anti-CD3ε for 30 or 60 minutes, whereas stimulation for 
10 minutes actually decreased the level of pZAP70 expression (Figure 39A). The 
CD4+CD25-Foxp3- Teff did not show any change of the expression of pZAP70 at all (data not 
shown). Furthermore, stimulation with anti-CD3ε antibody and IL-2 together also failed to 
enhance the expression of pZAP70, both in CD4+CD25+ and CD4+CD25- cells (Figure 39B 
and C). 
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Figure 39: Expression of pZAP70 in Treg and Teff after short-time stimulation. (A) Naïve 
splenocytes were cultivated either in cell culture medium alone (white bars) or in the presence 
of 0.5 µg/ml anti-CD3ε antibody (grey bars) for 10, 30 and 60 min. Cells were gated on 
CD4+CD25+Foxp3+ and the MFI of pZAP70 was determined. Shown is the mean + SD of two 
technical replicates. (B), (C) Naïve splenocytes were cultivated for 30 min either in the 
presence of 0.5 µg/ml anti-CD3ε alone (grey bars) or 0.5 µg/ml anti-CD3ε and 10 ng/ml IL-2 
(black bars). Non-stimulated (ns) cells, which were cultivated only in cell culture medium 
(white bars), served as a negative control. The MFI of pZAP70 in CD4+CD25+ (B) and 
CD4+CD25- (C) was determined. Shown is the mean + SD of two technical replicates. 
As it was shown that incubation with anti-CD3ε antibody did not result in any 
activation of ZAP70 in CD4+ cells, different stimulation techniques were performed: 
cross-linking of the anti-CD3ε antibody, activation with concanavalin A (Con A) and 
stimulation with H2O2. Cross-linking of the receptor or stimulation with the mitogen Con A 
are well-known methods to induce T cell activation and proliferation (246-249). For the 
anti-CD3ε cross-link, the lymphocytes were incubated with anti-CD3ε antibody, biotin-
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labelled IgG and streptavidin. Stimulation with H2O2 was performed because in a previous 
report it had been demonstrated that H2O2 is a more potent inducer of ZAP70 phosphorylation 
than the anti-CD3ε antibody (250). Both cross-linking of the anti-CD3ε antibody 
(Figure 40B) and stimulation with Con A (Figure 40C) elevated the expression of pZAP70 in 
CD4+ cells to a certain degree. H2O2, however, induced an obvious shift of pZAP70-positive 
cells in the CD4+ cell population (Figure 40D). Interestingly, a relatively large fraction of 
CD4- cells also showed pZAP70 expression (Figure 40D). This is unexpected since ZAP70 is 
only expressed in T cells and NK cells, but not in B cells (251). Nevertheless the mAB used 
for staining against pZAP70 is not specific and also cross-reacts with phosphorylated Syk, 
which is widely expressed in B cells (252). Thus, a high proportion of B220+ cells, 26.56 %, 
were also stained positive with this antibody (Figure 40E). Taken together, the best results for 
pZAP70 induction in T cells were achieved by applying the stimulation technique with H2O2. 
Thus, H2O2 was used for activation of lymphocytes in experiments on the expression of 
phosphorylated ZAP70 in regulatory and effector CD4+ T cells throughout this work.  
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Figure 40: Comparison of the effect of different activation methods on pZAP70 
expression. (A)-(D) pZAP70 expression in CD4+ cells. Naïve splenocytes were incubated for 
5 min with 1 µg/ml anti-CD3ε, 1 µg/ml biotin-labeled IgG and a 1:300 dilution of streptavidin 
(B), with 5 µg/ml Con A (C) or with 0.01 % H2O2 (D). Non-stimulated naïve splenocytes (A) 
served as a negative control. The percentages of CD4+pZap70+ cells (UR) were determined. 
(E) pZAP70 expression in B220+ cells. Naïve splenocytes were incubated with 0.01 % H2O2 
for 5 min. The percentages of B220+pZAP70+ cells (UR) and B220-pZAP70+ cells (upper left, 
UL) were determined. 
Further experiments were conducted in order to optimize the activation process with 
H2O2. In a study by Haas et al., 11 mM (0.035 %) H2O2 were used for stimulation (250). It 
was of interest, if the reducing or enhancing the concentration of H2O2 had an influence on 
the data quality and detectability of pZAP70. Thus, the pZAP70 expression was assessed 
following incubation with either 0.01 % or 0.05 % H2O2. Incubation for 15 minutes was 
chosen, because it had been shown that H2O2-induced pZAP70 expression reached its 
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maximum after 15 minutes (250). Additionally, the impact of diluting the primary antibody 
against pZAP70 was examined. To this end, the cells were stained with anti-pZAP70 in a 
100-fold or 50-fold dilution. As seen in Figure 41, H2O2 enhanced the expression of pZAP70 
in CD4+ cells in comparison to the non-stimulated controls. If 0.01 % H2O2 were used, the 
induction of pZAP70 was stronger. This was noticeable for both antibody dilutions. However, 
if the primary antibody was used in 50-fold dilution (Figure 41B), phosphorylated ZAP70 was 
detectable to a stronger extend than by applying a 100-fold dilution (Figure 41A). Taken 
together, optimal detection of pZAP70 in CD4+ lymphocytes was achieved by stimulating the 
cells with 0.01 % H2O2 and subsequently staining them with a 50-fold dilution of the primary 
antibody against pZAP70. 
0
6
0
1
2
0
1
8
0
2
4
0
3
0
0
C
o
u
n
ts
100 101 102 103 104
pZap70 cz5
0
6
0
1
2
0
1
8
0
2
4
0
3
0
0
C
o
u
n
ts
100 101 102 103 104
pZap70 cz5
Page 12
A B
	  
Figure 41: Effect of H2O2 on the expression of pZAP70 in CD4+ cells. Naïve splenocytes 
were activated with 0.01 % H2O2 (grey lines) and 0.05 % H2O2 (black lines) for 15 minutes. 
Non-stimulated cells (light grey lines) served as a negative control. Cells were then stained 
with a 1:100 (A) or a 1:50 (B) dilution of the mAB against pZAP70. The plots are gated on 
CD4+ cells and are representative for one of two technical replicates. 
Haas et al. have also shown that the maximal pZAP70 expression following anti-CD3ε 
stimulation was detected as early as 30 seconds after activation when using the phospho-flow 
technique (250). As demonstrated above, no pZAP70 expression was detectable after 
stimulation with 0.5 µg/ml anti-CD3ε antibody for 10, 30 or 60 minutes. Thus, it was of 
interest if pZAP70 is upregulated at earlier time points following the anti-CD3ε-induced cell 
activation. Moreover, it was examined if higher anti-CD3ε antibody concentrations were able 
to induce pZAP70 upregulation. For this purpose, the level of pZAP70 was compared 
between lymphocytes that were activated with 5 µg/ml anti-CD3ε antibody or 0.01 % H2O2 
for either 30 seconds or five minutes. As shown in Figure 42, stimulation with H2O2 enhanced 
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the expression of pZAP70 in CD4+ cells, both after incubation for 30 seconds (Figure 42A) 
and for five minutes (Figure 42B). Yet, pZAP70 induction was slightly higher following 
stimulation for 30 seconds. Stimulation with anti-CD3ε antibody for 30 seconds or 
five minutes actually reduced pZAP70 expression when compared to the non-stimulated 
controls. 
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Figure 42: Difference in the expression of pZAP70 in CD4+ cells after activation with 
anti-CD3ε antibody or H2O2. Naïve splenocytes were incubated with anti-CD3ε antibody 
(grey lin s) or H2O2 (bl ck lines) for 30 s (A) and 5 min (B); non-stimulated c lls (light grey 
lines) served as a negative control. The plots are gated on CD4+ cells. 
3.7.2 Analysis of the effect of TNCscTNF80 on the expression of pZAP70 
The activation process and staining protocol for pZAP70 in T cells could be optimized 
in the preliminary experiments. Thus, it was possible to study the effect of TNCscTNF80 on 
the phosphorylation of ZAP70 in both CD4+Foxp3- and CD4+Foxp3+ cells. In the following 
experiments, H2O2-stimulated splenocytes were treated with TNCscTNF80, fixed and 
permeabilized as described before for the detection of pStat5 (refer to 3.5.2) and then stained 
against pZAP70, CD4 and Foxp3. As demonstrated in Figure 43, the expression of pZAP70 
was enhanced if cells were stimulated with H2O2 and TNCscTNF80 simultaneously when 
compared to the stimulation with H2O2 alone. This effect could be observed in CD4+Foxp3- 
(Figure 43A) and CD4+Foxp3+ (Figure 43B) cells. However, in the following experiments 
those results could not be repeated (Figure 44). Moreover, if cells were incubated with 
TNCscTNF80 before the stimulation with H2O2 was started, no strong alteration of pZAP70 
expression was detected (Figure 43A and Figure 43B). Taken together, the experiments on the 
effect of TNCscTNF80 on pZAP70 induction in T cells showed conflicting results. Thus, it 
remained unclear if TNCscTNF80 has an influence on pZAP70 expression in Treg and Teff. 
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Figure 43: Impact of TNCscTNF80 on the expression of pZAP70 in CD4+Foxp3- (A) and 
CD4+Foxp3+ (B) cells. Naïve splenocytes were activated with 0.01 % H2O2 alone or in the 
presence of 10 ng/ml TNCscTNF80. Part of the cells received H2O2 at the same time as 
TNCscTNF80, whereas the other part was incubated with TNCscTNF80 for 15 min prior to 
the stimulation with H2O2. Non-stimulated (ns) cells and cells that only received 
TNCscTNF80 were used as controls. Shown is the MFI of pZAP70 in CD4+Foxp3- (A) and 
CD4+Foxp3+ (B) cells. 
	  
	   	  
Figure 44: Impact of TNCscTNF80 on the expression of pZAP70 in CD4+Foxp3- (A) and 
CD4+Foxp3+ (B) cells. Naïve splenocytes were activated with 0.01 % H2O2 alone or in the 
presence of 10 ng/ml TNCscTNF80. Non-stimulated (ns) cells and cells that only received 
TNCscTNF80 were used as controls. The MFI of pZAP70 in CD4+Foxp3- (A) and 
CD4+Foxp3+ (B) cells was determined. Shown is the mean + SD of three technical replicates. 
3.7.3 Serial dilution of TNCscTNF80 
As diverging results were found for the impact of TNCscTNF80 on pZAP70 
expression in CD4+Foxp3- and CD4+Foxp3+ cells, it was of interest if changing the 
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concentration of TNCscTNF80 had an effect on pZAP70 expression. Thus, splenocytes were 
treated with increasing concentration of TNCscTNF80, ranging from 0.1 ng/ml to 10 ng/ml. 
However, no increased pZAP70 expression in CD4+Foxp3- (Figure 45A) or CD4+Foxp3+ 
(Figure 45B) could be shown following TNCscTNF80 treatment. Even if 10 ng/ml 
TNCscTNF80, the concentration used in the suppression assays, were added to the cell 
cultures, no obvious change of pZAP70 expression was noticeable. Treatment with 0.1 ng/ml 
and especially 1 ng/ml TNCscTNF80 actually decreased pZAP70 levels in both CD4+Foxp3- 
and CD4+Foxp3+ cells. Nevertheless, the MFI values showed a relatively high standard 
deviation for those concentrations. If the percentage of CD4+Foxp3- or CD4+Foxp3+ being 
positive for pZAP70 were compared, no differences could be shown between stimulation with 
H2O2 alone or with H2O2 and any given concentration of TNCscTNF80 (data not shown). 
	   	  
Figure 45: Impact of the concentration of TNCscTNF80 on the expression of pZAP70 in 
CD4+Foxp3- (A) and CD4+Foxp3+ (B) cells. Naïve splenocytes were activated with 0.01 % 
H2O2 alone or in the presence of increasing concentrations of TNCscTNF80 for 5 min. 
Non-stimulated (ns) cells and cells that only received 10 ng/ml TNCscTNF80 were used as 
controls. The MFI of pZAP70 in CD4+Foxp3- (A) and CD4+Foxp3+ (B) cells was determined. 
The data is representative for two individual experiments. Shown is the mean + SD of two 
technical replicates. 
3.7.4 Time series of pZAP70 expression 
Further, the expression of pZAP70 in Teff and Treg cells following stimulation for up to 
60 minutes was analysed. Over the time there was a reduction in the expression of pZAP70 in 
CD4+Foxp3- (Figure 46A) and CD4+Foxp3+ (Figure 46B) cells. After activation for five 
minutes, both cell populations showed the highest level of pZAP70. The expression steadily 
decreased until, after 60 minutes, it was nearly as low as in the non-stimulated control. In both 
cell populations there was no considerable difference in between stimulation with or without 
TNCscTNF80. Taken together, the present data shows that TNCscTNF80 does not influence 
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the expression of pZAP70 in CD4+Foxp3- Teff or CD4+Foxp3+ Treg cells during the early 
H2O2-induced T cell activation. 
	  
Figure 46: Kinetics of the pZAP70 expression in CD4+Foxp3- (A) and CD4+Foxp3+ (B) 
cells following stimulation with H2O2 or H2O2 and TNCscTNF80. Naïve splenocytes were 
incubated with 0.01 % H2O2 (circles, black lines) or with 0.01 % H2O2 and 10 ng/ml 
TNCscTNF80 (squares, blue lines) for 5 up to 60 min. Staining against pZAP70 in 
non-stimulated cells served as a control for the initial pZAP70 expression. The MFI of 
pZAP70 in CD4+Foxp3- (A) and CD4+Foxp3+ (B) cells was determined. The data is 
representative for two independent experiments, shown is the mean + SD of two technical 
replicates. 
3.8 Suppression of lymphocytes by myeloid derived suppressor cells 
(MDSC) 
Myeloid-derived suppressor cells are a heterogeneous subset of immature myeloid 
cells that expand under pathological conditions, especially cancer (37). Previous studies had 
shown that myeloid cells have the capacity to suppress T cell proliferation in response to 
CD3/CD28 co-signalling (253). This MDSC-mediated suppression of immune responses is 
enhanced in tumor-bearing organisms and appears to play an essential part in the immune 
escape of tumor cells (40). It has been observed that TNF has enhancing effects on the 
survival and accumulation of MDSC in tumor-bearing mice (224) and that suppressive 
function of MDSC is attenuated when signalling via TNF receptor, and more specifically via 
TNFR2, on MDSC is abrogated (225, 226, 254). Thus, TNF appears to promote MDSC 
suppressor function. In the following experiments, it was studied how MDSC affect T cell 
proliferation and to what extend this is changed through signalling via TNFR2.  
3.8.1 Alteration of ratios of splenocytes and MDCS  
While MDSC mainly evolve under pathologic conditions in vivo (37), in vitro 
generation of MDSC is achieved by cultivation in the presence of GM-CSF. It has been 
observed that bone marrow derived cells acquired suppressive function after cultivation for 
four days with high doses of GM-CSF or cultivation for eight to ten days with low-dose 
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GM-CSF (42). In this work, it was of interest if bone marrow derived cells, which were 
cultured with GM-CSF for four days, acquired the ability to suppress the anti-CD3-induced 
proliferation of T cells. Furthermore, it was assessed at what ratio of MDSC to splenocytes 
the suppressor capacity was the strongest. As shown in Figure 47, the proliferation of CD4+ 
and CD8+ cells was readily suppressed when MDSC at ratios of 1:4 and higher were present 
in the culture. While 75.06 % of CD4+ and 95.73 % of CD8+ proliferated after stimulation 
with anti-CD3 for 72 hours, the fraction of proliferating cells was reduced to 1.36 % of CD4+ 
(Figure 47A) and 12.92 % of CD8+ (Figure 47B) cells respectively in the presence of MDSC 
at ratios of 1:1. Taken together, it could be shown that GM-CSF-generated bone marrow cells 
are capable of suppressing the anti-CD3-induced proliferation of T cells. 
	   	  
Figure 47: Suppression of CD4+ (A) and CD8+ (B) cells by MDSC at different ratios. 
2 x 105 CFSE-labeled splenocytes were stimulated for 72 hrs with 1 µg/ml anti-CD3ε 
antibody in the presence of MDSC. The MDSC were added at ratios of 1:8, 1:4, 1:2 or 1:1 
(black bars). Lymphocytes only stimulated with anti-CD3ε antibody (white bars) served as a 
positive control. Shown is the mean + SD of two technical replicates. 
3.8.2 Suppression of T cells by MDSC generated with TNCscTNF80  
The aim of the following studies was to examine to what extend MDSC are able to 
suppress T cell proliferation if they had been generated with the TNFR2 agonist 
TNCscTNF80. As shown in Figure 48, the proliferation of CD4+ and CD8+ cells after 72 
hours in culture was decreased by the MDSC in a concentration-dependent manner. 
Interestingly, low ratios of TNCscTNF80-treated MDSC (1:8 and 1:4) enhanced the T cell 
proliferation when compared to the proliferation in the absence of MDSC. Yet, the 
proliferation of both CD4+ (Figure 48A) and CD8+ (Figure 48B) cells was reduced in the 
presence of the pre-treated MDSC at ratios of 1:2 and 1:1. Thus, it could be demonstrated that 
MDSC are able to exert their suppressive function if they have been generated under the 
influence of the TNFR2 agonist TNCscTNF80.  
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Figure 48: Suppression of CD4+ (A) and CD8+ (B) cells by MDSC after pre-incubation 
with TNCscTNF80. 2 x 105 CFSE-labeled splenocytes were stimulated for 72 hrs with 
1 µg/ml anti-CD3ε antibody in the presence of MDSC, which had been in culture with 
GM-CSF and TNCscTNF80 for four days. The MDSC were added at ratios of 1:8, 1:4, 1:2 or 
1:1 (black bars). Lymphocytes stimulated with anti-CD3ε antibody alone (white bars) served 
as a positive control. Shown is the mean + SD of two technical replicates. 
3.8.3 Alteration of the suppressive capacity of MDSCs by TNCscTNF80 
After having shown that BMDC acquire suppressive function following cultivation for 
four days with GM-CSF alone or with GM-CSF and the TNFR2-specific agonist 
TNCscTNF80, the influence of TNCscTNF80 on the suppressor capacity was examined. 
Therefore, the MDSC-mediated suppression following generation with or without 
TNCscTNF80 was compared. In addition, the suppression mediated by WT and TNFR2-/- 
MDSC was compared. Moreover, it was also assessed if the length of cultivation under 
GM-CSF had an impact on the suppressor capacity of MDSC. Since MDSC can differentiate 
into mature cells without suppressive activity (42), prolonged periods of cultivation with 
GM-CSF might cause a reduction of total suppressor cell numbers and thus of T cell 
suppression.  
The suppression of both CD4+ and CD8+ cells by MDSC was most effective when WT 
MDSC had been cultivated with GM-CSF for four days prior to the suppression assay. WT 
MDSC, which had been stimulated for six or more days, were less suppressive. After 
generation with both GM-CSF and TNCscTNF80 for four days, the suppression of CD4+ cells 
(Figure 49A) and CD8+ cells (Figure 49B) was slightly alleviated when compared to 
generation with GM-CSF alone. 6.16% of CD4+ cells proliferated when co-cultured with WT 
MDSC that had been generated only with GM-CSF vs. 8.09 % of the CD4+ cells in 
co-cultures with WT MDSC that had been generated with additional TNCscTNF80. The 
proliferation of CD8+ cells was 46.85 % vs. 52.84 % respectively. This 
TNCscTNF80-induced attenuation of the suppression mediated by the WT MDSC was more 
pronounced after cultivation for six or more days. In the presence of TNFR2-/- MDSC, the 
III- Results 87 
proliferation of CD4+ and CD8+ cells was higher when compared to the co-cultures with WT 
MDSC (Figure 49), indicating that TNFR2-deficient MDSC are less suppressive than their 
WT counterparts. TNCscTNF80 did not noticeably affect the suppressive capacity of 
TNFR2-/- MDSC (data not shown). Thus, it was shown that bone marrow derived cells from 
WT mice were able to suppress T cell proliferation following stimulation with GM-CSF for 
four days, while the suppressor capacity was attenuated by prolonged periods of cultivation. 
Generation in the presence of the TNFR2-specific agonist TNCscTNF80 inhibited 
MDSC-induced suppression. This indicates that signalling via TNFR2 on MDSC limits their 
suppressive function. On the other hand, TNFR2-deficient MDSC showed reduced suppressor 
capacity, suggesting that TNFR2 signalling is important for MDSC-mediated suppression. 
	  
Figure 49: TNCscTNF80 alters the suppression of CD4+ (A) and CD8+ (B) cells by 
MDSCs. CFSE-labeled splenocytes were cultivated with 1 µg/ml anti-CD3ε antibody and 
0.5 µg/ml anti-CD28 antibody for 72 hrs in the presence of MDSC from WT mice at a ratio of 
1:1, which were generated with GM-CSF alone (white bars) or with additional TNCscTNF80 
(grey bars) for four up to ten days, or in the presence of MDSC from TNFR2-/- mice that were 
generated with GM-CSF alone for four up to ten days (black bars). Shown is the mean + SD 
of two technical replicates.  
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4 Discussion 
4.1 Effect of TNCscTNF80 on T cell proliferation and cytokine 
production 
Former studies have revealed that TNF, through signalling via the TNFR2, acts as a 
co-stimulatory factor for lymphocytes, promoting their survival and proliferation during the 
TCR-induced T cell activation (181, 183). Correspondingly, it was observed in this work that 
the TNFR2-specific agonist TNCscTNF80 increased the proliferation of CD4+ and CD8+ cells 
in response to stimulation with an anti-CD3ε antibody. Further, it was shown that this 
enhancing effect was exclusively mediated through the TNFR2, since TNFR2-deficient T 
cells failed to respond to TNCscTNF80 treatment.  
When lymphocytes were stimulated with high amounts of anti-CD3ε antibody and 
TNCscTNF80, the proliferation rate reached a plateau; further enhancing the concentration of 
anti-CD3ε did not increase the proliferation any more. It had been reported that co-stimulation 
via TNFR2 decreases the threshold for antigen-driven induction of cell activation (180, 255). 
Thus, cells might easily receive the required signals for full activation in the presence of high 
amounts of both TCR and TNFR2 stimulating agents; increasing the amount of anti-CD3ε 
will not further enhance the proliferative response in that case. Nevertheless, it could be 
shown in this work that the addition of increasing amounts of TNCscTNF80 still enhanced 
proliferation in a dose-dependent manner, even when cells were stimulated with high doses of 
anti-CD3ε. Thus, TNFR2 appears to mediate co-stimulatory signals even if T cells are 
optimally activated through their TCR. Moreover, it could be shown that the proliferation of 
TNFR2-deficient T cells in response to TCR stimulation was lower when compared to their 
WT counterparts. This provides further proof for the importance of TNFR2 as a 
co-stimulatory receptor during TCR-driven immune responses.  
Treatment with TNCscTNF80 did not only promote T cell proliferation, but also 
enhanced secretion of the proinflammatory cytokine IFN-γ in a dose-dependent manner. 
However, while the co-stimulatory effects of TNFR2 on cell proliferation were observable at 
all levels of anti-CD3ε stimulation, effects on IFN-γ secretion were only detectable when 
higher amounts of anti-CD3ε antibody were used for TCR stimulation. Conversely, increasing 
the amount of anti-CD3ε antibody in the presence of TNCscTNF80 promoted further 
production of IFN-γ. In line with the TNCscTNF80-induced effects on T cell proliferation, 
TNCscTNF80 also increased IFN-γ production in a dose-dependent manner in the presence of 
high concentrations of anti-CD3ε. This indicates that TNFR2 mediates strong co-stimulatory 
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signals for IFN-γ production. This is consistent with previous observations showing that T 
cells deficient for TNFR2 release considerably less IFN-γ (255) and that stimulation of 
TNFR2 enhanced IFN-γ production (181). Nevertheless, the combined TNFR1 and TNFR2 
agonist TNCwtTNF enhanced the secretion of IFN-γ to a higher extend than TNCscTNF80. 
This effect was observed after T cell stimulation for 48 and 72 hours. This suggests that 
TNFR1 signalling additionally promotes IFN-γ production. However, it has been shown that 
the production of IFN-γ upon CD3/CD28 stimulation in vitro is increased in TNFR1-deficient 
mice, indicating that TNFR1 signalling actually leads to a reduction of IFN-γ secretion (256). 
In vivo studies, on the other hand, have demonstrated that TNFR1-deficient mice show an 
impaired CD8+ expansion and IFN-γ production upon allogeneic stimulation, which suggests 
that TNFR1 might have an important role in T cell expansion and production of 
proinflammatory cytokines (256). Taken together, it could be shown that TNFR2 promotes 
proliferation and cytokine production of lymphocytes. However, the role TNFR1 plays as a 
co-stimulatory receptor for T cell proliferation and cytokine production remains to be 
elucidated. 
4.2 Change of CD4+CD25+ suppressor capacity by TNFR2-specific 
agonist TNCscTNF80 
Regulatory T cells are crucial for the maintenance of self-tolerance (18). Conversely, 
Treg dysfunction has been associated with different immunological disorders (205, 206, 218, 
257). A variety of those autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, 
Crohn’s disease and ulcerative colitis are nowadays treated with anti-TNF agents (193, 195). 
It could be demonstrated that, in addition to various other effects, neutralization of TNF 
restores Treg numbers and function in rheumatic patients and thus promotes control over 
activated self-reactive immune cells (205). Similar results were shown for IBD (207–209) and 
autoinflammatory diabetes mellitus type 1 (236, 257). Nevertheless, some patients do not 
respond to anti-TNF therapy or even show an onset of new inflammatory processes (194, 199, 
209, 243, 258). Thus, there is great interest in how exactly TNF influences Treg function.  
In this study, it was found that the TNFR2 agonist TNCscTNF80 has an inhibitory 
effect on Treg-mediated suppression of CD4+ and CD8+ cell proliferation. TNCscTNF80 
enhanced the proliferation of anti-CD3ε-activated T cells under Treg-mediated suppression to 
levels that were comparable to the proliferation levels found in the absence of Treg. Moreover, 
TNCscTNF80 failed to attenuate the suppressor capacity of TNFR2-deficient Treg. This 
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indicates that the inhibition of Treg-induced suppression by TNCscTNF80 is exclusively 
mediated via TNFR2.  
Previous studies have also shown that TNF impairs Treg-mediated suppression and that 
neutralizing TNF can restore their suppressor capacity (206, 211). Further, it has been 
reported that TNF induces inhibition of Treg suppressor function through signalling via 
TNFR2, which consecutively leads to an enhancement of NF-κB activation (210). However, 
Chen et al. reported that, although the Treg-driven suppression of Teff was partially abrogated 
after incubation with TNF for 48 hours, it was restored after exposure to TNF for 72 hours 
(216). Differences in the experimental set-up might account for the contradictory effects of 
TNF on Treg suppression seen in studies by Chen et al. and in this work. While TNF was used 
in a concentration 10 ng/ml in their suppression assays, 10 ng/ml of TNCscTNF80 were 
utilized in this study. TNF is supposed to influence Treg function only via TNFR2 (210, 217, 
218, 222). Yet, soluble TNF has only limited ability to stimulate TNFR2 (175), whereas the 
TNFR2-selective TNCscTNF80 mimics the membrane-bound form of TNF and thereby 
activates TNFR2 more efficiently (228). Therefore, TNCscTNF80 will mediate stronger 
effects than TNF when used in the same concentrations. Conversely, it has been reported in 
other studies that sTNF concentrations as high as 50 ng/ml were required to achieve 
modulation of human Treg function (210, 211). In line with this, it could be shown in the 
present study that the inhibition of Treg-induced suppression is reduced if the Teff-Treg 
co-cultures are treated with lower concentrations of TNCscTNF80.  
In addition to TNF-mediated effects on Treg, Chen et al. also observed a TNF-mediated 
reduction of the susceptibility of Teff towards Treg-induced suppression. They reported that a 
fraction of Teff cells upregulate TNFR2 upon TCR stimulation, which renders them more 
resistant towards suppression by conventional TNFR2- Treg. Highly activated TNFR2+ Treg, 
however, maintain the capacity to suppress those TNFR2+ Teff (218). Thus, signalling via 
TNFR2 might stimulate Teff to a greater extend than Treg under certain circumstances and, 
thereby, cause an impaired Treg-mediated suppression of T cell responses. Arguing against this 
theory, however, is the observation that TNF preferentially upregulates the TNFR2 on Treg 
and not on Teff (259). Moreover, it was demonstrated in the present work that TNCscTNF80 is 
capable of inhibiting Treg-mediated suppression of TNFR2-/- Teff cells, while it does not 
change the suppression induced by TNFR2-/- Treg, indicating that TNCscTNF80 influences 
Treg function rather than the responsiveness of Teff towards suppression.  
While TNCscTNF80 did not affect the suppression by TNFR2-/- Treg, it completely 
reversed the suppression induced by TNFR1-/- Treg. This indicates that TNFR1-deficient Treg 
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are more affected by TNFR2 signalling. A possible explanation for this is that signalling 
pathways downstream of TNFR2 are activated to a stronger extend in the absence of TNFR1 
signalling. Normally, the adaptor protein TRAF2, which is important for the signalling 
cascade downstream of the TNFR2, is subject to degradation when both TNF receptors are 
stimulated (187, 188). Thus, in case of TNFR1-deficiency, cytosolic TRAF2 concentrations 
might be higher, leading to an increased activation of NF-κB and c-Jun. Since enhanced 
activity of the transcription factors NF-κB and AP-1 stimulate IL-2 production by Treg (60), 
higher IL-2 concentrations might be found in the cell cultures. Il-2, then in turn, could 
promote higher proliferation levels of Teff. 
4.3 CD4+Foxp3+ Treg surface makers: Under the influence of 
TNCscTNF80 
Various surface markers are preferentially expressed by CD4+Foxp3+ Treg, part of 
which also appear to contribute to their regulatory function, such as CTLA-4, CD25, CD39 
and CD73 (109, 126, 155). It was demonstrated in this study that the TNFR2 agonist 
TNCscTNF80 attenuates Treg-mediated suppression of T cell responses. Yet, although TNF is 
known to influence Treg function (211), it is not clear what the underlying mechanisms are. 
Thus, the effect of TNCscTNF80 on the expression of surface molecules was studied over 
long-term anti-CD3ε-induced stimulation. 
4.3.1 CD25: A Treg and activation marker under the influence of TNCscTNF80 
The IL-2 receptor α-chain, CD25, has long been used as a Treg marker (17), yet 
effector T cells without suppressive activity also upregulate CD25 upon stimulation (260). In 
the present study, it was shown that the majority of Foxp3+ cells expressed CD25 
independently of their activation status. However, at the early time point of three hours 
approximately 25 % of the Foxp3+ cells were CD25-, indicating that Foxp3-expressing Treg do 
not necessarily need to express CD25. This is consistent with previous data, which showed 
that 20-30 % of CD4+Foxp3+ cells are CD25- (261) and that those CD4+CD25-Foxp3+ cells 
retain a Treg phenotype and suppressive activity (262). In this work, it was shown that Foxp3+ 
Treg upregulated CD25 upon activation via their TCR complex, which is also consistent with 
previous findings (260, 263–265). While additional stimulation with the TNFR2 agonist 
TNCscTNF80 for three or 24 hours did not alter CD25 expression on Treg cells, stimulation 
for 48 and 72 hours slightly reduced the anti-CD3-induced upregulation of CD25. In contrast 
to these results, it has been reported before that the expression of CD25 remains at the same 
level when Treg are treated with anti-CD3ε and activated monocytes, which release cytokines 
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such as TNF, IL-1β and IL-6 (266). Controversially, Chen et al. observed an enhancing effect 
of TNF on the expression of CD25 on Treg (216). Yet, differences in the experimental set-up 
might account for this discrepancy. First of all, the cells were stimulated with IL-2 and TNF 
in that study, while in the experiments for this work anti-CD3ε and TNCscTNF80 were used. 
Moreover, the effect of TNF on CD25 expression was examined in purified CD4+CD25+ cells 
that were later identified by gating on CD25+ cells. In the present study, however, Treg were 
identified by Foxp3 expression. By gating on CD25, not only Treg but also activated T cells 
might be included in the analysis, as enhanced expression of CD25 is expected upon 
stimulation with IL-2 (72). Nevertheless, a more recent report showed that in vivo stimulation 
with TNF results in higher expression of CD25 on CD4+Foxp3+ cells when compared to IL-2 
stimulation alone (267). Yet, in both studies the effects of unspecific TNF were examined. 
Ligation to the TNFR2 by a TNFR2-specific agonist, however, appears to downregulate the 
CD25 expression on Treg in later stages of the anti-CD3-induced cell activation. 
4.3.2 TNCscTNF80 influences the expression of adenosine-generating 
ectonucleotidases on Foxp3+ cells 
Several lines of evidence have shown that Treg express high amounts of CD39 and 
CD73, two ectonucleotidases that hydrolyse ATP into the inhibitory molecule adenosine, 
which interferes with T cell activation and function (155, 157, 158, 268, 269). In this work it 
was observed that almost all non-stimulated Foxp3+ Treg were CD39+, which is consistent 
with previous reports (157, 158). A slight reduction of CD39 surface expression on Treg upon 
TCR stimulation was seen here. Yet, this decrease might not be sufficient for a reduction of 
the overall ectonucleotidase activity. Conversely, it was shown that Treg maintain adenosine 
production upon activation (155). Noteworthy, CD39 expression was further reduced in the 
presence of the TNFR2 agonist TNCscTNF80. In contrast to these results, however, it has 
been previously demonstrated that Treg express the same level of CD39 when co-cultured with 
activated monocytes from synovial fluid of rheumatic patients that secret TNF, IL-1β and 
IL-6 (266). On the other hand, it was observed that Treg from the synovial fluid of patients 
with rheumatic arthritis, which is known to harbour high levels of TNF, exhibit higher 
amounts of CD39 (270). The divergent results are most likely due to differences in the 
experimental methods. In addition to TNF other factors might account for the alteration of 
CD39 expression on Treg in those studies, since a great variety of proinflammatory cells and 
mediators are present in the synovial fluid of rheumatic patients. 
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Moreover, it could be demonstrated that nearly all non-stimulated Foxp3+ Treg showed 
a constant high expression of CD73. Stimulation with anti-CD3ε did not alter the level of 
CD73, which is consistent with a previous study that showed that, upon stimulation, 
Foxp3+CD4+ cells maintain high levels of CD73, while Foxp3-CD4+ cells down-modulate 
CD73 expression (269). Furthermore, treatment with TNCscTNF80 did not influence the 
expression of CD73. Yet, a downregulation of CD73 was observed on human Foxp3+ Treg in 
the synovial fluid of patients suffering from rheumatoid arthritis (270). It remains to be 
clarified if and how TNF alters the expression of CD73 on Treg. The present results, however, 
do not indicate that TNCscTNF80 inhibits Treg function by reducing CD73 activity. 
Interestingly, TNFR2 signalling decreased the expression of CD39. CD39 catalyses that rate-
limiting step in the nucleotide metabolism cascade, i.e. the generation of adenosine 
monophosphate (AMP) from ATP (155, 157). Thus, limiting the amount of CD39 on Treg 
could pose a mechanism, by which TNF attenuates the Treg-driven suppression even when 
CD73 expression is maintained on Treg cells. As the downregulation of CD39 was observed at 
later stages of the cell activation, this abrogation of Treg function might require prolonged 
TCR and TNFR2 stimulation. 
4.3.3 Influence of TNCscTNF80 on the expression of the TNFR superfamily member 
OX40 on Foxp3+ cells 
OX40 is another surface marker that is predominately expressed on Treg cells, but also 
upregulated on effector T cells upon activation (271). It was observed in this work that the 
majority of naive Foxp3+ Treg were OX40+. In addition, OX40 was further upregulated on Treg 
after TCR stimulation, which is consistent with a previous report (272). The TNFR 
superfamily member OX40 has costimulatory effects on Tconv, promoting their proliferation 
and survival (273). Yet, the effects of OX40 engagement on Treg function are controversially 
discussed. Whereas some data suggests that OX40 expression is necessary for Treg suppressor 
capacity (274–276), others propose that OX40 stimulation actually attenuates Treg-induced 
suppression (271, 272, 277, 278). More recent data showed that OX40 stimulation together 
with exogenous IL-2 induced profound Treg expansion, whereas OX40 engagement in absence 
of additional IL-2 resulted in the abrogation of Treg function (279).  
It could be speculated that TNCscTNF80 enhances OX40 expression on Treg cells and 
thereby contributes to their reduced suppressor function. Yet, the presence of TNCscTNF80 
changed OX40 expression only marginally. Correspondingly, TNFR2-deficient Treg were 
shown to harbour equal amounts of OX40 when compared to their WT counterparts (280), 
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indicating that TNFR2 signalling does not influence OX40 expression. Other reports, 
however, suggested that TNF increases OX40 expression by Treg (210, 259). Methodical 
differences could account for the conflicting results. Preferential upregulation of OX40 on 
CD4+Foxp3+ was seen after three days of stimulation with IL-2 and TNF (259) or following 
stimulation with TNF alone, which, however, was used in unusually high concentration of 
50 ng/ml (210), while anti-CD3ε and lower concentrations of TNFR2-specific TNCscTNF80 
were used for stimulation in this work. In addition, OX40 upregulation was seen in a study 
that utilized isolated CD25++ and CD25- cells, which were classified as not being highly pure, 
and then used CD25 as a Treg marker for the analysis of OX40 expression (210). Yet, 
contaminating Teff cells might have outgrown the CD25++ Treg. Those Teff might have 
upregulated CD25 and OX40 expression in response to activation since both CD25 and OX40 
are markers for T cell activation (260, 273). Thus, it is feasible that not Treg but stimulated Teff 
upregulated OX40 in that study. 
4.3.4 TNCscTNF80 does not change expression of CTLA-4 on Foxp3+ cells 
CTLA-4 is an inhibitory receptor on T cells, which like CD28 binds to CD80/CD86 on 
APC, but instead of mediating costimulatory effects it actually reduces T cell responses (281). 
While conventional T cells only show CTLA-4 on their cell surface upon activation, Treg 
constantly express CTLA-4 (105, 122). It was also found in this study that non-stimulated Treg 
expressed relatively high amounts of CTLA-4. Strikingly, stimulated Treg did not enhance the 
expression of CTLA-4 on their cell surface. Expression of CTLA-4 was even attenuated after 
stimulation for 48 or 72 hours. In contrast to the present results, previous studies have 
reported that CTLA-4 is upregulated upon stimulation (105, 122, 282, 283), mainly through 
re-cycling to the cell surface (122). Yet, ConA (105), PMA (282, 283) or anti-CD3 together 
with anti-CD28 (122) were used for stimulation of T cells in those reports, while T cells were 
stimulated with anti-CD3ε antibody alone in the present study. However, it has been shown 
that CD28 co-stimulation is necessary for maximal CTLA-4 expression (284, 285). 
Furthermore, while surface expression of CTLA-4 is upregulated following T cell stimulation, 
it is also subject to rapid endocytosis. Therefore, only a small amount of CTLA-4 is steadily 
expressed on the cell surface upon stimulation despite a constant movement of CTLA-4 
molecules to the plasma membrane (285).  
Because CTLA-4 is essential for Treg-mediated suppression (109, 140), changing the 
surface expression of CTLA could be a possible inhibitory mechanism by which 
TNCscTNF80 limits Treg suppressor capacity. Yet, no change of CTLA-4 expression on 
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Foxp3+ cells could be observed if TNCscTNF80 was added to the cell cultures. Thus, 
TNCscTNF80 does not seem to modulate Treg suppression by alteration of the 
immunosuppressive receptor CTLA-4. 
4.3.5 TNSscTNF80 limits GITR expression on Foxp3+ Treg 
Engagement to GITR on Tconv has costimulatory effects resulting in T cell 
proliferation and increased cytokine production (265, 286, 287). Yet, its function on Treg has 
been the discussed controversially over the last years. Whereas some studies suggest that 
ligation to GITR attenuates Treg suppression (34) or that signalling via GITR does not 
influence Treg function but rather renders Teff resistant to Treg function (286), others found 
enhancing effects on Treg numbers and suppressor capacity (258, 287). However, the effects of 
GITR on Treg seem more complex, as a more recent report showed that GITR exerts 
contradictory functions in Treg depending on the circumstances. According to that study, 
GITR engagement results in the loss of Foxp3+ Treg under pathogenic situation, while it 
promotes Treg expansion in healthy mice (288). 
In the experiments for this thesis it was found that nearly all Foxp3+ cells expressed 
GITR over the whole incubation time of up to 72 hours regardless of stimulation or not. This 
is consistent with previous reports showing that naive ex vivo CD4+CD25+ Treg strongly 
express GITR (34, 261, 265). In addition, it was observed that Treg downmodulate GITR 
expression following treatment with the TNFR2 agonist TNCscTNF80 for 48 and 72 hours. 
Since GITR appears to promote Treg proliferation and function under physiological conditions 
(258, 265, 288), the TNFR2-driven downregulation of GITR on Treg might contribute to the 
TNCscTNF80-mediated abrogation of Treg suppressor capacity. Moreover, downregulation of 
GITR, like CD25 and CD39, was seen after prolonged stimulation with anti-CD3ε and 
TNCscTNF80 for 48 and 72 hours. Thus, TNCscTNF80 appears to inhibit those factors, 
which are important for Treg function, only at later stages of anti-CD3-driven activation. This 
is consistent with the results from the suppression assays that showed that TNCscTNF80 
induces abrogation of Treg suppression after stimulation for 72 hours. 
4.4 Effect of TNCscTNF80 on pStat5 expression in Teff and Treg 
It was observed that the TNFR2 agonist TNCscTNF80 inhibits the Treg-induced 
suppression of T cells, but the underlying molecular mechanism of TNF-driven alteration of 
Treg function is unknown. Prolonged stimulation with TNCscTNF80 reduced the levels of the 
surface expression of CD25, CD39 and GITR on Treg cells, which at least in part might 
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account for their defective suppressor function. Constant IL-2 signals are required in order for 
Treg to maintain high levels of CD25 (75, 289). Thus, impaired IL-2 signalling might be the 
reason for the TNCscTNF80-induced reduction of CD25. Moreover, disturbing the signalling 
cascade downstream of the IL-2R could explain why TNCscTNF80 abrogates Treg function, 
since IL-2 is essential for Treg function and homeostasis (13, 68). In Treg, ligation to the IL-2R 
predominately induces the phosphorylation and thereby activation of the transcription factor 
Stat5. However, the MAPK and PI3K pathways, which are induced in IL-2-stimulated Teff, 
are not activated (78). Thus, it was hypothesized that TNCscTNF80 could act via Stat5 and 
inhibit Treg function by reducing its activation. 
After the staining process against pStat5 had been optimized, the effects of TNFR 
agonists on Stat5 activation in Treg and Teff were examined during short- and long-term 
stimulation. First, it was demonstrated that pStat5 levels are enhanced in CD4+CD25+ cells 
after short-term stimulation with IL-2 and anti-CD3ε, while pStat5 expression did not increase 
in CD4+CD25- cells. Nevertheless, both CD4+CD25+ regulatory and CD4+CD25- effector T 
cells are supposed to respond to IL-2 stimulation with an increased Stat5 activation (13). 
However, the observation that pStat5 is only induced in CD4+CD25+ but not CD4+CD25- cells 
does not necessarily mean that Treg predominantly activate pStat5. T cells only express the 
high-affinity IL-2 receptor complex upon TCR-driven activation. Once upregulated, this 
receptor complex is more efficiently bound by IL-2, which in turn further enhances CD25 
expression in a Stat5-dependent manner (75, 290). Thus, gating on CD4+CD25+ might select 
activated rather than regulatory T cells. Conversely, it was shown that a high proportion of 
CD4+Foxp3- cells express CD25 in response to anti-CD3ε stimulation for as short as three 
hours. The differences of pStat5 expression in CD4+CD25- and CD4+CD25+ cells observed in 
these experiments were, therefore, due to the separation of non-activated and activated cells. 
During the short-term stimulation, addition of TNFR agonists enhanced pStat5 expression in 
those activated CD4+CD25+ cells. The increase of pStat5 was always highest in the presence 
of the TNFR2 agonist TNCscTNF80, while the TNFR1 agonist hTNF showed only minor 
changes of pStat5 expression and the combined TNFR1/TNFR2 agonist TNCwtTNF had 
intermediate effects. It has been reported that TNFR2 signalling enhances Akt and NF-κB 
expression during TCR stimulation and thereby promotes IL-2 production (183). Thus, 
TNFR2 signalling appears to increases IL-2 levels in the cell cultures, which in turn further 
promotes the IL-2 driven activation of Stat5 in the stimulated Teff cells. 
It is known that Stat5 is activated in response to IL-2 signalling (244). Yet, in the 
suppression assays in this thesis, which demonstrated the negative effect of TNCscTNF80 on 
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Treg suppressor function, T cells were stimulated only with anti-CD3ε antibody without any 
exogenous IL-2. However, it could be shown in this work that anti-CD3ε stimulated CD4+ 
cells express pStat5 during long-term incubation even in the absence of exogenous IL-2. 
Thus, it was demonstrated that no additional IL-2 is needed for anti-CD3-induced activation 
of Stat5. This can be explained by the upregulation of IL-2 production and CD25 expression 
in response to TCR stimulation (291). IL-2R signalling in T cells is, thereby, increased and 
subsequently induces Stat5 activation. In the present study, however, strong Stat5 activation 
was only observed upon stimulation for 24 hours, indicating that aCD3-induced IL-2 
production is only transiently upregulated. Conversely, it has been shown that IL-2 production 
is at its maximum 12-18 hours after TCR-mediated stimulation and then starts to decline 
(291).  
Upon long-term stimulation, the CD4+Foxp3+ cells showed enhanced pStat5 levels as 
early as three hours after stimulation, whereas pStat5 was not detectable in CD4+Foxp3- 
responder cells until 24 hours of stimulation. This is in line with a previous study, in which it 
was shown that Treg were the first to respond to IL-2 during the initiation of immune 
responses, while effector T cells required repetitive antigenic stimulation (292). Yet, in 
CD4+Foxp3- cells expression of pStat5 was only observed following activation with 
anti-CD3ε for 24 hours. A cardinal factor of Treg cells is their ability to supress IL-2 
production by Teff cells (56). Therefore, less IL-2 might be available in the cell culture for 
both Teff and Treg cells during the course of suppression. Those reduced IL-2 level might not 
be sufficient to induce pStat5 expression in Teff. Treg, however, are stimulated efficiently even 
by sub-optimal IL2-R signalling (289). Conversely, the present results showed that pStat5 was 
expressed in CD4+Foxp3+ Treg after prolonged stimulation as well, when IL-2 levels were 
presumably low. Furthermore, this observation is in line with the theory that Treg mediate 
suppression through consumption of IL-2 and, thereby, deprive Teff of the essential IL-2R 
signals (126). Regarding the TNFR agonists, neither the TNFR2-speficic TNCscTNF80 nor 
the TNFR1-speficic agonist hTNF considerably changed pStat5 expression in CD4+Foxp3+ 
cells. Only a minor reduction of pStat5 expression was observed after stimulation with 
TNCscTNF80 for 48 or 72 hours. This argues against the hypothesis that TNF affects Treg 
suppressor function by modulating the cell-signalling cascade downstream of the IL-2 
receptor.  
 In a different approach, CD45.1 and CD45.2 were used to separate Teff and Treg cells. 
When the effector cells were cultured alone, TNCscTNF80 only enhanced the pStat5 levels 
after 24 hours, while no difference was noticeable at other time-points. TNCwtTNF also 
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increased pStat5 levels in Teff (data not shown). As they both activate TNFR2, while only 
TNCwtTNF binds to TNFR1 as well, this effect is likely modulated through TNFR2. 
Conversely, neither control supernatant nor the TNFR1-specific hTNF could increase the 
level of pStat5 expression (data not shown). This is consistent with previous reports showing 
that TNFR2, and not TNFR1, acts as a co-stimulator during TCR-driven immune responses 
(181, 183). When Teff and Treg were co-cultured, the proportion of pStat5+ Teff and Treg cells 
was slightly enhanced after short-term stimulation with TNCscTNF80, while it was 
moderately decreased upon long-term stimulation with TNCscTNF80. Thus, TNFR2 
signalling seems to act as co-stimulator in both Teff and Treg after shorter periods of 
stimulation. Accordingly, TNCwtTNF enhanced the pStat5 expression in Treg cells after 24 
hours, while the TNFR1-specific agonist hTNF did not influence the pStat5 levels. However, 
TNFR2 signalling appears to limit Stat5 activation both in effector and regulatory T cells at 
later stages of the Treg-mediated suppression. This trend towards reduction of pStat5 
expression after prolonged treatment with TNCscTNF80 was also seen when Foxp3 was used 
to identify Treg.  
Contrarily, Chen et al. reported that TNF enhanced both CD25 expression and 
IL-2-induced activation of Stat5 in CD4+CD25+ Treg (216). Yet, in that study pStat5 
expression was examined separately in Treg and Teff monocultures. Thus, in contrast to the 
present work, the effect of TNF on pStat5 during the course of Treg-mediated suppression was 
not determined. Further, cell cultures were activated with IL-2 and TNF and subsequently the 
expression of pStat5 in CD25- and CD25+ cells was measured. As described above (4.3.1), 
this might not separate regulatory and effector but rather unactivated and activated cells. 
Conversely, more recent data, which demonstrated that TNF enhanced CD25 on CD4+Foxp3+ 
Treg, did not find any effect on the activation of Stat5 (267). Yet in that study, the pStat5 
levels were analysed four hours after in vivo stimulation, while the effects of long-term 
treatment with TNF on pStat5 expression were not examined. Whereas in the present work, 
no alteration of pStat5 in CD4+Foxp3+ cells could be shown after short-term stimulation with 
TNCscTNF80 for three hours, long-term stimulation with this TNFR2 agonist led to a slight 
reduction of pStat5. Thus, only prolonged exposure to TNF might reduce IL2-R signalling in 
Treg and consequently inhibit their suppressor capacity. Interestingly, it was also shown in this 
thesis that TNCscTNF80 enhanced CD25 expression on Foxp3+ Treg cells after 24 hours, but 
decreased its surface expression after 48 and 72 hours of stimulation. Thus, 
TNFR2-dependent downregulation of CD25 might cause inhibition of IL-2R signalling and 
thereby account for the reduced Stat5 activation. Moreover, TNCscTNF80 also induced 
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downregulation of the CD39 and GITR expression by Treg after stimulation for 48 and 72 
hours. Thus, it seems that especially prolonged TNFR2 stimulation inhibits Treg function.  
However, the results obtained in the experiments using Foxp3 to differentiate between 
effector and regulatory cells demonstrated only very mild effects of TNCscTNF80 on pStat5 
expression in CD4+Foxp3- Teff and CD4+Foxp3+ Treg. The conflicting results might be due to 
the methodical limitations that occurred when using the CD45.1/CD45.2 model for 
identification of Treg and Teff cells. Effector cells were defined as CD4+CD45.2-. Yet, naïve 
splenocytes from CD45.1 mice also comprise approximately 10 % CD4+CD25+ Treg. Thus, 
Treg cells have to be expected in the CD4+CD45.2- population, which therefore does not 
entirely represent the Teff subset. In contrast, gating on CD4+Foxp3- will identify only true 
effector cells. Moreover, the recovery of CD4+CD25+ cells after magnetic separation is 
relatively low, which can contribute to the reduced data quality. Thus, further studies are 
required to clarify the effect of TNFR2 signalling on the activation of IL-2-depended 
transcription factors in Treg and its possible implications on Treg suppressor capacity.  
4.5 Effect of TNCscTNF80 on pZAP70 expression in Teff and Treg 
It was demonstrated that the TNFR2 agonist TNCscTNF80 did not have major effects 
on IL-2 receptor signalling. Yet, it is also possible that TNFR2 stimulation changes Treg 
suppression by influencing the signalling cascade downstream of the TCR. In order to assess 
the effect of TNCscTNF80 on TCR signalling, the expression of pZAP70, a downstream 
molecule of this receptor complex, was studied. Similar to the experiments with pStat5 
staining, a series of preliminary studies had to be performed in order to optimize the 
phospho-flow staining protocol for the detection of pZAP70 in Foxp3+ Treg and Foxp3- Teff. 
Although it was shown in a previous report that ZAP70, both in its non-phosphorylated and 
phosphorylated form, was upregulated in Treg and non-Treg CD4+ cells upon activation with 
anti-CD3ε antibody for at least 30 minutes (238), in the present study no pZAP70 was 
detectable after stimulation with anti-CD3ε antibody. Moreover, no enhanced levels of 
pZAP70 were detectable in Treg and Teff upon combined aCD3/IL-2 stimulation. Therefore, 
other methods of stimulation needed to be found. 
Previous studies on the detection of signalling events with western blots have 
demonstrated that H2O2 can be used as a stimulator for tyrosine phosphorylation of signalling 
molecules downstream of the TCR (293, 294). It is not completely clear, how H2O2 can 
simulate antigenic stimulation of T cells. H2O2, being a generator of free radicals, might 
promote the formation of ROS that inhibit protein tyrosine phosphatases, resulting in the 
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relatively higher activity of protein tyrosine kinases. Those kinases in turn can facilitate the 
phosphorylation of mediators like ZAP70 (293). When signalling events are studied in limited 
cell population, techniques like western blot are not practical because they require large cell 
numbers. The phospho-flow method, on the other hand, allows simultaneous analysis of 
surface markers for the identification of small cellular subsets and phosphorylated 
intracellular signalling molecules. Regarding the compatibility of H2O2 stimulation and flow 
cytometric analysis, it has been shown that pZAP70 is detectable by both western blot and 
flow cytometry upon H2O2 stimulation (250). In the present study, it could also be 
demonstrated that stimulation with H2O2 resulted in a pronounced expression of pZAP70 by 
CD4+ cells. Thus, H2O2 stimulation could be used as an efficient method for the activation of 
the proximal TCR signalling cascade.  
After establishing a suitable activation method, it was possible to analyse the impact of 
TNFR2 signalling on pZAP70 expression in both CD4+Foxp3- Teff and CD4+Foxp3+ Treg 
cells. Nevertheless, the effects of TNCscTNF80 on H2O2-stimulated cells were not consistent. 
While TNCscTNF80 enhanced pZAP70 expression in Treg and Teff in one experiment, those 
results could not be replicated in future experiments. Furthermore, comparing the pZAP70 
expression in CD4+Foxp3- and CD4+Foxp3+ cells showed that both Treg and Teff activate 
ZAP70 to the same extend regardless of their activation status. Thus, the present results 
suggest that proximal TCR signalling is not different in Treg or Teff cells and that signalling via 
the TNFR2 does not influence the activation of ZAP70 in neither of those cells. On the 
contrary, Hanschen et al. have demonstrated that Treg upregulate pZAP70 more rapidly and to 
a higher extend than non-Treg cells (238). Differences in the experimental set-up might 
account for the contrasting results, as T cells were activated with anti-CD3ε in that study, 
whereas in the present work the more unphysiological H2O2 was used. In a different study it 
was demonstrated that CD4+CD25+ Treg show reduction of proximal TCR signalling 
following CD3 cross-linking, including an impaired recruitment of ZAP70 to the CD3ζ chain 
and diminished ZAP70 activity (58). In that report western blotting was performed to show 
coimmunoprecipitation of CD3ζ and ZAP70, which might produce different results than the 
measurement of the ZAP70 phosphorylation level by flow cytometry. 
In order to exclude that the concentration of TNCscTNF80 has potential effects on 
pZAP70 expression, serial dilutions of TNCscTNF80 were performed. Once again, 
stimulation with 10 ng/ml TNCscTNF80 did not increase pZAP70 expression in H2O2-
activated Treg and Teff cells. Reducing the concentration of TNCscTNF80 did not have 
considerable effects on pZAP70 levels in Teff or Treg either. The expression of pZAP70 was 
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also examined depending on the incubation time. The maximal expression of pZAP70 in both 
CD4+Foxp3- and CD4+Foxp3+ was noticed after stimulation with H2O2 for five minutes, while 
it declined constantly until the 60-minute end point. This is in contrast to the observation 
made by Haas et al. who found that stimulation with H2O2 for 15 minutes led to the maximal 
expression of pZAP70 (250). Yet, in the present study staining was performed with a mAB 
against phosphorylated tyrosine 319 (Tyr319) of pZAP70, whereas Haas et al. studied the 
phosphorylation levels of pZAP70 at Tyr493 and Tyr292 (250). Following TCR stimulation, 
ZAP70 is recruited to the receptor complex (49). ZAP70 then in turn is phosphorylated at 
Tyr319, resulting in the release from its autoinhibited conformation. Subsequently, 
phosphorylation of Tyr493 is induced, which is required for full catalytic activity of ZAP70 
(49, 295). Thus, phosphorylation at Tyr319 precedes phosphorylation of Tyr493. This might 
explain the different kinetics of pZAP70 upregulation upon H2O2 stimulation that were found 
in both studies. Regarding TNFR2 signalling, however, no considerable difference of the 
pZAP70 level could be shown in the presence of TNCscTNF80 at any time point. Thus, it was 
concluded that TNCscTNF80 and, therefore, signalling via TNFR2 does not change the 
activation of ZAP70. As ZAP70 is one the earliest mediators of the TCR signalling cascade, 
this indicated that TNCscTNF80 does not influence Treg-induced suppression by changing 
proximal TCR signalling events. 
4.6 Change of MDSC-induced suppression by TNFR2-agonist 
TNCscTNF80 
Not only Treg exhibit immunoregulatory functions, myeloid-derived suppressor cells 
are also enabled to limit T cell numbers and functions. It has been shown formerly that 
MDSC efficiently suppress T cell proliferation in vitro (253), which could be reproduced in 
this thesis. In the present study a marked suppression of CD4+ and CD8+ proliferation in 
response to anti-CD3 stimulation could be observed, especially when higher ratios of MDSC 
to splenocytes were utilized. Furthermore, it was shown in this work that MDSC, which had 
been cultured for six up to ten days prior to the suppression assays, showed a reduced ability 
to suppress T cell proliferation when compared to MDSC that had been cultured for only four 
days. In a previous report it was reported that suppressive MDSC develop from bone marrow 
cells after stimulation in vitro with GM-CSF for four days, while they differentiated into 
mature cells without suppressor capacity following longer periods of stimulation (42). Thus, 
the reduction of suppressor capacity of MDSC that were cultured for more than four days 
might be due to advanced cell maturation towards non-suppressive cells.  
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MDSC, which had been generated with GM-CSF and the TNFR2-specific agonist 
TNCscTNF80, were also able to suppress T cell proliferation. However, cultivation in the 
presence of TNCscTNF80 resulted in the generation of MDSC that showed reduced 
suppression of T cell proliferation, indicating that TNFR2 signalling inhibits the generation of 
suppressive MDSC. Contrarily, Zhao et al. suggested that TNF does not change the 
suppressor capacity of MDSC, but rather mediates anti-apoptotic effects in those cells. This is 
thought to contribute to the survival and peripheral accumulation of MDSC in tumor-bearing 
mice, thereby facilitating MDSC-induced suppression of antitumor immune response (224). 
Moreover, there is also data available that suggests that TNF enhances suppressor capacity of 
MDSC (225, 226). 
Interestingly, it was observed in the present study that TNFR2-deficient MDSC were 
less suppressive when compared to their WT counterparts, indicating that TNFR2 signalling 
promotes the suppressive capacity of MDSC. This stands in stark contrast to the observation 
that the TNFR2 agonist TNCscTNF80 attenuated MDSC-induced T cell suppression. A 
possible explanation for this phenomenon is that MDSC appear to undergo more rapid 
maturation in the absence of TNFR2 signalling (225, 254). Cultivation for more than fours 
days did not considerably reduce the suppressive activity of MDSC from TNFR2-/- mice, 
while WT MDSC gradually lost their suppressor capacity. A great proportion of the TNFR2-/- 
bone marrow cells might have already developed into mature non-suppressive DC after four 
days of stimulation. WT MDSC, on the other hand, do not differentiate as quickly and thereby 
retain their suppressor capacity even after longer periods of cultivation. Thus, TNFR2 
signalling seems to play a role in the disruption of myeloid cell maturation, which results in 
the accumulation of immature myeloid cells with suppressive functions. However, if TNFR2 
signalling was blocking MDSC maturation, GM-CSF-induced generation with additional 
TNCscTNF80 should have slowed down the maturation of MDSC and resulted in an 
enhancement of MDSC suppressor function. Nevertheless, the present results showed that 
generation with TNCscTNF80 abrogated MDSC-induced T cell suppression. This suggests 
that TNFR2 signalling inhibits rather than enhances MDSC-mediated suppression. More in 
depth studies are required to clarify the reasons for the discrepancy of the existing data.  
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5  Conclusion 
In this work, it could be shown that TNFR2 signalling has a co-stimulatory effect on 
the proliferation and cytokine production of effector T cells and inhibits Treg- and 
MDSC-mediated suppression of these effector lymphocytes. It could also be demonstrate that 
signalling via the TNFR2 has certain implications on Treg phenotype and intracellular 
signalling events. It was shown that Treg down-regulate the surface molecules CD25, GITR 
and CD39 after prolonged exposure to TNFR2 agonists. It is possible that the reduced activity 
of those surface molecules leads to a reduction of IL-2R signalling, adenosine production and 
stimulatory signals for Treg expansion and, thereby, eventually results in an abrogation of Treg 
suppressor capacity. Regarding intracellular signalling events, it was found that stimulation of 
TNFR2 has marginal effects on the IL-2-induced activation of Stat5, while it does not affect 
proximal TCR signalling pathways. This reduction of pStat5 up-regulation was only seen 
after long-term stimulation. Since the TNFR2-mediated down-regulation of surface molecules 
was only seen at later time-points as well, this indicates that mainly prolonged TNFR2 
signalling negatively affects Treg suppressor function. Likewise, the MDSC-induced 
suppression was also more pronounced when those cells were exposed to TNFR2 agonists for 
longer periods of time. Since TNF is mainly produced during the course of inflammation, the 
defective function of regulatory immune cells in response to prolonged exposure towards 
TNF could contribute to an impaired clearing of proinflammatory cells, especially after the 
acute phase of an immune response. Eventually, overshooting inflammatory processes and 
autoimmune disorders may develop or be worsened. Thus, anti-TNF reagents might have the 
potential to promote both Treg and MDSC function and thereby contain dysregulated immune 
responses.  
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